Antibody_Name,Antibody_Type,Indication,Phase,Dose_mg_m2,Dose_Frequency,Enrollment,Duration_Days,Age_Range,Gender,ECOG_Performance,Adverse_Event,Organ_System,Severity,Affected_Patients,Fraction_Affected_%,Reversible,Manageable,Management_Strategy,Time_to_Onset_Days,Resolution_Days,Dose_Reduction_Required,Treatment_Discontinuation,Fatal_Outcome
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,1200,Weekly,150,120,57-72,Female only,0-3,Severe Colitis,Gastrointestinal,Severe,15,10.0,Yes,Yes,"Corticosteroids, infliximab",5,13,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,840,Weekly,50,314,50-84,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,5,10.0,Partial,Yes,"Corticosteroids, oxygen therapy",44,8,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,840,Bi-weekly,193,100,36-84,Female only,0-1,Severe Neuropathy,Neurological,Severe,19,9.84,Partial,Yes,"Dose reduction, pain management",77,41,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1680,Weekly,96,338,54-68,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,9,9.38,Yes,Yes,"Corticosteroids, infliximab",6,8,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,840,Every 3 weeks,212,147,42-79,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,19,8.96,Partial,Yes,"Corticosteroids, cardiac support",66,30,Yes,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1200,Every 3 weeks,103,279,30-72,All,0-3,Severe Colitis,Gastrointestinal,Severe,9,8.74,Yes,Yes,"Corticosteroids, infliximab",70,3,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1200,Bi-weekly,234,193,41-73,Female only,0-2,Anaphylaxis,Immunological,Severe,19,8.12,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",46,37,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1200,Bi-weekly,37,217,31-84,Male only,0-2,Anaphylaxis,Immunological,Severe,3,8.11,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",40,38,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,840,Monthly,235,145,49-77,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,19,8.09,Partial,Yes,"Corticosteroids, oxygen therapy",19,60,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,840,Weekly,50,314,50-84,Female only,0-3,Severe Neutropenia,Hematological,Severe,4,8.0,Yes,Yes,"G-CSF, antibiotics, dose reduction",72,26,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1200,Every 3 weeks,256,117,31-65,Female only,0-1,Severe Colitis,Gastrointestinal,Severe,20,7.81,Yes,Yes,"Corticosteroids, infliximab",10,8,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1200,Every 3 weeks,256,117,31-65,Female only,0-1,Severe Neuropathy,Neurological,Severe,20,7.81,Partial,Yes,"Dose reduction, pain management",13,13,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,840,Bi-weekly,193,100,36-84,Female only,0-1,Severe Neutropenia,Hematological,Severe,15,7.77,Yes,Yes,"G-CSF, antibiotics, dose reduction",69,14,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,840,Every 3 weeks,26,164,31-65,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,2,7.69,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",87,13,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1200,Bi-weekly,237,135,36-65,All,0-1,Anaphylaxis,Immunological,Severe,18,7.59,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",41,39,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,1680,Bi-weekly,55,287,52-70,Male only,0-2,Severe Neuropathy,Neurological,Severe,4,7.27,Partial,Yes,"Dose reduction, pain management",59,34,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,1680,Bi-weekly,55,287,52-70,Male only,0-2,Severe Neutropenia,Hematological,Severe,4,7.27,Yes,Yes,"G-CSF, antibiotics, dose reduction",47,25,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,1680,Monthly,210,226,31-68,Female only,0-3,Anaphylaxis,Immunological,Severe,15,7.14,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",51,5,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1680,Weekly,285,76,38-81,All,0-3,Severe Thrombocytopenia,Hematological,Severe,20,7.02,Yes,Yes,"Platelet transfusion, dose adjustment",16,60,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1680,Monthly,114,227,36-69,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,8,7.02,Partial,Yes,"Liver function monitoring, dose adjustment",49,10,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,840,Monthly,292,62,62-66,All,0-1,Anaphylaxis,Immunological,Severe,20,6.85,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",43,17,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1680,Weekly,266,305,29-66,All,0-2,Severe Myocarditis,Cardiovascular,Severe,18,6.77,Partial,Yes,"Corticosteroids, cardiac support",54,56,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,1680,Monthly,210,226,31-68,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,14,6.67,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",48,6,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,840,Monthly,292,62,62-66,All,0-1,Severe Colitis,Gastrointestinal,Severe,19,6.51,Yes,Yes,"Corticosteroids, infliximab",17,9,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,1680,Every 3 weeks,244,238,48-70,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,15,6.15,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",84,51,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,1680,Every 3 weeks,147,69,50-70,Male only,0-3,Severe Colitis,Gastrointestinal,Severe,9,6.12,Yes,Yes,"Corticosteroids, infliximab",74,47,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,840,Bi-weekly,341,119,39-66,Female only,0-2,Severe Neutropenia,Hematological,Severe,20,5.87,Yes,Yes,"G-CSF, antibiotics, dose reduction",58,11,Yes,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1200,Weekly,309,293,47-65,Female only,0-2,Severe Colitis,Gastrointestinal,Severe,18,5.83,Yes,Yes,"Corticosteroids, infliximab",29,10,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1200,Every 3 weeks,103,279,30-72,All,0-3,Severe Pneumonitis,Respiratory,Severe,6,5.83,Partial,Yes,"Corticosteroids, oxygen therapy",24,1,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1200,Bi-weekly,237,135,36-65,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,13,5.49,Partial,Yes,"Liver function monitoring, dose adjustment",70,44,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,1680,Bi-weekly,55,287,52-70,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,3,5.45,Partial,Yes,"Liver function monitoring, dose adjustment",45,24,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1200,Bi-weekly,37,217,31-84,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,2,5.41,Partial,Yes,"Liver function monitoring, dose adjustment",58,55,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,1680,Every 3 weeks,244,238,48-70,All,1-2,Severe Thrombocytopenia,Hematological,Severe,13,5.33,Yes,Yes,"Platelet transfusion, dose adjustment",50,20,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,1680,Weekly,95,124,32-83,All,0-2,Severe Myocarditis,Cardiovascular,Severe,5,5.26,Partial,Yes,"Corticosteroids, cardiac support",32,25,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1680,Weekly,285,76,38-81,All,0-3,Cytokine Release Syndrome,Immunological,Severe,15,5.26,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",86,56,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1680,Bi-weekly,363,354,60-78,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,19,5.23,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",51,48,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1200,Weekly,309,293,47-65,Female only,0-2,Severe Colitis,Gastrointestinal,Severe,16,5.18,Yes,Yes,"Corticosteroids, infliximab",39,35,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1200,Weekly,309,293,47-65,Female only,0-2,Severe Neuropathy,Neurological,Severe,16,5.18,Partial,Yes,"Dose reduction, pain management",53,25,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,1200,Every 3 weeks,375,96,54-84,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,18,4.8,Partial,Yes,"Corticosteroids, oxygen therapy",6,26,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1200,Every 3 weeks,256,117,31-65,Female only,0-1,Severe Colitis,Gastrointestinal,Severe,12,4.69,Yes,Yes,"Corticosteroids, infliximab",85,58,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,1200,Weekly,150,120,57-72,Female only,0-3,Cytokine Release Syndrome,Immunological,Severe,7,4.67,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",88,18,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,840,Bi-weekly,193,100,36-84,Female only,0-1,Severe Thrombocytopenia,Hematological,Severe,9,4.66,Yes,Yes,"Platelet transfusion, dose adjustment",8,60,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,840,Bi-weekly,341,119,39-66,Female only,0-2,Severe Hepatotoxicity,Hepatic,Severe,15,4.4,Partial,Yes,"Liver function monitoring, dose adjustment",45,14,Yes,Yes,Yes
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,840,Weekly,368,97,28-78,All,0-2,Severe Neuropathy,Neurological,Severe,15,4.08,Partial,Yes,"Dose reduction, pain management",4,9,Yes,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,1680,Every 3 weeks,327,132,64-81,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,13,3.98,Partial,Yes,"Liver function monitoring, dose adjustment",24,32,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,840,Weekly,458,83,18-68,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,18,3.93,Yes,Yes,"Platelet transfusion, dose adjustment",72,29,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1200,Monthly,414,253,43-76,All,0-3,Anaphylaxis,Immunological,Severe,16,3.86,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",20,35,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,840,Monthly,235,145,49-77,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,9,3.83,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",88,10,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,840,Monthly,455,196,47-74,All,0-2,Severe Neuropathy,Neurological,Severe,17,3.74,Partial,Yes,"Dose reduction, pain management",82,28,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1680,Weekly,285,76,38-81,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,10,3.51,Partial,Yes,"Liver function monitoring, dose adjustment",54,36,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1680,Monthly,114,227,36-69,All,0-3,Severe Neutropenia,Hematological,Severe,4,3.51,Yes,Yes,"G-CSF, antibiotics, dose reduction",81,36,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,840,Every 3 weeks,467,193,36-74,Female only,0-2,Severe Pneumonitis,Respiratory,Severe,16,3.43,Partial,Yes,"Corticosteroids, oxygen therapy",81,46,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1200,Weekly,309,293,47-65,Female only,0-2,Severe Thrombocytopenia,Hematological,Severe,10,3.24,Yes,Yes,"Platelet transfusion, dose adjustment",7,22,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1680,Every 3 weeks,377,46,53-83,Male only,0-2,Severe Neuropathy,Neurological,Severe,12,3.18,Partial,Yes,"Dose reduction, pain management",52,35,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1680,Bi-weekly,481,42,26-74,Male only,1-2,Severe Neutropenia,Hematological,Severe,15,3.12,Yes,Yes,"G-CSF, antibiotics, dose reduction",9,53,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1680,Weekly,96,338,54-68,Male only,0-1,Severe Neutropenia,Hematological,Severe,3,3.12,Yes,Yes,"G-CSF, antibiotics, dose reduction",24,2,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1680,Weekly,96,338,54-68,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,3,3.12,Partial,Yes,"Corticosteroids, cardiac support",7,44,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,1200,Weekly,307,151,21-68,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,9,2.93,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",54,4,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,840,Weekly,458,83,18-68,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,13,2.84,Partial,Yes,"Liver function monitoring, dose adjustment",44,44,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,840,Every 3 weeks,467,193,36-74,Female only,0-2,Cytokine Release Syndrome,Immunological,Severe,13,2.78,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",29,41,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1680,Every 3 weeks,377,46,53-83,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,10,2.65,Partial,Yes,"Corticosteroids, oxygen therapy",26,40,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,840,Weekly,458,83,18-68,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,12,2.62,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",48,46,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,1200,Weekly,467,135,26-85,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,12,2.57,Yes,Yes,"Platelet transfusion, dose adjustment",58,13,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,840,Weekly,478,164,64-78,Female only,0-2,Severe Neuropathy,Neurological,Severe,12,2.51,Partial,Yes,"Dose reduction, pain management",68,8,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,1680,Bi-weekly,282,111,42-76,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,7,2.48,Yes,Yes,"Platelet transfusion, dose adjustment",63,51,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,1200,Weekly,446,281,34-78,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,11,2.47,Yes,Yes,"Platelet transfusion, dose adjustment",45,36,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,1200,Weekly,446,281,34-78,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,11,2.47,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",74,22,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,1200,Every 3 weeks,375,96,54-84,Male only,0-3,Anaphylaxis,Immunological,Severe,9,2.4,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",68,5,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1680,Every 3 weeks,377,46,53-83,Male only,0-2,Cardiac Toxicity,Cardiovascular,Severe,9,2.39,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",24,6,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,840,Monthly,382,155,54-77,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,9,2.36,Yes,Yes,"Corticosteroids, infliximab",41,48,Yes,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,840,Monthly,382,155,54-77,Female only,1-2,Severe Neuropathy,Neurological,Severe,9,2.36,Partial,Yes,"Dose reduction, pain management",85,31,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1680,Monthly,431,131,47-67,All,1-2,Severe Pneumonitis,Respiratory,Severe,10,2.32,Partial,Yes,"Corticosteroids, oxygen therapy",6,2,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1680,Bi-weekly,481,42,26-74,Male only,1-2,Severe Neuropathy,Neurological,Severe,11,2.29,Partial,Yes,"Dose reduction, pain management",19,58,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,840,Monthly,455,196,47-74,All,0-2,Severe Myocarditis,Cardiovascular,Severe,10,2.2,Partial,Yes,"Corticosteroids, cardiac support",8,12,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1200,Bi-weekly,237,135,36-65,All,0-1,Cytokine Release Syndrome,Immunological,Severe,5,2.11,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",9,50,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,840,Bi-weekly,415,334,56-65,Female only,1-2,Severe Pneumonitis,Respiratory,Severe,8,1.93,Partial,Yes,"Corticosteroids, oxygen therapy",32,27,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1200,Monthly,414,253,43-76,All,0-3,Severe Pneumonitis,Respiratory,Severe,8,1.93,Partial,Yes,"Corticosteroids, oxygen therapy",31,51,Yes,Yes,Yes
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,1680,Monthly,210,226,31-68,Female only,0-3,Severe Thrombocytopenia,Hematological,Severe,4,1.9,Yes,Yes,"Platelet transfusion, dose adjustment",69,36,Yes,Yes,Yes
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,1200,Monthly,430,154,41-82,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,8,1.86,Yes,Yes,"Platelet transfusion, dose adjustment",83,58,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,840,Bi-weekly,341,119,39-66,Female only,0-2,Cardiac Toxicity,Cardiovascular,Severe,6,1.76,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",60,12,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1680,Monthly,114,227,36-69,All,0-3,Severe Pneumonitis,Respiratory,Severe,2,1.75,Partial,Yes,"Corticosteroids, oxygen therapy",3,46,No,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1200,Bi-weekly,237,135,36-65,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,4,1.69,Partial,Yes,"Liver function monitoring, dose adjustment",65,2,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,840,Every 3 weeks,425,184,62-83,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,7,1.65,Partial,Yes,"Corticosteroids, cardiac support",70,28,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1200,Every 3 weeks,121,271,43-68,All,0-1,Severe Neutropenia,Hematological,Severe,2,1.65,Yes,Yes,"G-CSF, antibiotics, dose reduction",78,4,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,840,Weekly,368,97,28-78,All,0-2,Cardiac Toxicity,Cardiovascular,Severe,6,1.63,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",18,24,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1680,Monthly,431,131,47-67,All,1-2,Anaphylaxis,Immunological,Severe,7,1.62,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",14,2,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1680,Monthly,431,131,47-67,All,1-2,Severe Thrombocytopenia,Hematological,Severe,7,1.62,Yes,Yes,"Platelet transfusion, dose adjustment",39,9,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1680,Weekly,266,305,29-66,All,0-2,Cytokine Release Syndrome,Immunological,Severe,4,1.5,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",43,14,No,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,840,Bi-weekly,415,334,56-65,Female only,1-2,Cytokine Release Syndrome,Immunological,Severe,6,1.45,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",66,45,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1680,Every 3 weeks,377,46,53-83,Male only,0-2,Severe Colitis,Gastrointestinal,Severe,5,1.33,Yes,Yes,"Corticosteroids, infliximab",46,13,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,1200,Weekly,467,135,26-85,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,6,1.28,Partial,Yes,"Liver function monitoring, dose adjustment",55,31,Yes,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,1200,Weekly,446,281,34-78,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,5,1.12,Yes,Yes,"Platelet transfusion, dose adjustment",16,39,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,840,Monthly,455,196,47-74,All,0-2,Cardiac Toxicity,Cardiovascular,Severe,5,1.1,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",81,32,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,1200,Every 3 weeks,375,96,54-84,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,4,1.07,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",13,20,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1200,Monthly,414,253,43-76,All,0-3,Severe Neutropenia,Hematological,Severe,4,0.97,Yes,Yes,"G-CSF, antibiotics, dose reduction",82,58,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,1200,Monthly,430,154,41-82,Male only,0-2,Severe Colitis,Gastrointestinal,Severe,4,0.93,Yes,Yes,"Corticosteroids, infliximab",27,15,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,1680,Monthly,114,227,36-69,All,0-3,Severe Pneumonitis,Respiratory,Severe,1,0.88,Partial,Yes,"Corticosteroids, oxygen therapy",36,52,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,840,Weekly,458,83,18-68,Male only,0-3,Severe Neuropathy,Neurological,Severe,4,0.87,Partial,Yes,"Dose reduction, pain management",30,23,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1680,Bi-weekly,363,354,60-78,Male only,0-3,Severe Colitis,Gastrointestinal,Severe,3,0.83,Yes,Yes,"Corticosteroids, infliximab",2,37,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1200,Every 3 weeks,256,117,31-65,Female only,0-1,Severe Myocarditis,Cardiovascular,Severe,2,0.78,Partial,Yes,"Corticosteroids, cardiac support",76,2,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1680,Weekly,266,305,29-66,All,0-2,Severe Neutropenia,Hematological,Severe,2,0.75,Yes,Yes,"G-CSF, antibiotics, dose reduction",82,52,Yes,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1200,Monthly,414,253,43-76,All,0-3,Severe Neuropathy,Neurological,Severe,3,0.72,Partial,Yes,"Dose reduction, pain management",34,24,No,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,840,Bi-weekly,193,100,36-84,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,1,0.52,Partial,Yes,"Corticosteroids, oxygen therapy",32,59,No,Yes,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,840,Monthly,235,145,49-77,Female only,0-1,Severe Neuropathy,Neurological,Severe,1,0.43,Partial,Yes,"Dose reduction, pain management",31,1,Yes,No,No
Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,1680,Bi-weekly,481,42,26-74,Male only,1-2,Anaphylaxis,Immunological,Severe,2,0.42,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",20,59,Yes,No,No
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,1680,Monthly,431,131,47-67,All,1-2,Severe Pneumonitis,Respiratory,Severe,1,0.23,Partial,Yes,"Corticosteroids, oxygen therapy",18,41,No,Yes,Yes
Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,1200,Weekly,467,135,26-85,Male only,0-2,Cardiac Toxicity,Cardiovascular,Severe,1,0.21,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",62,2,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,5,Monthly,40,145,56-69,All,0-3,Severe Neuropathy,Neurological,Severe,4,10.0,Partial,Yes,"Dose reduction, pain management",87,24,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,5,Bi-weekly,80,264,62-76,Female only,1-2,Cytokine Release Syndrome,Immunological,Severe,8,10.0,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",19,11,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,7.5,Every 3 weeks,197,116,32-82,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,19,9.64,Partial,Yes,"Corticosteroids, cardiac support",3,47,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,10,Monthly,21,52,63-81,Male only,0-1,Severe Neutropenia,Hematological,Severe,2,9.52,Yes,Yes,"G-CSF, antibiotics, dose reduction",40,36,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,15,Every 3 weeks,74,147,24-67,All,0-1,Severe Myocarditis,Cardiovascular,Severe,7,9.46,Partial,Yes,"Corticosteroids, cardiac support",73,6,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,7.5,Every 3 weeks,150,132,25-84,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,14,9.33,Partial,Yes,"Liver function monitoring, dose adjustment",68,30,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,5,Bi-weekly,86,114,42-68,Female only,1-2,Anaphylaxis,Immunological,Severe,8,9.3,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",37,38,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,5,Every 3 weeks,43,87,55-79,All,1-2,Severe Neutropenia,Hematological,Severe,4,9.3,Yes,Yes,"G-CSF, antibiotics, dose reduction",82,43,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,15,Bi-weekly,151,54,35-65,Female only,0-1,Severe Neuropathy,Neurological,Severe,14,9.27,Partial,Yes,"Dose reduction, pain management",1,51,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,7.5,Weekly,151,344,35-66,Male only,0-2,Cardiac Toxicity,Cardiovascular,Severe,14,9.27,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",86,55,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,5,Monthly,88,39,25-76,Male only,0-2,Severe Neuropathy,Neurological,Severe,8,9.09,Partial,Yes,"Dose reduction, pain management",45,35,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,7.5,Every 3 weeks,178,206,24-65,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,16,8.99,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",73,39,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,5,Monthly,112,70,32-74,All,0-3,Severe Pneumonitis,Respiratory,Severe,10,8.93,Partial,Yes,"Corticosteroids, oxygen therapy",30,56,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,15,Monthly,184,118,34-74,Female only,0-3,Cytokine Release Syndrome,Immunological,Severe,16,8.7,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",76,41,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,7.5,Weekly,151,344,35-66,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,13,8.61,Partial,Yes,"Corticosteroids, cardiac support",84,3,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,10,Monthly,94,38,33-66,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,8,8.51,Partial,Yes,"Corticosteroids, cardiac support",67,7,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,10,Weekly,236,244,40-82,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,20,8.47,Partial,Yes,"Liver function monitoring, dose adjustment",22,59,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,10,Every 3 weeks,48,129,28-80,Male only,0-2,Severe Neutropenia,Hematological,Severe,4,8.33,Yes,Yes,"G-CSF, antibiotics, dose reduction",64,54,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,7.5,Bi-weekly,206,281,60-71,Female only,1-2,Cytokine Release Syndrome,Immunological,Severe,17,8.25,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",57,58,Yes,No,Yes
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,5,Weekly,37,336,19-82,Female only,0-3,Severe Hepatotoxicity,Hepatic,Severe,3,8.11,Partial,Yes,"Liver function monitoring, dose adjustment",7,9,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,10,Bi-weekly,136,294,32-75,Female only,0-3,Anaphylaxis,Immunological,Severe,11,8.09,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",51,44,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,15,Monthly,150,92,61-81,Male only,0-3,Severe Neutropenia,Hematological,Severe,12,8.0,Yes,Yes,"G-CSF, antibiotics, dose reduction",11,44,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,5,Every 3 weeks,215,35,64-76,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,17,7.91,Partial,Yes,"Liver function monitoring, dose adjustment",72,57,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,10,Every 3 weeks,242,33,37-81,All,0-1,Severe Myocarditis,Cardiovascular,Severe,19,7.85,Partial,Yes,"Corticosteroids, cardiac support",6,45,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,7.5,Weekly,128,33,45-75,Male only,0-3,Severe Neutropenia,Hematological,Severe,10,7.81,Yes,Yes,"G-CSF, antibiotics, dose reduction",30,60,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,15,Weekly,172,178,40-84,All,0-1,Cytokine Release Syndrome,Immunological,Severe,13,7.56,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",10,32,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,5,Bi-weekly,253,231,43-83,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,19,7.51,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",77,44,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,5,Bi-weekly,80,264,62-76,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,6,7.5,Partial,Yes,"Corticosteroids, cardiac support",53,30,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,10,Monthly,94,38,33-66,Male only,0-1,Severe Neuropathy,Neurological,Severe,7,7.45,Partial,Yes,"Dose reduction, pain management",37,39,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,7.5,Every 3 weeks,150,132,25-84,All,0-1,Severe Myocarditis,Cardiovascular,Severe,11,7.33,Partial,Yes,"Corticosteroids, cardiac support",59,39,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,10,Monthly,41,60,49-70,Female only,0-2,Severe Hepatotoxicity,Hepatic,Severe,3,7.32,Partial,Yes,"Liver function monitoring, dose adjustment",55,48,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,7.5,Weekly,151,344,35-66,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,11,7.28,Partial,Yes,"Liver function monitoring, dose adjustment",62,8,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,10,Weekly,236,244,40-82,Male only,1-2,Severe Myocarditis,Cardiovascular,Severe,17,7.2,Partial,Yes,"Corticosteroids, cardiac support",16,32,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,7.5,Monthly,252,67,39-69,All,0-2,Cytokine Release Syndrome,Immunological,Severe,18,7.14,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",90,4,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,15,Monthly,184,118,34-74,Female only,0-3,Severe Neutropenia,Hematological,Severe,13,7.07,Yes,Yes,"G-CSF, antibiotics, dose reduction",20,16,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,10,Every 3 weeks,242,33,37-81,All,0-1,Severe Myocarditis,Cardiovascular,Severe,17,7.02,Partial,Yes,"Corticosteroids, cardiac support",43,22,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,5,Every 3 weeks,43,87,55-79,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,3,6.98,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",67,56,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,5,Monthly,88,39,25-76,Male only,0-2,Severe Neuropathy,Neurological,Severe,6,6.82,Partial,Yes,"Dose reduction, pain management",76,37,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,7.5,Bi-weekly,206,281,60-71,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,14,6.8,Yes,Yes,"Platelet transfusion, dose adjustment",80,30,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,15,Every 3 weeks,74,147,24-67,All,0-1,Severe Neuropathy,Neurological,Severe,5,6.76,Partial,Yes,"Dose reduction, pain management",16,50,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,15,Every 3 weeks,74,147,24-67,All,0-1,Severe Neutropenia,Hematological,Severe,5,6.76,Yes,Yes,"G-CSF, antibiotics, dose reduction",47,47,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,7.5,Monthly,224,61,24-81,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,15,6.7,Partial,Yes,"Liver function monitoring, dose adjustment",86,13,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,15,Every 3 weeks,287,106,50-79,Male only,0-1,Severe Neuropathy,Neurological,Severe,19,6.62,Partial,Yes,"Dose reduction, pain management",10,3,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,15,Monthly,232,57,42-79,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,15,6.47,Yes,Yes,"Platelet transfusion, dose adjustment",54,31,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,10,Weekly,279,309,30-71,All,1-2,Severe Pneumonitis,Respiratory,Severe,18,6.45,Partial,Yes,"Corticosteroids, oxygen therapy",3,43,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,10,Weekly,279,309,30-71,All,1-2,Severe Colitis,Gastrointestinal,Severe,18,6.45,Yes,Yes,"Corticosteroids, infliximab",33,16,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,15,Weekly,172,178,40-84,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,11,6.4,Partial,Yes,"Liver function monitoring, dose adjustment",83,40,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,7.5,Every 3 weeks,178,206,24-65,All,1-2,Severe Myocarditis,Cardiovascular,Severe,11,6.18,Partial,Yes,"Corticosteroids, cardiac support",64,14,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,5,Monthly,308,34,45-68,Female only,1-2,Severe Neuropathy,Neurological,Severe,19,6.17,Partial,Yes,"Dose reduction, pain management",82,37,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,7.5,Monthly,252,67,39-69,All,0-2,Severe Thrombocytopenia,Hematological,Severe,15,5.95,Yes,Yes,"Platelet transfusion, dose adjustment",74,1,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,5,Monthly,308,34,45-68,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,18,5.84,Yes,Yes,"Platelet transfusion, dose adjustment",40,18,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,7.5,Bi-weekly,206,281,60-71,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,12,5.83,Yes,Yes,"Corticosteroids, infliximab",25,12,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,15,Weekly,120,84,26-66,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,7,5.83,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",22,35,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,10,Weekly,279,309,30-71,All,1-2,Severe Neutropenia,Hematological,Severe,16,5.73,Yes,Yes,"G-CSF, antibiotics, dose reduction",61,26,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,5,Monthly,339,322,35-74,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,19,5.6,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",27,57,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,15,Every 3 weeks,287,106,50-79,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,16,5.57,Partial,Yes,"Corticosteroids, cardiac support",10,49,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,7.5,Bi-weekly,253,264,45-75,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,14,5.53,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",42,39,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,5,Monthly,308,34,45-68,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,17,5.52,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",71,31,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,10,Bi-weekly,328,65,51-73,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,18,5.49,Partial,Yes,"Liver function monitoring, dose adjustment",56,3,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,15,Bi-weekly,221,262,36-75,Female only,0-2,Cardiac Toxicity,Cardiovascular,Severe,12,5.43,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",70,60,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,5,Weekly,37,336,19-82,Female only,0-3,Severe Hepatotoxicity,Hepatic,Severe,2,5.41,Partial,Yes,"Liver function monitoring, dose adjustment",6,22,No,No,Yes
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,10,Every 3 weeks,333,101,34-78,Male only,0-2,Severe Neuropathy,Neurological,Severe,18,5.41,Partial,Yes,"Dose reduction, pain management",30,49,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,10,Weekly,279,309,30-71,All,1-2,Severe Neuropathy,Neurological,Severe,15,5.38,Partial,Yes,"Dose reduction, pain management",4,54,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,15,Bi-weekly,150,178,40-67,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,8,5.33,Partial,Yes,"Liver function monitoring, dose adjustment",8,7,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,7.5,Bi-weekly,379,329,49-80,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,20,5.28,Yes,Yes,"Corticosteroids, infliximab",83,40,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,10,Bi-weekly,190,178,22-75,All,1-2,Severe Neuropathy,Neurological,Severe,10,5.26,Partial,Yes,"Dose reduction, pain management",25,46,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,15,Monthly,287,166,46-82,All,0-1,Severe Colitis,Gastrointestinal,Severe,15,5.23,Yes,Yes,"Corticosteroids, infliximab",2,32,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,15,Monthly,287,166,46-82,All,0-1,Severe Neuropathy,Neurological,Severe,15,5.23,Partial,Yes,"Dose reduction, pain management",10,9,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,15,Bi-weekly,313,54,37-83,Female only,0-1,Severe Myocarditis,Cardiovascular,Severe,16,5.11,Partial,Yes,"Corticosteroids, cardiac support",1,58,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,7.5,Monthly,352,204,21-85,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,18,5.11,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",56,42,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,7.5,Every 3 weeks,178,206,24-65,All,1-2,Severe Colitis,Gastrointestinal,Severe,9,5.06,Yes,Yes,"Corticosteroids, infliximab",16,26,No,Yes,Yes
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,7.5,Every 3 weeks,178,206,24-65,All,1-2,Severe Neuropathy,Neurological,Severe,9,5.06,Partial,Yes,"Dose reduction, pain management",25,59,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,5,Bi-weekly,80,264,62-76,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,4,5.0,Partial,Yes,"Corticosteroids, cardiac support",8,56,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,10,Monthly,41,60,49-70,Female only,0-2,Cytokine Release Syndrome,Immunological,Severe,2,4.88,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",24,40,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,10,Monthly,41,60,49-70,Female only,0-2,Severe Colitis,Gastrointestinal,Severe,2,4.88,Yes,Yes,"Corticosteroids, infliximab",6,8,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,10,Bi-weekly,104,92,60-78,Female only,0-2,Severe Neuropathy,Neurological,Severe,5,4.81,Partial,Yes,"Dose reduction, pain management",40,46,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,7.5,Every 3 weeks,396,176,63-83,Female only,0-3,Anaphylaxis,Immunological,Severe,19,4.8,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",77,21,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,10,Every 3 weeks,356,143,56-75,Male only,0-1,Cytokine Release Syndrome,Immunological,Severe,17,4.78,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",80,16,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,10,Monthly,21,52,63-81,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,1,4.76,Partial,Yes,"Corticosteroids, oxygen therapy",37,54,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,10,Monthly,21,52,63-81,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,1,4.76,Partial,Yes,"Corticosteroids, cardiac support",86,7,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,5,Monthly,339,322,35-74,All,1-2,Severe Myocarditis,Cardiovascular,Severe,16,4.72,Partial,Yes,"Corticosteroids, cardiac support",4,2,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,5,Monthly,339,322,35-74,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,16,4.72,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",8,11,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,10,Weekly,407,230,35-84,All,1-2,Severe Pneumonitis,Respiratory,Severe,19,4.67,Partial,Yes,"Corticosteroids, oxygen therapy",86,44,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,10,Monthly,257,240,24-85,Female only,0-1,Cardiac Toxicity,Cardiovascular,Severe,12,4.67,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",76,15,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,15,Weekly,386,137,34-75,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,18,4.66,Yes,Yes,"Corticosteroids, infliximab",2,36,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,7.5,Every 3 weeks,86,186,29-83,All,0-2,Cytokine Release Syndrome,Immunological,Severe,4,4.65,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",72,44,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,15,Weekly,172,178,40-84,All,0-1,Severe Neuropathy,Neurological,Severe,8,4.65,Partial,Yes,"Dose reduction, pain management",66,37,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,5,Bi-weekly,348,149,50-81,Female only,0-2,Cardiac Toxicity,Cardiovascular,Severe,16,4.6,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",7,29,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,7.5,Monthly,413,290,57-67,Male only,1-2,Cytokine Release Syndrome,Immunological,Severe,19,4.6,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",23,34,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,10,Weekly,371,316,46-85,Male only,0-1,Cardiac Toxicity,Cardiovascular,Severe,17,4.58,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",27,22,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,7.5,Monthly,352,204,21-85,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,16,4.55,Partial,Yes,"Corticosteroids, cardiac support",76,11,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,7.5,Monthly,352,204,21-85,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,16,4.55,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",22,5,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,5,Monthly,45,75,32-84,Female only,1-2,Cytokine Release Syndrome,Immunological,Severe,2,4.44,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",56,40,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,5,Monthly,339,322,35-74,All,1-2,Severe Thrombocytopenia,Hematological,Severe,15,4.42,Yes,Yes,"Platelet transfusion, dose adjustment",79,38,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,10,Bi-weekly,136,294,32-75,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,6,4.41,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",50,46,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,10,Weekly,371,316,46-85,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,16,4.31,Partial,Yes,"Corticosteroids, cardiac support",24,58,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,10,Monthly,257,240,24-85,Female only,0-1,Cardiac Toxicity,Cardiovascular,Severe,11,4.28,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",62,38,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,5,Monthly,351,219,61-83,Female only,0-2,Anaphylaxis,Immunological,Severe,15,4.27,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",31,10,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,10,Monthly,450,145,55-75,All,0-3,Severe Pneumonitis,Respiratory,Severe,19,4.22,Partial,Yes,"Corticosteroids, oxygen therapy",64,19,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,10,Monthly,450,145,55-75,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,19,4.22,Partial,Yes,"Liver function monitoring, dose adjustment",25,33,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,7.5,Weekly,430,261,42-65,All,0-3,Anaphylaxis,Immunological,Severe,18,4.19,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",70,39,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,10,Every 3 weeks,48,129,28-80,Male only,0-2,Anaphylaxis,Immunological,Severe,2,4.17,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",71,30,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,10,Every 3 weeks,48,129,28-80,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,2,4.17,Partial,Yes,"Corticosteroids, cardiac support",56,27,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,5,Bi-weekly,388,258,40-70,All,0-1,Cytokine Release Syndrome,Immunological,Severe,16,4.12,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",55,45,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,7.5,Every 3 weeks,197,116,32-82,Male only,0-1,Severe Neutropenia,Hematological,Severe,8,4.06,Yes,Yes,"G-CSF, antibiotics, dose reduction",90,49,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,7.5,Every 3 weeks,396,176,63-83,Female only,0-3,Severe Neutropenia,Hematological,Severe,16,4.04,Yes,Yes,"G-CSF, antibiotics, dose reduction",69,59,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,15,Every 3 weeks,372,303,28-74,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,15,4.03,Partial,Yes,"Corticosteroids, oxygen therapy",58,59,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,7.5,Every 3 weeks,374,321,34-67,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,15,4.01,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",72,4,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,5,Bi-weekly,253,231,43-83,Male only,1-2,Severe Neuropathy,Neurological,Severe,10,3.95,Partial,Yes,"Dose reduction, pain management",56,33,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,15,Every 3 weeks,332,305,53-78,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,13,3.92,Partial,Yes,"Liver function monitoring, dose adjustment",72,51,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,7.5,Monthly,52,101,34-85,Female only,0-3,Cytokine Release Syndrome,Immunological,Severe,2,3.85,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",49,10,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,10,Every 3 weeks,500,318,42-70,Female only,0-2,Severe Neutropenia,Hematological,Severe,19,3.8,Yes,Yes,"G-CSF, antibiotics, dose reduction",89,35,Yes,No,Yes
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,7.5,Weekly,343,346,44-71,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,13,3.79,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",31,20,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,15,Every 3 weeks,480,51,42-85,All,1-2,Severe Thrombocytopenia,Hematological,Severe,18,3.75,Yes,Yes,"Platelet transfusion, dose adjustment",52,13,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,7.5,Weekly,268,181,24-72,Male only,1-2,Anaphylaxis,Immunological,Severe,10,3.73,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",43,22,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,5,Monthly,487,117,51-74,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,18,3.7,Yes,Yes,"Platelet transfusion, dose adjustment",45,2,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,15,Weekly,386,137,34-75,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,14,3.63,Partial,Yes,"Liver function monitoring, dose adjustment",76,11,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,15,Every 3 weeks,444,146,35-80,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,16,3.6,Partial,Yes,"Liver function monitoring, dose adjustment",34,28,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,15,Every 3 weeks,444,146,35-80,Male only,0-2,Severe Neuropathy,Neurological,Severe,16,3.6,Partial,Yes,"Dose reduction, pain management",15,7,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,15,Every 3 weeks,392,363,24-67,Female only,0-3,Severe Colitis,Gastrointestinal,Severe,14,3.57,Yes,Yes,"Corticosteroids, infliximab",38,13,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,7.5,Monthly,224,61,24-81,Female only,0-1,Severe Neutropenia,Hematological,Severe,8,3.57,Yes,Yes,"G-CSF, antibiotics, dose reduction",42,13,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,7.5,Monthly,224,61,24-81,Female only,0-1,Anaphylaxis,Immunological,Severe,8,3.57,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",12,59,No,No,Yes
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,10,Monthly,450,145,55-75,All,0-3,Severe Pneumonitis,Respiratory,Severe,16,3.56,Partial,Yes,"Corticosteroids, oxygen therapy",53,34,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,7.5,Every 3 weeks,197,116,32-82,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,7,3.55,Partial,Yes,"Corticosteroids, oxygen therapy",22,41,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,15,Monthly,423,40,33-68,All,0-2,Severe Thrombocytopenia,Hematological,Severe,15,3.55,Yes,Yes,"Platelet transfusion, dose adjustment",68,37,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,15,Every 3 weeks,480,51,42-85,All,1-2,Severe Colitis,Gastrointestinal,Severe,17,3.54,Yes,Yes,"Corticosteroids, infliximab",30,45,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,5,Weekly,453,336,36-75,Male only,1-2,Severe Thrombocytopenia,Hematological,Severe,16,3.53,Yes,Yes,"Platelet transfusion, dose adjustment",19,27,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,7.5,Weekly,343,346,44-71,Female only,0-1,Severe Neutropenia,Hematological,Severe,12,3.5,Yes,Yes,"G-CSF, antibiotics, dose reduction",47,11,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,15,Every 3 weeks,490,35,38-65,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,17,3.47,Partial,Yes,"Liver function monitoring, dose adjustment",36,27,Yes,Yes,Yes
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,7.5,Bi-weekly,206,281,60-71,Female only,1-2,Severe Pneumonitis,Respiratory,Severe,7,3.4,Partial,Yes,"Corticosteroids, oxygen therapy",86,17,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,10,Weekly,236,244,40-82,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,8,3.39,Yes,Yes,"Corticosteroids, infliximab",9,21,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,15,Monthly,150,92,61-81,Male only,0-3,Severe Myocarditis,Cardiovascular,Severe,5,3.33,Partial,Yes,"Corticosteroids, cardiac support",48,36,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,10,Monthly,450,145,55-75,All,0-3,Severe Pneumonitis,Respiratory,Severe,15,3.33,Partial,Yes,"Corticosteroids, oxygen therapy",34,24,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,7.5,Weekly,475,194,32-81,All,0-3,Anaphylaxis,Immunological,Severe,15,3.16,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",70,42,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,5,Bi-weekly,348,149,50-81,Female only,0-2,Severe Myocarditis,Cardiovascular,Severe,11,3.16,Partial,Yes,"Corticosteroids, cardiac support",86,4,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,15,Weekly,386,137,34-75,Male only,0-1,Severe Neutropenia,Hematological,Severe,12,3.11,Yes,Yes,"G-CSF, antibiotics, dose reduction",13,28,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,15,Weekly,386,137,34-75,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,12,3.11,Partial,Yes,"Liver function monitoring, dose adjustment",11,33,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,5,Monthly,452,128,64-71,All,0-3,Severe Neuropathy,Neurological,Severe,14,3.1,Partial,Yes,"Dose reduction, pain management",52,54,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,10,Every 3 weeks,356,143,56-75,Male only,0-1,Anaphylaxis,Immunological,Severe,11,3.09,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",88,4,Yes,No,Yes
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,15,Every 3 weeks,392,363,24-67,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,12,3.06,Partial,Yes,"Corticosteroids, oxygen therapy",83,24,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,15,Every 3 weeks,332,305,53-78,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,10,3.01,Yes,Yes,"Platelet transfusion, dose adjustment",41,52,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,7.5,Monthly,387,159,50-83,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,11,2.84,Partial,Yes,"Corticosteroids, oxygen therapy",15,36,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,7.5,Monthly,387,159,50-83,Male only,0-3,Severe Neuropathy,Neurological,Severe,11,2.84,Partial,Yes,"Dose reduction, pain management",42,56,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,15,Every 3 weeks,287,106,50-79,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,8,2.79,Partial,Yes,"Corticosteroids, cardiac support",68,49,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,5,Every 3 weeks,215,35,64-76,All,1-2,Anaphylaxis,Immunological,Severe,6,2.79,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",50,32,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,15,Monthly,184,118,34-74,Female only,0-3,Severe Myocarditis,Cardiovascular,Severe,5,2.72,Partial,Yes,"Corticosteroids, cardiac support",69,57,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,5,Weekly,37,336,19-82,Female only,0-3,Severe Thrombocytopenia,Hematological,Severe,1,2.7,Yes,Yes,"Platelet transfusion, dose adjustment",83,31,No,Yes,Yes
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,5,Monthly,112,70,32-74,All,0-3,Severe Neutropenia,Hematological,Severe,3,2.68,Yes,Yes,"G-CSF, antibiotics, dose reduction",51,58,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,10,Monthly,228,176,36-68,Male only,0-2,Severe Neutropenia,Hematological,Severe,6,2.63,Yes,Yes,"G-CSF, antibiotics, dose reduction",31,33,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,7.5,Weekly,498,332,50-76,All,1-2,Severe Colitis,Gastrointestinal,Severe,13,2.61,Yes,Yes,"Corticosteroids, infliximab",71,52,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,15,Weekly,307,199,60-71,Female only,0-3,Anaphylaxis,Immunological,Severe,8,2.61,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",66,54,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,5,Bi-weekly,499,95,35-76,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,13,2.61,Partial,Yes,"Liver function monitoring, dose adjustment",27,33,No,No,Yes
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,10,Every 3 weeks,500,318,42-70,Female only,0-2,Cytokine Release Syndrome,Immunological,Severe,13,2.6,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",40,57,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,5,Monthly,308,34,45-68,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,8,2.6,Yes,Yes,"Corticosteroids, infliximab",80,39,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,15,Every 3 weeks,392,363,24-67,Female only,0-3,Severe Colitis,Gastrointestinal,Severe,10,2.55,Yes,Yes,"Corticosteroids, infliximab",47,21,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,7.5,Every 3 weeks,482,353,42-73,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,12,2.49,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",73,22,No,Yes,Yes
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,10,Weekly,371,316,46-85,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,9,2.43,Yes,Yes,"Corticosteroids, infliximab",64,49,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,5,Monthly,452,128,64-71,All,0-3,Severe Pneumonitis,Respiratory,Severe,11,2.43,Partial,Yes,"Corticosteroids, oxygen therapy",67,46,Yes,Yes,Yes
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,7.5,Weekly,498,332,50-76,All,1-2,Anaphylaxis,Immunological,Severe,12,2.41,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",3,11,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,7.5,Weekly,128,33,45-75,Male only,0-3,Severe Neutropenia,Hematological,Severe,3,2.34,Yes,Yes,"G-CSF, antibiotics, dose reduction",25,22,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,5,Every 3 weeks,43,87,55-79,All,1-2,Severe Thrombocytopenia,Hematological,Severe,1,2.33,Yes,Yes,"Platelet transfusion, dose adjustment",31,45,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,7.5,Every 3 weeks,475,267,63-67,Female only,1-2,Severe Pneumonitis,Respiratory,Severe,11,2.32,Partial,Yes,"Corticosteroids, oxygen therapy",18,9,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,10,Monthly,260,363,64-83,All,0-2,Anaphylaxis,Immunological,Severe,6,2.31,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",63,11,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,7.5,Every 3 weeks,482,353,42-73,Female only,0-3,Severe Colitis,Gastrointestinal,Severe,11,2.28,Yes,Yes,"Corticosteroids, infliximab",27,16,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,5,Monthly,487,117,51-74,Male only,0-2,Severe Neutropenia,Hematological,Severe,11,2.26,Yes,Yes,"G-CSF, antibiotics, dose reduction",78,33,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,15,Every 3 weeks,444,146,35-80,Male only,0-2,Cytokine Release Syndrome,Immunological,Severe,10,2.25,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",85,17,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,5,Monthly,45,75,32-84,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,1,2.22,Partial,Yes,"Liver function monitoring, dose adjustment",22,45,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,10,Bi-weekly,136,294,32-75,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,3,2.21,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",52,51,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,10,Monthly,94,38,33-66,Male only,0-1,Cardiac Toxicity,Cardiovascular,Severe,2,2.13,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",6,38,Yes,No,Yes
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,7.5,Weekly,475,194,32-81,All,0-3,Severe Neutropenia,Hematological,Severe,10,2.11,Yes,Yes,"G-CSF, antibiotics, dose reduction",21,12,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,7.5,Weekly,430,261,42-65,All,0-3,Cardiac Toxicity,Cardiovascular,Severe,9,2.09,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",11,12,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,10,Every 3 weeks,48,129,28-80,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,1,2.08,Partial,Yes,"Liver function monitoring, dose adjustment",29,25,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,7.5,Every 3 weeks,482,353,42-73,Female only,0-3,Severe Neuropathy,Neurological,Severe,10,2.07,Partial,Yes,"Dose reduction, pain management",31,54,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,5,Bi-weekly,499,95,35-76,Male only,0-2,Severe Neuropathy,Neurological,Severe,10,2.0,Partial,Yes,"Dose reduction, pain management",80,37,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,15,Bi-weekly,151,54,35-65,Female only,0-1,Severe Neutropenia,Hematological,Severe,3,1.99,Yes,Yes,"G-CSF, antibiotics, dose reduction",37,48,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,7.5,Monthly,352,204,21-85,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,7,1.99,Partial,Yes,"Corticosteroids, cardiac support",19,21,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,10,Weekly,407,230,35-84,All,1-2,Severe Thrombocytopenia,Hematological,Severe,8,1.97,Yes,Yes,"Platelet transfusion, dose adjustment",71,25,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,10,Bi-weekly,104,92,60-78,Female only,0-2,Severe Hepatotoxicity,Hepatic,Severe,2,1.92,Partial,Yes,"Liver function monitoring, dose adjustment",90,21,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,7.5,Monthly,52,101,34-85,Female only,0-3,Severe Thrombocytopenia,Hematological,Severe,1,1.92,Yes,Yes,"Platelet transfusion, dose adjustment",73,6,Yes,No,Yes
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,7.5,Monthly,52,101,34-85,Female only,0-3,Severe Thrombocytopenia,Hematological,Severe,1,1.92,Yes,Yes,"Platelet transfusion, dose adjustment",24,9,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,10,Monthly,260,363,64-83,All,0-2,Severe Thrombocytopenia,Hematological,Severe,5,1.92,Yes,Yes,"Platelet transfusion, dose adjustment",42,14,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,5,Every 3 weeks,215,35,64-76,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,4,1.86,Partial,Yes,"Liver function monitoring, dose adjustment",69,20,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,5,Every 3 weeks,215,35,64-76,All,1-2,Severe Colitis,Gastrointestinal,Severe,4,1.86,Yes,Yes,"Corticosteroids, infliximab",3,4,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,10,Bi-weekly,328,65,51-73,Male only,0-1,Anaphylaxis,Immunological,Severe,6,1.83,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",73,37,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,5,Monthly,452,128,64-71,All,0-3,Cytokine Release Syndrome,Immunological,Severe,8,1.77,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",72,11,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,15,Weekly,172,178,40-84,All,0-1,Severe Neutropenia,Hematological,Severe,3,1.74,Yes,Yes,"G-CSF, antibiotics, dose reduction",36,31,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,15,Monthly,232,57,42-79,Male only,0-1,Cytokine Release Syndrome,Immunological,Severe,4,1.72,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",14,9,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,10,Weekly,236,244,40-82,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,4,1.69,Yes,Yes,"Corticosteroids, infliximab",23,33,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,15,Every 3 weeks,480,51,42-85,All,1-2,Severe Pneumonitis,Respiratory,Severe,8,1.67,Partial,Yes,"Corticosteroids, oxygen therapy",13,36,Yes,No,Yes
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,7.5,Every 3 weeks,482,353,42-73,Female only,0-3,Severe Neuropathy,Neurological,Severe,8,1.66,Partial,Yes,"Dose reduction, pain management",33,15,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,10,Every 3 weeks,371,203,36-76,Female only,0-1,Severe Colitis,Gastrointestinal,Severe,6,1.62,Yes,Yes,"Corticosteroids, infliximab",63,45,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,10,Weekly,371,316,46-85,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,6,1.62,Partial,Yes,"Corticosteroids, cardiac support",6,2,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,7.5,Every 3 weeks,374,321,34-67,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,6,1.6,Yes,Yes,"Corticosteroids, infliximab",90,45,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,10,Bi-weekly,190,178,22-75,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,3,1.58,Partial,Yes,"Liver function monitoring, dose adjustment",25,11,No,Yes,Yes
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,7.5,Every 3 weeks,197,116,32-82,Male only,0-1,Cardiac Toxicity,Cardiovascular,Severe,3,1.52,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",58,16,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,10,Bi-weekly,328,65,51-73,Male only,0-1,Cardiac Toxicity,Cardiovascular,Severe,5,1.52,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",56,25,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,15,Every 3 weeks,332,305,53-78,Male only,0-3,Severe Myocarditis,Cardiovascular,Severe,5,1.51,Partial,Yes,"Corticosteroids, cardiac support",62,34,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,10,Weekly,407,230,35-84,All,1-2,Anaphylaxis,Immunological,Severe,6,1.47,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",57,33,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,5,Bi-weekly,415,178,33-73,Female only,1-2,Anaphylaxis,Immunological,Severe,6,1.45,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",7,35,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,5,Bi-weekly,348,149,50-81,Female only,0-2,Severe Thrombocytopenia,Hematological,Severe,5,1.44,Yes,Yes,"Platelet transfusion, dose adjustment",49,32,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,5,Monthly,487,117,51-74,Male only,0-2,Severe Neuropathy,Neurological,Severe,7,1.44,Partial,Yes,"Dose reduction, pain management",44,20,Yes,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,5,Monthly,351,219,61-83,Female only,0-2,Cardiac Toxicity,Cardiovascular,Severe,5,1.42,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",1,34,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,10,Every 3 weeks,356,143,56-75,Male only,0-1,Severe Neuropathy,Neurological,Severe,5,1.4,Partial,Yes,"Dose reduction, pain management",29,35,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,5,Bi-weekly,445,171,46-84,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,6,1.35,Partial,Yes,"Corticosteroids, oxygen therapy",29,28,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,15,Every 3 weeks,74,147,24-67,All,0-1,Severe Neuropathy,Neurological,Severe,1,1.35,Partial,Yes,"Dose reduction, pain management",68,9,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,15,Bi-weekly,150,178,40-67,Female only,0-1,Severe Thrombocytopenia,Hematological,Severe,2,1.33,Yes,Yes,"Platelet transfusion, dose adjustment",58,3,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,7.5,Bi-weekly,379,329,49-80,Male only,0-1,Anaphylaxis,Immunological,Severe,5,1.32,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",80,5,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,5,Every 3 weeks,473,269,19-73,All,1-2,Severe Neutropenia,Hematological,Severe,6,1.27,Yes,Yes,"G-CSF, antibiotics, dose reduction",81,32,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,7.5,Weekly,475,194,32-81,All,0-3,Severe Thrombocytopenia,Hematological,Severe,6,1.26,Yes,Yes,"Platelet transfusion, dose adjustment",65,21,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,10,Weekly,407,230,35-84,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,5,1.23,Partial,Yes,"Liver function monitoring, dose adjustment",60,29,Yes,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,7.5,Every 3 weeks,493,197,32-74,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,6,1.22,Partial,Yes,"Corticosteroids, oxygen therapy",20,58,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,7.5,Every 3 weeks,493,197,32-74,Female only,0-1,Anaphylaxis,Immunological,Severe,6,1.22,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",1,39,No,No,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,5,Monthly,344,283,51-81,All,0-3,Severe Pneumonitis,Respiratory,Severe,4,1.16,Partial,Yes,"Corticosteroids, oxygen therapy",36,40,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,5,Weekly,261,331,19-72,All,0-1,Severe Neutropenia,Hematological,Severe,3,1.15,Yes,Yes,"G-CSF, antibiotics, dose reduction",63,18,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,5,Monthly,88,39,25-76,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,1,1.14,Partial,Yes,"Corticosteroids, cardiac support",89,14,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,15,Monthly,184,118,34-74,Female only,0-3,Severe Hepatotoxicity,Hepatic,Severe,2,1.09,Partial,Yes,"Liver function monitoring, dose adjustment",54,18,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,15,Every 3 weeks,372,303,28-74,Male only,0-3,Severe Colitis,Gastrointestinal,Severe,4,1.08,Yes,Yes,"Corticosteroids, infliximab",3,12,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,10,Weekly,473,225,34-68,Female only,0-3,Severe Neuropathy,Neurological,Severe,5,1.06,Partial,Yes,"Dose reduction, pain management",38,10,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,15,Every 3 weeks,287,106,50-79,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,3,1.05,Partial,Yes,"Corticosteroids, cardiac support",32,18,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,5,Bi-weekly,388,258,40-70,All,0-1,Severe Neuropathy,Neurological,Severe,4,1.03,Partial,Yes,"Dose reduction, pain management",14,55,No,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,7.5,Every 3 weeks,493,197,32-74,Female only,0-1,Severe Neuropathy,Neurological,Severe,5,1.01,Partial,Yes,"Dose reduction, pain management",12,16,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,5,Weekly,453,336,36-75,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,4,0.88,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",16,49,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,5,Monthly,351,219,61-83,Female only,0-2,Cytokine Release Syndrome,Immunological,Severe,3,0.85,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",49,33,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,10,Every 3 weeks,500,318,42-70,Female only,0-2,Cardiac Toxicity,Cardiovascular,Severe,4,0.8,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",49,15,No,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,10,Every 3 weeks,500,318,42-70,Female only,0-2,Severe Thrombocytopenia,Hematological,Severe,4,0.8,Yes,Yes,"Platelet transfusion, dose adjustment",54,5,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,7.5,Weekly,498,332,50-76,All,1-2,Severe Neuropathy,Neurological,Severe,4,0.8,Partial,Yes,"Dose reduction, pain management",20,37,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,7.5,Bi-weekly,253,264,45-75,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,2,0.79,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",74,30,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,7.5,Monthly,387,159,50-83,Male only,0-3,Anaphylaxis,Immunological,Severe,3,0.78,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",37,7,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,10,Bi-weekly,136,294,32-75,Female only,0-3,Severe Neutropenia,Hematological,Severe,1,0.74,Yes,Yes,"G-CSF, antibiotics, dose reduction",33,30,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,15,Every 3 weeks,444,146,35-80,Male only,0-2,Severe Neuropathy,Neurological,Severe,3,0.68,Partial,Yes,"Dose reduction, pain management",21,9,No,No,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,5,Bi-weekly,445,171,46-84,Male only,0-3,Anaphylaxis,Immunological,Severe,3,0.67,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",80,47,Yes,Yes,No
Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,15,Bi-weekly,150,178,40-67,Female only,0-1,Severe Neuropathy,Neurological,Severe,1,0.67,Partial,Yes,"Dose reduction, pain management",29,31,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,15,Bi-weekly,151,54,35-65,Female only,0-1,Severe Colitis,Gastrointestinal,Severe,1,0.66,Yes,Yes,"Corticosteroids, infliximab",74,33,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,7.5,Every 3 weeks,374,321,34-67,Male only,1-2,Cytokine Release Syndrome,Immunological,Severe,2,0.53,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",62,12,No,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,15,Monthly,232,57,42-79,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,1,0.43,Partial,Yes,"Corticosteroids, cardiac support",71,41,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,7.5,Every 3 weeks,499,217,61-71,All,0-1,Anaphylaxis,Immunological,Severe,2,0.4,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",67,34,Yes,Yes,No
Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,10,Monthly,257,240,24-85,Female only,0-1,Severe Thrombocytopenia,Hematological,Severe,1,0.39,Yes,Yes,"Platelet transfusion, dose adjustment",35,31,Yes,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,10,Every 3 weeks,371,203,36-76,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,1,0.27,Partial,Yes,"Corticosteroids, oxygen therapy",85,49,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,7.5,Bi-weekly,379,329,49-80,Male only,0-1,Severe Neutropenia,Hematological,Severe,1,0.26,Yes,Yes,"G-CSF, antibiotics, dose reduction",58,2,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,15,Bi-weekly,420,350,22-68,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,1,0.24,Partial,Yes,"Liver function monitoring, dose adjustment",53,5,No,No,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,15,Bi-weekly,420,350,22-68,All,1-2,Severe Neutropenia,Hematological,Severe,1,0.24,Yes,Yes,"G-CSF, antibiotics, dose reduction",6,8,Yes,Yes,No
Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,7.5,Weekly,498,332,50-76,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,1,0.2,Partial,Yes,"Liver function monitoring, dose adjustment",56,28,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,250,Every 3 weeks,60,270,42-71,All,1-2,Severe Myocarditis,Cardiovascular,Severe,6,10.0,Partial,Yes,"Corticosteroids, cardiac support",4,5,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,500,Weekly,182,365,61-83,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,17,9.34,Partial,Yes,"Corticosteroids, oxygen therapy",29,46,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,250,Bi-weekly,227,258,26-74,Male only,0-2,Anaphylaxis,Immunological,Severe,20,8.81,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",15,36,Yes,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,500,Weekly,182,365,61-83,Female only,0-3,Severe Colitis,Gastrointestinal,Severe,16,8.79,Yes,Yes,"Corticosteroids, infliximab",29,39,Yes,Yes,Yes
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,250,Every 3 weeks,46,234,50-76,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,4,8.7,Yes,Yes,"Corticosteroids, infliximab",64,33,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,250,Every 3 weeks,46,234,50-76,Male only,1-2,Severe Neuropathy,Neurological,Severe,4,8.7,Partial,Yes,"Dose reduction, pain management",37,28,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,250,Monthly,221,140,20-69,Male only,0-2,Cytokine Release Syndrome,Immunological,Severe,19,8.6,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",3,9,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,250,Monthly,187,257,55-76,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,16,8.56,Partial,Yes,"Corticosteroids, oxygen therapy",5,24,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,250,Monthly,187,257,55-76,Male only,1-2,Anaphylaxis,Immunological,Severe,16,8.56,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",34,41,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,400,Bi-weekly,59,345,27-83,All,1-2,Severe Neutropenia,Hematological,Severe,5,8.47,Yes,Yes,"G-CSF, antibiotics, dose reduction",5,30,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,250,Bi-weekly,227,258,26-74,Male only,0-2,Severe Neutropenia,Hematological,Severe,18,7.93,Yes,Yes,"G-CSF, antibiotics, dose reduction",32,43,Yes,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,400,Monthly,26,209,36-75,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,2,7.69,Partial,Yes,"Liver function monitoring, dose adjustment",71,42,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,250,Every 3 weeks,96,229,37-71,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,7,7.29,Partial,Yes,"Liver function monitoring, dose adjustment",36,7,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,400,Weekly,275,330,49-71,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,20,7.27,Partial,Yes,"Corticosteroids, oxygen therapy",52,27,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,250,Monthly,111,175,41-66,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,8,7.21,Partial,Yes,"Liver function monitoring, dose adjustment",87,30,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,400,Every 3 weeks,208,201,26-75,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,15,7.21,Yes,Yes,"Corticosteroids, infliximab",9,25,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,400,Bi-weekly,59,345,27-83,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,4,6.78,Partial,Yes,"Liver function monitoring, dose adjustment",7,18,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,250,Monthly,303,208,24-66,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,20,6.6,Yes,Yes,"Corticosteroids, infliximab",13,2,No,No,Yes
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,250,Every 3 weeks,46,234,50-76,Male only,1-2,Severe Neuropathy,Neurological,Severe,3,6.52,Partial,Yes,"Dose reduction, pain management",49,18,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,250,Every 3 weeks,46,234,50-76,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,3,6.52,Partial,Yes,"Liver function monitoring, dose adjustment",14,10,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,400,Every 3 weeks,185,73,20-73,Male only,0-2,Severe Neuropathy,Neurological,Severe,12,6.49,Partial,Yes,"Dose reduction, pain management",72,16,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,250,Monthly,221,140,20-69,Male only,0-2,Severe Neuropathy,Neurological,Severe,14,6.33,Partial,Yes,"Dose reduction, pain management",63,27,No,Yes,Yes
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,500,Weekly,182,365,61-83,Female only,0-3,Cytokine Release Syndrome,Immunological,Severe,11,6.04,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",15,58,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,500,Monthly,268,266,18-85,All,0-1,Severe Colitis,Gastrointestinal,Severe,16,5.97,Yes,Yes,"Corticosteroids, infliximab",22,26,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,400,Every 3 weeks,185,73,20-73,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,11,5.95,Partial,Yes,"Liver function monitoring, dose adjustment",23,60,Yes,Yes,Yes
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,250,Every 3 weeks,287,359,54-76,All,1-2,Anaphylaxis,Immunological,Severe,17,5.92,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",71,50,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,400,Every 3 weeks,343,69,20-69,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,20,5.83,Partial,Yes,"Corticosteroids, cardiac support",42,28,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,500,Weekly,122,293,56-72,Female only,1-2,Severe Neutropenia,Hematological,Severe,7,5.74,Yes,Yes,"G-CSF, antibiotics, dose reduction",18,47,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,400,Weekly,227,143,50-73,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,13,5.73,Partial,Yes,"Liver function monitoring, dose adjustment",64,38,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,250,Bi-weekly,321,255,48-80,All,0-1,Severe Colitis,Gastrointestinal,Severe,18,5.61,Yes,Yes,"Corticosteroids, infliximab",30,10,Yes,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,500,Monthly,268,266,18-85,All,0-1,Anaphylaxis,Immunological,Severe,15,5.6,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",56,35,Yes,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,400,Bi-weekly,73,51,57-66,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,4,5.48,Partial,Yes,"Corticosteroids, oxygen therapy",40,15,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,400,Bi-weekly,331,293,46-84,All,0-2,Severe Thrombocytopenia,Hematological,Severe,18,5.44,Yes,Yes,"Platelet transfusion, dose adjustment",29,22,Yes,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,500,Every 3 weeks,325,343,41-73,Male only,0-2,Severe Neuropathy,Neurological,Severe,17,5.23,Partial,Yes,"Dose reduction, pain management",90,37,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,500,Weekly,325,277,18-68,All,0-3,Severe Pneumonitis,Respiratory,Severe,17,5.23,Partial,Yes,"Corticosteroids, oxygen therapy",77,41,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,500,Every 3 weeks,353,194,21-70,Female only,0-3,Severe Thrombocytopenia,Hematological,Severe,18,5.1,Yes,Yes,"Platelet transfusion, dose adjustment",66,17,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,500,Every 3 weeks,353,194,21-70,Female only,0-3,Severe Thrombocytopenia,Hematological,Severe,17,4.82,Yes,Yes,"Platelet transfusion, dose adjustment",40,37,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,500,Every 3 weeks,325,343,41-73,Male only,0-2,Cardiac Toxicity,Cardiovascular,Severe,15,4.62,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",41,43,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,400,Bi-weekly,304,167,34-72,All,0-3,Severe Neutropenia,Hematological,Severe,14,4.61,Yes,Yes,"G-CSF, antibiotics, dose reduction",78,18,Yes,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,250,Weekly,328,106,59-76,All,1-2,Severe Thrombocytopenia,Hematological,Severe,15,4.57,Yes,Yes,"Platelet transfusion, dose adjustment",77,36,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,250,Weekly,328,106,59-76,All,1-2,Anaphylaxis,Immunological,Severe,15,4.57,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",62,36,No,No,Yes
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,400,Bi-weekly,379,361,61-80,All,0-2,Anaphylaxis,Immunological,Severe,17,4.49,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",80,9,Yes,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,500,Monthly,268,266,18-85,All,0-1,Cytokine Release Syndrome,Immunological,Severe,12,4.48,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",73,10,Yes,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,250,Weekly,405,210,19-71,Male only,0-1,Anaphylaxis,Immunological,Severe,18,4.44,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",24,16,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,250,Bi-weekly,227,258,26-74,Male only,0-2,Cardiac Toxicity,Cardiovascular,Severe,10,4.41,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",87,6,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,400,Weekly,227,143,50-73,All,0-3,Cardiac Toxicity,Cardiovascular,Severe,10,4.41,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",78,39,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,400,Every 3 weeks,208,201,26-75,Male only,0-1,Severe Neutropenia,Hematological,Severe,9,4.33,Yes,Yes,"G-CSF, antibiotics, dose reduction",51,31,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,250,Every 3 weeks,335,31,65-73,All,0-1,Severe Thrombocytopenia,Hematological,Severe,14,4.18,Yes,Yes,"Platelet transfusion, dose adjustment",44,20,Yes,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,500,Monthly,410,212,28-75,Female only,0-2,Cytokine Release Syndrome,Immunological,Severe,17,4.15,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",40,8,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,400,Bi-weekly,73,51,57-66,Female only,0-1,Severe Colitis,Gastrointestinal,Severe,3,4.11,Yes,Yes,"Corticosteroids, infliximab",4,52,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,400,Bi-weekly,73,51,57-66,Female only,0-1,Cardiac Toxicity,Cardiovascular,Severe,3,4.11,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",58,54,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,500,Monthly,419,208,37-69,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,17,4.06,Partial,Yes,"Corticosteroids, cardiac support",5,8,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,400,Bi-weekly,379,361,61-80,All,0-2,Cytokine Release Syndrome,Immunological,Severe,15,3.96,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",18,26,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,250,Bi-weekly,227,258,26-74,Male only,0-2,Severe Neuropathy,Neurological,Severe,9,3.96,Partial,Yes,"Dose reduction, pain management",19,1,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,500,Monthly,101,171,52-70,Female only,0-2,Severe Thrombocytopenia,Hematological,Severe,4,3.96,Yes,Yes,"Platelet transfusion, dose adjustment",10,44,Yes,Yes,Yes
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,500,Monthly,360,193,42-66,All,0-2,Cytokine Release Syndrome,Immunological,Severe,14,3.89,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",43,55,Yes,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,400,Monthly,26,209,36-75,Male only,0-2,Severe Neuropathy,Neurological,Severe,1,3.85,Partial,Yes,"Dose reduction, pain management",21,8,Yes,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,400,Monthly,26,209,36-75,Male only,0-2,Severe Neuropathy,Neurological,Severe,1,3.85,Partial,Yes,"Dose reduction, pain management",23,49,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,400,Monthly,26,209,36-75,Male only,0-2,Severe Colitis,Gastrointestinal,Severe,1,3.85,Yes,Yes,"Corticosteroids, infliximab",30,51,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,500,Every 3 weeks,453,200,36-73,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,17,3.75,Partial,Yes,"Corticosteroids, oxygen therapy",23,59,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,250,Weekly,405,210,19-71,Male only,0-1,Severe Neuropathy,Neurological,Severe,15,3.7,Partial,Yes,"Dose reduction, pain management",84,21,Yes,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,400,Every 3 weeks,432,155,21-69,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,16,3.7,Partial,Yes,"Corticosteroids, oxygen therapy",68,12,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,250,Every 3 weeks,497,77,53-83,Male only,0-3,Severe Neutropenia,Hematological,Severe,18,3.62,Yes,Yes,"G-CSF, antibiotics, dose reduction",74,27,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,400,Bi-weekly,304,167,34-72,All,0-3,Severe Neuropathy,Neurological,Severe,11,3.62,Partial,Yes,"Dose reduction, pain management",71,6,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,250,Every 3 weeks,426,84,47-77,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,15,3.52,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",17,31,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,400,Weekly,227,143,50-73,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,8,3.52,Partial,Yes,"Liver function monitoring, dose adjustment",8,37,Yes,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,250,Weekly,405,210,19-71,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,14,3.46,Yes,Yes,"Platelet transfusion, dose adjustment",82,41,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,250,Bi-weekly,321,255,48-80,All,0-1,Cardiac Toxicity,Cardiovascular,Severe,11,3.43,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",15,44,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,500,Monthly,268,266,18-85,All,0-1,Cytokine Release Syndrome,Immunological,Severe,9,3.36,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",14,2,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,250,Every 3 weeks,60,270,42-71,All,1-2,Severe Pneumonitis,Respiratory,Severe,2,3.33,Partial,Yes,"Corticosteroids, oxygen therapy",35,40,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,400,Bi-weekly,331,293,46-84,All,0-2,Cardiac Toxicity,Cardiovascular,Severe,11,3.32,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",36,31,Yes,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,500,Weekly,302,85,20-83,Female only,0-1,Anaphylaxis,Immunological,Severe,10,3.31,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",64,30,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,500,Weekly,122,293,56-72,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,4,3.28,Yes,Yes,"Corticosteroids, infliximab",15,48,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,400,Every 3 weeks,343,69,20-69,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,11,3.21,Yes,Yes,"Platelet transfusion, dose adjustment",66,20,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,400,Weekly,470,154,18-83,Male only,1-2,Severe Thrombocytopenia,Hematological,Severe,15,3.19,Yes,Yes,"Platelet transfusion, dose adjustment",57,24,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,400,Weekly,227,143,50-73,All,0-3,Severe Colitis,Gastrointestinal,Severe,7,3.08,Yes,Yes,"Corticosteroids, infliximab",13,8,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,500,Weekly,325,277,18-68,All,0-3,Cytokine Release Syndrome,Immunological,Severe,10,3.08,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",42,24,Yes,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,250,Monthly,303,208,24-66,Male only,1-2,Severe Myocarditis,Cardiovascular,Severe,9,2.97,Partial,Yes,"Corticosteroids, cardiac support",4,50,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,500,Every 3 weeks,453,200,36-73,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,13,2.87,Yes,Yes,"Platelet transfusion, dose adjustment",59,16,Yes,Yes,Yes
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,250,Monthly,461,92,18-69,Male only,0-3,Severe Neuropathy,Neurological,Severe,13,2.82,Partial,Yes,"Dose reduction, pain management",43,29,Yes,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,400,Every 3 weeks,432,155,21-69,Female only,0-1,Severe Neutropenia,Hematological,Severe,12,2.78,Yes,Yes,"G-CSF, antibiotics, dose reduction",76,15,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,500,Weekly,325,277,18-68,All,0-3,Severe Pneumonitis,Respiratory,Severe,9,2.77,Partial,Yes,"Corticosteroids, oxygen therapy",44,49,Yes,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,250,Every 3 weeks,335,31,65-73,All,0-1,Severe Colitis,Gastrointestinal,Severe,9,2.69,Yes,Yes,"Corticosteroids, infliximab",52,44,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,250,Monthly,187,257,55-76,Male only,1-2,Anaphylaxis,Immunological,Severe,5,2.67,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",18,35,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,500,Every 3 weeks,453,200,36-73,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,12,2.65,Yes,Yes,"Platelet transfusion, dose adjustment",28,38,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,400,Every 3 weeks,208,201,26-75,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,5,2.4,Yes,Yes,"Platelet transfusion, dose adjustment",3,42,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,500,Monthly,419,208,37-69,Male only,0-2,Severe Neutropenia,Hematological,Severe,10,2.39,Yes,Yes,"G-CSF, antibiotics, dose reduction",59,7,Yes,Yes,Yes
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,400,Weekly,275,330,49-71,Female only,0-3,Severe Neuropathy,Neurological,Severe,6,2.18,Partial,Yes,"Dose reduction, pain management",74,16,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,400,Weekly,275,330,49-71,Female only,0-3,Severe Myocarditis,Cardiovascular,Severe,6,2.18,Partial,Yes,"Corticosteroids, cardiac support",30,2,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,400,Every 3 weeks,185,73,20-73,Male only,0-2,Cytokine Release Syndrome,Immunological,Severe,4,2.16,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",30,36,Yes,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,400,Every 3 weeks,343,69,20-69,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,7,2.04,Yes,Yes,"Corticosteroids, infliximab",46,3,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,400,Bi-weekly,304,167,34-72,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,6,1.97,Partial,Yes,"Liver function monitoring, dose adjustment",61,49,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,250,Bi-weekly,321,255,48-80,All,0-1,Severe Neutropenia,Hematological,Severe,6,1.87,Yes,Yes,"G-CSF, antibiotics, dose reduction",53,2,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,400,Bi-weekly,331,293,46-84,All,0-2,Severe Colitis,Gastrointestinal,Severe,6,1.81,Yes,Yes,"Corticosteroids, infliximab",61,41,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,400,Bi-weekly,59,345,27-83,All,1-2,Cytokine Release Syndrome,Immunological,Severe,1,1.69,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",13,48,No,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,500,Weekly,484,350,33-82,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,8,1.65,Partial,Yes,"Liver function monitoring, dose adjustment",70,52,Yes,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,400,Bi-weekly,379,361,61-80,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,6,1.58,Partial,Yes,"Liver function monitoring, dose adjustment",19,53,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,500,Weekly,325,277,18-68,All,0-3,Severe Neuropathy,Neurological,Severe,5,1.54,Partial,Yes,"Dose reduction, pain management",28,50,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 3,400,Weekly,275,330,49-71,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,4,1.45,Partial,Yes,"Corticosteroids, oxygen therapy",81,30,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,500,Monthly,419,208,37-69,Male only,0-2,Severe Colitis,Gastrointestinal,Severe,6,1.43,Yes,Yes,"Corticosteroids, infliximab",47,41,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,500,Monthly,419,208,37-69,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,6,1.43,Partial,Yes,"Liver function monitoring, dose adjustment",53,45,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,250,Monthly,303,208,24-66,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,4,1.32,Partial,Yes,"Liver function monitoring, dose adjustment",51,30,No,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,400,Bi-weekly,304,167,34-72,All,0-3,Cytokine Release Syndrome,Immunological,Severe,4,1.32,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",76,5,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,500,Bi-weekly,461,326,58-65,All,0-3,Severe Neuropathy,Neurological,Severe,5,1.08,Partial,Yes,"Dose reduction, pain management",27,2,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,400,Bi-weekly,379,361,61-80,All,0-2,Anaphylaxis,Immunological,Severe,4,1.06,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",67,2,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,250,Every 3 weeks,287,359,54-76,All,1-2,Severe Colitis,Gastrointestinal,Severe,3,1.05,Yes,Yes,"Corticosteroids, infliximab",20,39,Yes,No,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,500,Weekly,484,350,33-82,All,0-3,Severe Thrombocytopenia,Hematological,Severe,5,1.03,Yes,Yes,"Platelet transfusion, dose adjustment",33,32,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,400,Every 3 weeks,208,201,26-75,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,2,0.96,Yes,Yes,"Corticosteroids, infliximab",18,58,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,250,Bi-weekly,321,255,48-80,All,0-1,Severe Neuropathy,Neurological,Severe,3,0.93,Partial,Yes,"Dose reduction, pain management",5,55,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,250,Every 3 weeks,335,31,65-73,All,0-1,Severe Neutropenia,Hematological,Severe,3,0.9,Yes,Yes,"G-CSF, antibiotics, dose reduction",7,34,Yes,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,500,Monthly,376,32,29-83,All,0-1,Cardiac Toxicity,Cardiovascular,Severe,3,0.8,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",33,5,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 2,500,Weekly,302,85,20-83,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,2,0.66,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",61,50,Yes,Yes,Yes
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 1,400,Bi-weekly,331,293,46-84,All,0-2,Cytokine Release Syndrome,Immunological,Severe,2,0.6,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",55,6,Yes,Yes,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 3,250,Monthly,187,257,55-76,Male only,1-2,Severe Thrombocytopenia,Hematological,Severe,1,0.53,Yes,Yes,"Platelet transfusion, dose adjustment",86,43,No,No,Yes
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,500,Monthly,410,212,28-75,Female only,0-2,Severe Thrombocytopenia,Hematological,Severe,2,0.49,Yes,Yes,"Platelet transfusion, dose adjustment",32,14,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,250,Every 3 weeks,335,31,65-73,All,0-1,Cytokine Release Syndrome,Immunological,Severe,1,0.3,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",84,33,No,Yes,No
Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,500,Monthly,410,212,28-75,Female only,0-2,Severe Myocarditis,Cardiovascular,Severe,1,0.24,Partial,Yes,"Corticosteroids, cardiac support",44,7,No,No,No
Cetuximab,Anti-EGFR,Head and Neck Cancer,Phase 2,500,Every 3 weeks,453,200,36-73,Male only,0-2,Severe Colitis,Gastrointestinal,Severe,1,0.22,Yes,Yes,"Corticosteroids, infliximab",66,44,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,8,Every 3 weeks,130,85,40-65,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,13,10.0,Partial,Yes,"Corticosteroids, oxygen therapy",9,52,No,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,8,Every 3 weeks,130,85,40-65,Male only,0-2,Severe Neuropathy,Neurological,Severe,12,9.23,Partial,Yes,"Dose reduction, pain management",88,24,No,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,16,Monthly,132,362,32-84,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,12,9.09,Partial,Yes,"Liver function monitoring, dose adjustment",78,37,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,1800,Bi-weekly,100,191,39-67,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,9,9.0,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",4,17,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,16,Bi-weekly,233,204,31-80,All,0-1,Severe Colitis,Gastrointestinal,Severe,20,8.58,Yes,Yes,"Corticosteroids, infliximab",72,36,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,8,Bi-weekly,71,53,48-70,Male only,0-2,Cytokine Release Syndrome,Immunological,Severe,6,8.45,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",63,54,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,1800,Weekly,214,84,25-77,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,18,8.41,Partial,Yes,"Liver function monitoring, dose adjustment",75,27,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,8,Bi-weekly,135,176,38-72,All,1-2,Severe Pneumonitis,Respiratory,Severe,11,8.15,Partial,Yes,"Corticosteroids, oxygen therapy",36,20,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,16,Monthly,112,36,48-70,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,9,8.04,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",43,54,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,16,Monthly,112,36,48-70,Male only,1-2,Severe Neuropathy,Neurological,Severe,9,8.04,Partial,Yes,"Dose reduction, pain management",24,22,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,16,Bi-weekly,233,204,31-80,All,0-1,Severe Thrombocytopenia,Hematological,Severe,18,7.73,Yes,Yes,"Platelet transfusion, dose adjustment",39,35,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,8,Bi-weekly,135,176,38-72,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,10,7.41,Partial,Yes,"Liver function monitoring, dose adjustment",52,47,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,16,Monthly,112,36,48-70,Male only,1-2,Anaphylaxis,Immunological,Severe,8,7.14,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",33,41,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,8,Every 3 weeks,157,107,46-67,Female only,1-2,Cytokine Release Syndrome,Immunological,Severe,11,7.01,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",36,49,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,1800,Bi-weekly,100,191,39-67,Female only,0-1,Anaphylaxis,Immunological,Severe,7,7.0,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",73,53,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,16,Monthly,229,300,36-67,Male only,0-3,Severe Myocarditis,Cardiovascular,Severe,16,6.99,Partial,Yes,"Corticosteroids, cardiac support",29,8,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,16,Weekly,288,304,56-68,All,1-2,Severe Neutropenia,Hematological,Severe,20,6.94,Yes,Yes,"G-CSF, antibiotics, dose reduction",4,29,No,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,1800,Monthly,103,90,24-78,All,1-2,Severe Pneumonitis,Respiratory,Severe,7,6.8,Partial,Yes,"Corticosteroids, oxygen therapy",46,41,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,16,Bi-weekly,255,332,36-71,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,17,6.67,Partial,Yes,"Liver function monitoring, dose adjustment",49,11,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,16,Weekly,288,304,56-68,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,19,6.6,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",27,43,No,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,16,Monthly,112,36,48-70,Male only,1-2,Severe Myocarditis,Cardiovascular,Severe,7,6.25,Partial,Yes,"Corticosteroids, cardiac support",51,27,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,8,Bi-weekly,135,176,38-72,All,1-2,Severe Neutropenia,Hematological,Severe,8,5.93,Yes,Yes,"G-CSF, antibiotics, dose reduction",11,21,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,16,Monthly,132,362,32-84,Male only,0-2,Anaphylaxis,Immunological,Severe,7,5.3,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",21,11,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,16,Monthly,229,300,36-67,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,12,5.24,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",66,9,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,16,Weekly,288,304,56-68,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,14,4.86,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",56,53,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,16,Bi-weekly,233,204,31-80,All,0-1,Severe Neutropenia,Hematological,Severe,11,4.72,Yes,Yes,"G-CSF, antibiotics, dose reduction",89,6,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,16,Bi-weekly,255,332,36-71,All,0-3,Cytokine Release Syndrome,Immunological,Severe,12,4.71,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",29,4,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,8,Every 3 weeks,130,85,40-65,Male only,0-2,Severe Colitis,Gastrointestinal,Severe,6,4.62,Yes,Yes,"Corticosteroids, infliximab",64,45,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,16,Every 3 weeks,350,43,38-71,All,0-1,Severe Colitis,Gastrointestinal,Severe,14,4.0,Yes,Yes,"Corticosteroids, infliximab",75,54,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,1800,Bi-weekly,100,191,39-67,Female only,0-1,Severe Thrombocytopenia,Hematological,Severe,4,4.0,Yes,Yes,"Platelet transfusion, dose adjustment",18,4,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,1800,Weekly,459,235,22-84,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,18,3.92,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",20,16,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,8,Every 3 weeks,334,180,50-65,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,13,3.89,Partial,Yes,"Corticosteroids, oxygen therapy",43,55,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,1800,Monthly,103,90,24-78,All,1-2,Anaphylaxis,Immunological,Severe,4,3.88,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",90,42,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,8,Bi-weekly,495,60,42-72,Female only,0-2,Severe Hepatotoxicity,Hepatic,Severe,17,3.43,Partial,Yes,"Liver function monitoring, dose adjustment",83,18,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,16,Every 3 weeks,350,43,38-71,All,0-1,Severe Thrombocytopenia,Hematological,Severe,11,3.14,Yes,Yes,"Platelet transfusion, dose adjustment",32,38,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,16,Weekly,288,304,56-68,All,1-2,Severe Neuropathy,Neurological,Severe,9,3.12,Partial,Yes,"Dose reduction, pain management",18,9,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,16,Monthly,132,362,32-84,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,4,3.03,Yes,Yes,"Platelet transfusion, dose adjustment",77,10,No,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,1800,Bi-weekly,100,191,39-67,Female only,0-1,Severe Myocarditis,Cardiovascular,Severe,3,3.0,Partial,Yes,"Corticosteroids, cardiac support",20,14,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,8,Every 3 weeks,334,180,50-65,Male only,0-3,Severe Neutropenia,Hematological,Severe,10,2.99,Yes,Yes,"G-CSF, antibiotics, dose reduction",53,33,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,8,Every 3 weeks,334,180,50-65,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,10,2.99,Yes,Yes,"Platelet transfusion, dose adjustment",72,12,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,1800,Monthly,103,90,24-78,All,1-2,Severe Colitis,Gastrointestinal,Severe,3,2.91,Yes,Yes,"Corticosteroids, infliximab",46,1,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,1800,Weekly,174,99,65-70,All,0-3,Cardiac Toxicity,Cardiovascular,Severe,5,2.87,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",69,58,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,8,Bi-weekly,71,53,48-70,Male only,0-2,Severe Neutropenia,Hematological,Severe,2,2.82,Yes,Yes,"G-CSF, antibiotics, dose reduction",58,45,No,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,16,Bi-weekly,255,332,36-71,All,0-3,Severe Neuropathy,Neurological,Severe,7,2.75,Partial,Yes,"Dose reduction, pain management",49,25,No,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,16,Monthly,229,300,36-67,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,6,2.62,Partial,Yes,"Liver function monitoring, dose adjustment",82,58,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,1800,Weekly,459,235,22-84,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,12,2.61,Partial,Yes,"Corticosteroids, oxygen therapy",79,10,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,1800,Weekly,408,350,55-68,Female only,0-1,Severe Neuropathy,Neurological,Severe,10,2.45,Partial,Yes,"Dose reduction, pain management",26,53,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,8,Monthly,473,56,63-75,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,11,2.33,Partial,Yes,"Liver function monitoring, dose adjustment",13,13,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,1800,Weekly,174,99,65-70,All,0-3,Anaphylaxis,Immunological,Severe,4,2.3,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",45,4,Yes,No,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,16,Monthly,132,362,32-84,Male only,0-2,Anaphylaxis,Immunological,Severe,3,2.27,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",73,2,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,1800,Monthly,103,90,24-78,All,1-2,Severe Neutropenia,Hematological,Severe,2,1.94,Yes,Yes,"G-CSF, antibiotics, dose reduction",10,1,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,16,Every 3 weeks,350,43,38-71,All,0-1,Cytokine Release Syndrome,Immunological,Severe,5,1.43,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",79,55,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,16,Monthly,229,300,36-67,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,3,1.31,Partial,Yes,"Corticosteroids, oxygen therapy",62,15,No,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,1800,Bi-weekly,285,90,32-84,All,0-1,Severe Pneumonitis,Respiratory,Severe,3,1.05,Partial,Yes,"Corticosteroids, oxygen therapy",82,49,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,1800,Bi-weekly,285,90,32-84,All,0-1,Anaphylaxis,Immunological,Severe,2,0.7,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",33,52,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,8,Every 3 weeks,157,107,46-67,Female only,1-2,Severe Pneumonitis,Respiratory,Severe,1,0.64,Partial,Yes,"Corticosteroids, oxygen therapy",20,7,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,1800,Weekly,174,99,65-70,All,0-3,Severe Thrombocytopenia,Hematological,Severe,1,0.57,Yes,Yes,"Platelet transfusion, dose adjustment",83,45,Yes,Yes,No
Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,8,Every 3 weeks,334,180,50-65,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,1,0.3,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",66,46,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,1,Monthly,117,250,31-74,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,11,9.4,Partial,Yes,"Liver function monitoring, dose adjustment",19,9,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,1,Monthly,43,89,46-71,Female only,0-3,Severe Neuropathy,Neurological,Severe,4,9.3,Partial,Yes,"Dose reduction, pain management",62,42,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,10,Weekly,218,151,48-84,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,20,9.17,Partial,Yes,"Liver function monitoring, dose adjustment",65,38,Yes,No,Yes
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,3,Every 3 weeks,35,210,60-68,Female only,0-3,Cytokine Release Syndrome,Immunological,Severe,3,8.57,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",89,38,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,3,Every 3 weeks,35,210,60-68,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,3,8.57,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",1,29,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,3,Every 3 weeks,35,210,60-68,Female only,0-3,Severe Myocarditis,Cardiovascular,Severe,3,8.57,Partial,Yes,"Corticosteroids, cardiac support",26,60,No,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,10,Bi-weekly,72,43,62-76,All,0-2,Severe Neuropathy,Neurological,Severe,6,8.33,Partial,Yes,"Dose reduction, pain management",15,7,No,Yes,Yes
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,1,Every 3 weeks,74,280,28-84,All,0-2,Severe Neuropathy,Neurological,Severe,6,8.11,Partial,Yes,"Dose reduction, pain management",24,8,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,1,Monthly,100,110,48-77,All,0-2,Severe Myocarditis,Cardiovascular,Severe,8,8.0,Partial,Yes,"Corticosteroids, cardiac support",89,32,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,1,Monthly,117,250,31-74,Male only,0-1,Anaphylaxis,Immunological,Severe,9,7.69,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",5,9,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,1,Monthly,117,250,31-74,Male only,0-1,Severe Neutropenia,Hematological,Severe,9,7.69,Yes,Yes,"G-CSF, antibiotics, dose reduction",9,10,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,3,Every 3 weeks,117,287,61-83,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,9,7.69,Yes,Yes,"Platelet transfusion, dose adjustment",84,35,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,1,Bi-weekly,263,200,43-80,Male only,1-2,Severe Neutropenia,Hematological,Severe,19,7.22,Yes,Yes,"G-CSF, antibiotics, dose reduction",86,8,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,10,Monthly,253,80,29-85,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,18,7.11,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",20,54,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,1,Monthly,100,110,48-77,All,0-2,Severe Thrombocytopenia,Hematological,Severe,7,7.0,Yes,Yes,"Platelet transfusion, dose adjustment",8,58,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,3,Bi-weekly,209,140,49-81,All,0-2,Severe Thrombocytopenia,Hematological,Severe,14,6.7,Yes,Yes,"Platelet transfusion, dose adjustment",86,15,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,3,Bi-weekly,209,140,49-81,All,0-2,Severe Neuropathy,Neurological,Severe,14,6.7,Partial,Yes,"Dose reduction, pain management",22,57,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,1,Weekly,286,75,43-80,All,0-3,Severe Neutropenia,Hematological,Severe,18,6.29,Yes,Yes,"G-CSF, antibiotics, dose reduction",70,46,No,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,1,Monthly,100,110,48-77,All,0-2,Severe Neutropenia,Hematological,Severe,6,6.0,Yes,Yes,"G-CSF, antibiotics, dose reduction",20,20,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,3,Every 3 weeks,117,287,61-83,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,7,5.98,Partial,Yes,"Corticosteroids, oxygen therapy",62,20,No,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,3,Every 3 weeks,35,210,60-68,Female only,0-3,Severe Thrombocytopenia,Hematological,Severe,2,5.71,Yes,Yes,"Platelet transfusion, dose adjustment",13,17,No,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,3,Monthly,36,129,34-66,Female only,0-3,Severe Thrombocytopenia,Hematological,Severe,2,5.56,Yes,Yes,"Platelet transfusion, dose adjustment",6,24,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,10,Weekly,218,151,48-84,All,0-3,Cardiac Toxicity,Cardiovascular,Severe,12,5.5,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",37,12,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,10,Weekly,218,151,48-84,All,0-3,Cytokine Release Syndrome,Immunological,Severe,12,5.5,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",79,30,No,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,3,Every 3 weeks,356,214,38-65,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,18,5.06,Partial,Yes,"Corticosteroids, oxygen therapy",51,26,No,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,1,Monthly,100,110,48-77,All,0-2,Severe Myocarditis,Cardiovascular,Severe,5,5.0,Partial,Yes,"Corticosteroids, cardiac support",69,20,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,1,Every 3 weeks,362,89,33-69,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,18,4.97,Yes,Yes,"Platelet transfusion, dose adjustment",84,30,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,1,Monthly,43,89,46-71,Female only,0-3,Cytokine Release Syndrome,Immunological,Severe,2,4.65,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",53,12,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,10,Weekly,218,151,48-84,All,0-3,Severe Myocarditis,Cardiovascular,Severe,10,4.59,Partial,Yes,"Corticosteroids, cardiac support",86,43,No,Yes,Yes
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,10,Bi-weekly,394,242,27-69,Female only,0-2,Severe Neutropenia,Hematological,Severe,17,4.31,Yes,Yes,"G-CSF, antibiotics, dose reduction",29,8,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,1,Bi-weekly,263,200,43-80,Male only,1-2,Cytokine Release Syndrome,Immunological,Severe,11,4.18,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",42,11,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,10,Bi-weekly,72,43,62-76,All,0-2,Severe Neuropathy,Neurological,Severe,3,4.17,Partial,Yes,"Dose reduction, pain management",39,47,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,3,Weekly,492,258,42-65,Female only,0-1,Anaphylaxis,Immunological,Severe,20,4.07,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",65,43,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,3,Weekly,356,296,60-70,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,13,3.65,Yes,Yes,"Platelet transfusion, dose adjustment",17,60,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,1,Weekly,286,75,43-80,All,0-3,Severe Myocarditis,Cardiovascular,Severe,10,3.5,Partial,Yes,"Corticosteroids, cardiac support",26,1,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,10,Bi-weekly,394,242,27-69,Female only,0-2,Cytokine Release Syndrome,Immunological,Severe,12,3.05,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",68,56,No,Yes,Yes
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,1,Bi-weekly,263,200,43-80,Male only,1-2,Severe Myocarditis,Cardiovascular,Severe,8,3.04,Partial,Yes,"Corticosteroids, cardiac support",51,34,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,3,Weekly,492,258,42-65,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,14,2.85,Partial,Yes,"Liver function monitoring, dose adjustment",20,55,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,3,Weekly,356,296,60-70,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,10,2.81,Yes,Yes,"Platelet transfusion, dose adjustment",23,16,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,10,Bi-weekly,394,242,27-69,Female only,0-2,Severe Colitis,Gastrointestinal,Severe,11,2.79,Yes,Yes,"Corticosteroids, infliximab",17,21,No,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,3,Monthly,36,129,34-66,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,1,2.78,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",20,22,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,1,Every 3 weeks,74,280,28-84,All,0-2,Cardiac Toxicity,Cardiovascular,Severe,2,2.7,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",18,22,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,3,Weekly,492,258,42-65,Female only,0-1,Anaphylaxis,Immunological,Severe,13,2.64,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",1,12,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,10,Bi-weekly,364,166,43-65,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,9,2.47,Partial,Yes,"Corticosteroids, oxygen therapy",77,56,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,1,Bi-weekly,263,200,43-80,Male only,1-2,Cytokine Release Syndrome,Immunological,Severe,6,2.28,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",62,26,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,10,Bi-weekly,394,242,27-69,Female only,0-2,Anaphylaxis,Immunological,Severe,9,2.28,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",90,43,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,10,Monthly,253,80,29-85,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,5,1.98,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",85,14,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,1,Every 3 weeks,362,89,33-69,Male only,0-2,Cardiac Toxicity,Cardiovascular,Severe,7,1.93,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",77,18,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,3,Every 3 weeks,117,287,61-83,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,2,1.71,Yes,Yes,"Corticosteroids, infliximab",45,16,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,3,Every 3 weeks,117,287,61-83,Male only,0-1,Cytokine Release Syndrome,Immunological,Severe,2,1.71,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",10,21,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,3,Weekly,492,258,42-65,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,8,1.63,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",5,25,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,10,Monthly,425,197,59-70,Female only,0-3,Severe Thrombocytopenia,Hematological,Severe,6,1.41,Yes,Yes,"Platelet transfusion, dose adjustment",58,41,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,1,Every 3 weeks,74,280,28-84,All,0-2,Severe Colitis,Gastrointestinal,Severe,1,1.35,Yes,Yes,"Corticosteroids, infliximab",45,53,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,10,Bi-weekly,407,312,30-69,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,4,0.98,Partial,Yes,"Liver function monitoring, dose adjustment",36,21,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,10,Monthly,425,197,59-70,Female only,0-3,Cytokine Release Syndrome,Immunological,Severe,4,0.94,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",42,54,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,3,Every 3 weeks,356,214,38-65,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,3,0.84,Partial,Yes,"Corticosteroids, oxygen therapy",84,3,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,3,Every 3 weeks,356,214,38-65,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,3,0.84,Partial,Yes,"Corticosteroids, oxygen therapy",15,32,Yes,No,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,3,Every 3 weeks,294,324,36-83,Male only,1-2,Severe Neutropenia,Hematological,Severe,2,0.68,Yes,Yes,"G-CSF, antibiotics, dose reduction",64,1,No,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,3,Monthly,463,45,29-76,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,2,0.43,Partial,Yes,"Liver function monitoring, dose adjustment",53,56,Yes,Yes,No
Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,1,Weekly,286,75,43-80,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,1,0.35,Partial,Yes,"Liver function monitoring, dose adjustment",38,54,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,240,Every 3 weeks,151,361,41-65,All,0-2,Cytokine Release Syndrome,Immunological,Severe,15,9.93,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",21,12,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,240,Every 3 weeks,101,200,22-73,Male only,0-3,Severe Neutropenia,Hematological,Severe,10,9.9,Yes,Yes,"G-CSF, antibiotics, dose reduction",70,4,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,10,Every 3 weeks,157,225,43-85,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,15,9.55,Partial,Yes,"Corticosteroids, oxygen therapy",33,58,Yes,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,10,Every 3 weeks,42,147,55-78,Female only,0-2,Cytokine Release Syndrome,Immunological,Severe,4,9.52,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",49,37,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,10,Monthly,183,258,59-69,Female only,0-2,Severe Thrombocytopenia,Hematological,Severe,16,8.74,Yes,Yes,"Platelet transfusion, dose adjustment",16,15,Yes,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,3,Bi-weekly,117,351,54-79,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,10,8.55,Partial,Yes,"Corticosteroids, oxygen therapy",24,47,Yes,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,10,Bi-weekly,225,287,19-69,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,19,8.44,Partial,Yes,"Liver function monitoring, dose adjustment",64,40,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,10,Bi-weekly,168,152,49-84,All,0-2,Severe Pneumonitis,Respiratory,Severe,14,8.33,Partial,Yes,"Corticosteroids, oxygen therapy",18,16,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,10,Monthly,226,121,47-71,All,0-2,Severe Thrombocytopenia,Hematological,Severe,18,7.96,Yes,Yes,"Platelet transfusion, dose adjustment",37,10,No,No,Yes
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,240,Every 3 weeks,182,171,65-72,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,14,7.69,Partial,Yes,"Corticosteroids, cardiac support",26,31,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,3,Monthly,262,246,45-81,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,20,7.63,Yes,Yes,"Platelet transfusion, dose adjustment",40,51,No,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,3,Monthly,158,212,64-69,All,0-3,Anaphylaxis,Immunological,Severe,12,7.59,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",34,43,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,3,Bi-weekly,257,208,50-78,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,19,7.39,Partial,Yes,"Corticosteroids, oxygen therapy",50,15,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,10,Every 3 weeks,42,147,55-78,Female only,0-2,Cardiac Toxicity,Cardiovascular,Severe,3,7.14,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",17,38,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,240,Every 3 weeks,101,200,22-73,Male only,0-3,Severe Myocarditis,Cardiovascular,Severe,7,6.93,Partial,Yes,"Corticosteroids, cardiac support",89,29,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,10,Every 3 weeks,212,293,57-79,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,14,6.6,Partial,Yes,"Corticosteroids, cardiac support",22,53,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,10,Monthly,183,258,59-69,Female only,0-2,Severe Hepatotoxicity,Hepatic,Severe,12,6.56,Partial,Yes,"Liver function monitoring, dose adjustment",60,36,Yes,Yes,Yes
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,240,Every 3 weeks,305,129,36-67,All,0-2,Severe Pneumonitis,Respiratory,Severe,20,6.56,Partial,Yes,"Corticosteroids, oxygen therapy",14,39,Yes,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,10,Bi-weekly,188,358,29-79,Female only,1-2,Anaphylaxis,Immunological,Severe,12,6.38,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",17,39,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,10,Monthly,224,33,56-75,Female only,0-3,Severe Hepatotoxicity,Hepatic,Severe,14,6.25,Partial,Yes,"Liver function monitoring, dose adjustment",8,20,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,10,Every 3 weeks,212,293,57-79,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,13,6.13,Partial,Yes,"Corticosteroids, oxygen therapy",66,11,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,240,Every 3 weeks,295,345,65-68,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,18,6.1,Partial,Yes,"Liver function monitoring, dose adjustment",59,47,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,10,Bi-weekly,263,275,51-77,All,0-2,Severe Myocarditis,Cardiovascular,Severe,16,6.08,Partial,Yes,"Corticosteroids, cardiac support",80,50,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,10,Bi-weekly,168,152,49-84,All,0-2,Cytokine Release Syndrome,Immunological,Severe,10,5.95,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",26,14,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,10,Monthly,286,341,37-85,Female only,1-2,Anaphylaxis,Immunological,Severe,17,5.94,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",57,12,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,240,Every 3 weeks,101,200,22-73,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,6,5.94,Yes,Yes,"Platelet transfusion, dose adjustment",34,25,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,3,Every 3 weeks,69,361,28-81,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,4,5.8,Yes,Yes,"Platelet transfusion, dose adjustment",45,47,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,10,Every 3 weeks,157,225,43-85,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,9,5.73,Partial,Yes,"Liver function monitoring, dose adjustment",43,4,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,3,Weekly,356,121,36-69,All,0-1,Anaphylaxis,Immunological,Severe,20,5.62,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",57,23,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,10,Bi-weekly,362,351,42-84,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,20,5.52,Partial,Yes,"Corticosteroids, cardiac support",1,28,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,3,Weekly,354,287,52-67,All,0-3,Severe Neuropathy,Neurological,Severe,19,5.37,Partial,Yes,"Dose reduction, pain management",10,40,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,3,Bi-weekly,299,279,55-85,Female only,0-2,Severe Neutropenia,Hematological,Severe,16,5.35,Yes,Yes,"G-CSF, antibiotics, dose reduction",34,4,No,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,240,Weekly,75,332,21-67,Female only,0-1,Severe Colitis,Gastrointestinal,Severe,4,5.33,Yes,Yes,"Corticosteroids, infliximab",26,38,No,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,240,Monthly,375,99,23-75,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,20,5.33,Partial,Yes,"Corticosteroids, oxygen therapy",66,50,No,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,240,Every 3 weeks,151,361,41-65,All,0-2,Cytokine Release Syndrome,Immunological,Severe,8,5.3,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",2,43,No,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,240,Monthly,209,202,36-76,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,11,5.26,Partial,Yes,"Liver function monitoring, dose adjustment",59,31,No,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,10,Every 3 weeks,153,45,54-84,Female only,1-2,Severe Neuropathy,Neurological,Severe,8,5.23,Partial,Yes,"Dose reduction, pain management",5,54,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,3,Monthly,349,37,58-73,All,0-2,Cytokine Release Syndrome,Immunological,Severe,18,5.16,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",6,25,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,3,Bi-weekly,369,265,43-82,Female only,1-2,Severe Neuropathy,Neurological,Severe,19,5.15,Partial,Yes,"Dose reduction, pain management",77,17,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,10,Every 3 weeks,157,225,43-85,Female only,0-1,Severe Myocarditis,Cardiovascular,Severe,8,5.1,Partial,Yes,"Corticosteroids, cardiac support",62,26,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,3,Every 3 weeks,315,325,52-79,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,16,5.08,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",33,6,Yes,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,3,Monthly,158,212,64-69,All,0-3,Cardiac Toxicity,Cardiovascular,Severe,8,5.06,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",62,1,Yes,No,Yes
Nivolumab,Anti-PD-1,Melanoma,Phase 1,240,Bi-weekly,317,332,54-71,All,1-2,Severe Pneumonitis,Respiratory,Severe,16,5.05,Partial,Yes,"Corticosteroids, oxygen therapy",69,4,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,10,Bi-weekly,263,275,51-77,All,0-2,Severe Myocarditis,Cardiovascular,Severe,13,4.94,Partial,Yes,"Corticosteroids, cardiac support",36,30,No,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,10,Bi-weekly,188,358,29-79,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,9,4.79,Partial,Yes,"Liver function monitoring, dose adjustment",33,14,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,240,Monthly,86,52,48-73,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,4,4.65,Partial,Yes,"Corticosteroids, cardiac support",70,55,No,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,10,Monthly,110,233,22-76,All,0-1,Severe Neuropathy,Neurological,Severe,5,4.55,Partial,Yes,"Dose reduction, pain management",32,48,No,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,240,Monthly,200,253,41-72,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,9,4.5,Partial,Yes,"Liver function monitoring, dose adjustment",30,52,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,10,Weekly,402,195,63-81,Female only,1-2,Cytokine Release Syndrome,Immunological,Severe,18,4.48,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",10,50,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,3,Monthly,448,70,29-81,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,20,4.46,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",48,60,Yes,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,10,Bi-weekly,225,287,19-69,All,0-2,Severe Thrombocytopenia,Hematological,Severe,10,4.44,Yes,Yes,"Platelet transfusion, dose adjustment",1,29,Yes,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,3,Every 3 weeks,69,361,28-81,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,3,4.35,Partial,Yes,"Corticosteroids, oxygen therapy",62,34,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,3,Weekly,461,72,28-67,All,1-2,Severe Neutropenia,Hematological,Severe,20,4.34,Yes,Yes,"G-CSF, antibiotics, dose reduction",66,42,Yes,Yes,Yes
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,3,Weekly,466,285,58-65,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,20,4.29,Partial,Yes,"Liver function monitoring, dose adjustment",23,50,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,3,Bi-weekly,117,351,54-79,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,5,4.27,Partial,Yes,"Liver function monitoring, dose adjustment",15,27,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,240,Every 3 weeks,305,129,36-67,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,13,4.26,Partial,Yes,"Liver function monitoring, dose adjustment",49,8,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,10,Every 3 weeks,212,293,57-79,Male only,0-1,Cardiac Toxicity,Cardiovascular,Severe,9,4.25,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",59,18,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,3,Monthly,448,70,29-81,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,19,4.24,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",21,7,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,10,Bi-weekly,263,275,51-77,All,0-2,Severe Neuropathy,Neurological,Severe,11,4.18,Partial,Yes,"Dose reduction, pain management",3,36,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,240,Monthly,478,137,24-69,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,20,4.18,Partial,Yes,"Liver function monitoring, dose adjustment",10,41,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,3,Weekly,461,72,28-67,All,1-2,Anaphylaxis,Immunological,Severe,19,4.12,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",21,32,No,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,240,Bi-weekly,317,332,54-71,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,13,4.1,Partial,Yes,"Liver function monitoring, dose adjustment",35,43,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,3,Bi-weekly,369,265,43-82,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,15,4.07,Yes,Yes,"Corticosteroids, infliximab",32,53,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,3,Monthly,448,70,29-81,Male only,0-3,Severe Neutropenia,Hematological,Severe,18,4.02,Yes,Yes,"G-CSF, antibiotics, dose reduction",29,5,No,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,3,Bi-weekly,299,279,55-85,Female only,0-2,Cardiac Toxicity,Cardiovascular,Severe,12,4.01,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",41,47,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,240,Every 3 weeks,400,53,45-69,Female only,0-3,Cytokine Release Syndrome,Immunological,Severe,16,4.0,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",73,58,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,3,Every 3 weeks,76,71,64-70,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,3,3.95,Partial,Yes,"Liver function monitoring, dose adjustment",69,18,No,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,10,Every 3 weeks,153,45,54-84,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,6,3.92,Partial,Yes,"Liver function monitoring, dose adjustment",51,41,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,3,Bi-weekly,343,196,39-80,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,13,3.79,Partial,Yes,"Corticosteroids, cardiac support",1,31,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,3,Weekly,356,121,36-69,All,0-1,Cardiac Toxicity,Cardiovascular,Severe,13,3.65,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",79,32,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,10,Monthly,110,233,22-76,All,0-1,Anaphylaxis,Immunological,Severe,4,3.64,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",12,46,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,3,Bi-weekly,444,134,32-81,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,16,3.6,Yes,Yes,"Corticosteroids, infliximab",81,14,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,240,Bi-weekly,336,86,59-85,Male only,1-2,Anaphylaxis,Immunological,Severe,12,3.57,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",17,28,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,240,Bi-weekly,421,355,48-78,All,1-2,Cytokine Release Syndrome,Immunological,Severe,15,3.56,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",37,32,Yes,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,3,Bi-weekly,343,196,39-80,Female only,1-2,Severe Pneumonitis,Respiratory,Severe,12,3.5,Partial,Yes,"Corticosteroids, oxygen therapy",75,53,Yes,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,10,Weekly,202,88,50-71,All,0-3,Cytokine Release Syndrome,Immunological,Severe,7,3.47,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",10,48,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,10,Bi-weekly,497,310,30-70,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,17,3.42,Partial,Yes,"Liver function monitoring, dose adjustment",58,35,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,3,Weekly,354,287,52-67,All,0-3,Severe Colitis,Gastrointestinal,Severe,12,3.39,Yes,Yes,"Corticosteroids, infliximab",15,22,No,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,3,Weekly,386,124,51-77,Female only,0-3,Severe Hepatotoxicity,Hepatic,Severe,13,3.37,Partial,Yes,"Liver function monitoring, dose adjustment",6,25,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,3,Weekly,386,124,51-77,Female only,0-3,Severe Neuropathy,Neurological,Severe,13,3.37,Partial,Yes,"Dose reduction, pain management",44,42,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,3,Every 3 weeks,301,231,37-71,All,0-3,Severe Thrombocytopenia,Hematological,Severe,10,3.32,Yes,Yes,"Platelet transfusion, dose adjustment",39,19,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,10,Bi-weekly,362,351,42-84,Male only,0-2,Severe Neuropathy,Neurological,Severe,12,3.31,Partial,Yes,"Dose reduction, pain management",36,8,Yes,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,10,Bi-weekly,225,287,19-69,All,0-2,Severe Thrombocytopenia,Hematological,Severe,7,3.11,Yes,Yes,"Platelet transfusion, dose adjustment",46,24,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,3,Weekly,354,287,52-67,All,0-3,Severe Myocarditis,Cardiovascular,Severe,11,3.11,Partial,Yes,"Corticosteroids, cardiac support",42,34,Yes,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,10,Weekly,452,232,28-71,Male only,0-2,Cytokine Release Syndrome,Immunological,Severe,14,3.1,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",29,26,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,10,Bi-weekly,497,310,30-70,Male only,0-1,Cytokine Release Syndrome,Immunological,Severe,15,3.02,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",18,23,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,3,Weekly,466,285,58-65,All,1-2,Severe Neuropathy,Neurological,Severe,14,3.0,Partial,Yes,"Dose reduction, pain management",35,54,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,10,Bi-weekly,168,152,49-84,All,0-2,Severe Myocarditis,Cardiovascular,Severe,5,2.98,Partial,Yes,"Corticosteroids, cardiac support",38,28,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,3,Every 3 weeks,69,361,28-81,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,2,2.9,Yes,Yes,"Corticosteroids, infliximab",11,13,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,3,Every 3 weeks,383,299,35-80,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,11,2.87,Partial,Yes,"Liver function monitoring, dose adjustment",25,36,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,10,Weekly,140,195,37-69,Female only,0-3,Severe Myocarditis,Cardiovascular,Severe,4,2.86,Partial,Yes,"Corticosteroids, cardiac support",67,21,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,3,Every 3 weeks,315,325,52-79,Female only,0-3,Cytokine Release Syndrome,Immunological,Severe,9,2.86,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",66,17,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,3,Every 3 weeks,319,94,22-81,All,1-2,Severe Myocarditis,Cardiovascular,Severe,9,2.82,Partial,Yes,"Corticosteroids, cardiac support",35,43,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,3,Weekly,356,121,36-69,All,0-1,Severe Neuropathy,Neurological,Severe,10,2.81,Partial,Yes,"Dose reduction, pain management",86,51,No,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,3,Weekly,466,285,58-65,All,1-2,Severe Neutropenia,Hematological,Severe,13,2.79,Yes,Yes,"G-CSF, antibiotics, dose reduction",39,56,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,240,Monthly,218,31,26-82,Female only,0-1,Severe Neuropathy,Neurological,Severe,6,2.75,Partial,Yes,"Dose reduction, pain management",10,24,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,240,Every 3 weeks,295,345,65-68,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,8,2.71,Yes,Yes,"Corticosteroids, infliximab",25,36,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,3,Bi-weekly,369,265,43-82,Female only,1-2,Severe Pneumonitis,Respiratory,Severe,10,2.71,Partial,Yes,"Corticosteroids, oxygen therapy",79,58,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,10,Monthly,226,121,47-71,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,6,2.65,Partial,Yes,"Liver function monitoring, dose adjustment",56,49,No,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,10,Monthly,226,121,47-71,All,0-2,Cytokine Release Syndrome,Immunological,Severe,6,2.65,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",79,9,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,3,Every 3 weeks,76,71,64-70,Male only,1-2,Severe Myocarditis,Cardiovascular,Severe,2,2.63,Partial,Yes,"Corticosteroids, cardiac support",2,34,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,3,Every 3 weeks,76,71,64-70,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,2,2.63,Partial,Yes,"Corticosteroids, oxygen therapy",4,27,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,3,Every 3 weeks,383,299,35-80,All,0-1,Anaphylaxis,Immunological,Severe,10,2.61,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",55,42,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,10,Bi-weekly,349,137,60-85,All,0-3,Cardiac Toxicity,Cardiovascular,Severe,9,2.58,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",74,11,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,10,Every 3 weeks,157,225,43-85,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,4,2.55,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",24,51,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,10,Every 3 weeks,431,53,32-75,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,11,2.55,Partial,Yes,"Corticosteroids, oxygen therapy",42,52,No,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,240,Bi-weekly,317,332,54-71,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,8,2.52,Partial,Yes,"Liver function monitoring, dose adjustment",48,2,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,10,Every 3 weeks,479,257,19-69,Female only,0-1,Severe Neuropathy,Neurological,Severe,12,2.51,Partial,Yes,"Dose reduction, pain management",57,42,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,3,Monthly,479,155,65-81,All,1-2,Severe Pneumonitis,Respiratory,Severe,12,2.51,Partial,Yes,"Corticosteroids, oxygen therapy",59,28,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,240,Monthly,478,137,24-69,All,0-1,Severe Myocarditis,Cardiovascular,Severe,12,2.51,Partial,Yes,"Corticosteroids, cardiac support",73,18,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,240,Monthly,200,253,41-72,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,5,2.5,Yes,Yes,"Platelet transfusion, dose adjustment",39,18,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,10,Every 3 weeks,212,293,57-79,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,5,2.36,Partial,Yes,"Corticosteroids, oxygen therapy",42,2,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,3,Monthly,349,37,58-73,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,8,2.29,Partial,Yes,"Liver function monitoring, dose adjustment",39,45,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,10,Bi-weekly,497,310,30-70,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,11,2.21,Yes,Yes,"Corticosteroids, infliximab",36,35,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,240,Bi-weekly,95,175,51-79,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,2,2.11,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",60,57,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,10,Every 3 weeks,431,53,32-75,Male only,0-3,Severe Myocarditis,Cardiovascular,Severe,9,2.09,Partial,Yes,"Corticosteroids, cardiac support",77,10,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,10,Weekly,292,152,57-70,All,0-2,Cardiac Toxicity,Cardiovascular,Severe,6,2.05,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",50,36,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,240,Every 3 weeks,442,364,19-67,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,9,2.04,Partial,Yes,"Liver function monitoring, dose adjustment",62,33,No,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,240,Bi-weekly,297,143,37-69,All,1-2,Severe Myocarditis,Cardiovascular,Severe,6,2.02,Partial,Yes,"Corticosteroids, cardiac support",49,10,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,10,Every 3 weeks,153,45,54-84,Female only,1-2,Anaphylaxis,Immunological,Severe,3,1.96,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",47,5,Yes,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,10,Bi-weekly,362,351,42-84,Male only,0-2,Severe Neuropathy,Neurological,Severe,7,1.93,Partial,Yes,"Dose reduction, pain management",39,7,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,240,Weekly,430,187,28-84,Female only,0-1,Severe Myocarditis,Cardiovascular,Severe,8,1.86,Partial,Yes,"Corticosteroids, cardiac support",48,40,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,3,Monthly,448,70,29-81,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,8,1.79,Yes,Yes,"Platelet transfusion, dose adjustment",79,3,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,240,Bi-weekly,336,86,59-85,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,6,1.79,Partial,Yes,"Liver function monitoring, dose adjustment",9,37,No,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,10,Weekly,292,152,57-70,All,0-2,Severe Colitis,Gastrointestinal,Severe,5,1.71,Yes,Yes,"Corticosteroids, infliximab",27,39,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,3,Monthly,479,155,65-81,All,1-2,Severe Pneumonitis,Respiratory,Severe,8,1.67,Partial,Yes,"Corticosteroids, oxygen therapy",47,23,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,10,Monthly,183,258,59-69,Female only,0-2,Cytokine Release Syndrome,Immunological,Severe,3,1.64,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",73,10,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,3,Monthly,479,155,65-81,All,1-2,Severe Colitis,Gastrointestinal,Severe,7,1.46,Yes,Yes,"Corticosteroids, infliximab",43,20,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,240,Monthly,478,137,24-69,All,0-1,Cardiac Toxicity,Cardiovascular,Severe,7,1.46,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",67,55,Yes,No,Yes
Nivolumab,Anti-PD-1,Melanoma,Phase 3,3,Every 3 weeks,69,361,28-81,Male only,0-1,Severe Neuropathy,Neurological,Severe,1,1.45,Partial,Yes,"Dose reduction, pain management",15,51,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,240,Bi-weekly,421,355,48-78,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,6,1.43,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",70,32,Yes,Yes,Yes
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,10,Bi-weekly,349,137,60-85,All,0-3,Anaphylaxis,Immunological,Severe,5,1.43,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",72,16,Yes,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,240,Monthly,428,259,56-78,Male only,0-3,Severe Neuropathy,Neurological,Severe,6,1.4,Partial,Yes,"Dose reduction, pain management",70,20,Yes,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,10,Bi-weekly,362,351,42-84,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,5,1.38,Partial,Yes,"Corticosteroids, oxygen therapy",83,15,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,10,Weekly,452,232,28-71,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,6,1.33,Partial,Yes,"Corticosteroids, cardiac support",70,37,Yes,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,240,Every 3 weeks,151,361,41-65,All,0-2,Severe Neuropathy,Neurological,Severe,2,1.32,Partial,Yes,"Dose reduction, pain management",46,58,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,3,Every 3 weeks,76,71,64-70,Male only,1-2,Severe Neutropenia,Hematological,Severe,1,1.32,Yes,Yes,"G-CSF, antibiotics, dose reduction",34,44,Yes,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 2,10,Weekly,452,232,28-71,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,5,1.11,Partial,Yes,"Corticosteroids, cardiac support",74,46,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,240,Every 3 weeks,295,345,65-68,Female only,1-2,Severe Neuropathy,Neurological,Severe,3,1.02,Partial,Yes,"Dose reduction, pain management",58,11,Yes,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,10,Weekly,202,88,50-71,All,0-3,Cardiac Toxicity,Cardiovascular,Severe,2,0.99,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",39,18,Yes,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,10,Bi-weekly,225,287,19-69,All,0-2,Severe Pneumonitis,Respiratory,Severe,2,0.89,Partial,Yes,"Corticosteroids, oxygen therapy",58,23,Yes,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,3,Bi-weekly,343,196,39-80,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,3,0.87,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",32,34,No,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,3,Bi-weekly,117,351,54-79,Male only,0-3,Severe Neutropenia,Hematological,Severe,1,0.85,Yes,Yes,"G-CSF, antibiotics, dose reduction",3,7,No,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,240,Monthly,375,99,23-75,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,3,0.8,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",3,28,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,10,Bi-weekly,263,275,51-77,All,0-2,Severe Neutropenia,Hematological,Severe,2,0.76,Yes,Yes,"G-CSF, antibiotics, dose reduction",4,30,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,10,Weekly,140,195,37-69,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,1,0.71,Partial,Yes,"Corticosteroids, oxygen therapy",14,1,Yes,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,3,Weekly,461,72,28-67,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,3,0.65,Partial,Yes,"Liver function monitoring, dose adjustment",53,44,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,10,Every 3 weeks,153,45,54-84,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,1,0.65,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",55,36,No,No,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,3,Every 3 weeks,319,94,22-81,All,1-2,Severe Myocarditis,Cardiovascular,Severe,2,0.63,Partial,Yes,"Corticosteroids, cardiac support",31,12,Yes,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,3,Bi-weekly,369,265,43-82,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,2,0.54,Partial,Yes,"Corticosteroids, cardiac support",49,52,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 1,240,Every 3 weeks,400,53,45-69,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,2,0.5,Partial,Yes,"Corticosteroids, oxygen therapy",22,33,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,10,Every 3 weeks,479,257,19-69,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,2,0.42,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",65,45,No,Yes,No
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,240,Monthly,478,137,24-69,All,0-1,Severe Myocarditis,Cardiovascular,Severe,2,0.42,Partial,Yes,"Corticosteroids, cardiac support",47,47,Yes,No,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 2,240,Bi-weekly,297,143,37-69,All,1-2,Severe Thrombocytopenia,Hematological,Severe,1,0.34,Yes,Yes,"Platelet transfusion, dose adjustment",46,4,No,Yes,No
Nivolumab,Anti-PD-1,Renal Cancer,Phase 3,240,Every 3 weeks,305,129,36-67,All,0-2,Severe Myocarditis,Cardiovascular,Severe,1,0.33,Partial,Yes,"Corticosteroids, cardiac support",20,50,Yes,Yes,No
Nivolumab,Anti-PD-1,Melanoma,Phase 1,240,Bi-weekly,317,332,54-71,All,1-2,Cytokine Release Syndrome,Immunological,Severe,1,0.32,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",64,29,Yes,No,No
Nivolumab,Anti-PD-1,Melanoma,Phase 3,3,Bi-weekly,343,196,39-80,Female only,1-2,Anaphylaxis,Immunological,Severe,1,0.29,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",90,16,Yes,Yes,Yes
Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,3,Monthly,479,155,65-81,All,1-2,Severe Neutropenia,Hematological,Severe,1,0.21,Yes,Yes,"G-CSF, antibiotics, dose reduction",27,33,Yes,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,100,Bi-weekly,100,337,60-79,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,10,10.0,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",27,45,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,2000,Weekly,138,81,28-74,Male only,0-3,Anaphylaxis,Immunological,Severe,13,9.42,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",76,47,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,1000,Every 3 weeks,59,179,43-66,All,0-1,Cytokine Release Syndrome,Immunological,Severe,5,8.47,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",15,49,Yes,No,Yes
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,1000,Every 3 weeks,59,179,43-66,All,0-1,Severe Myocarditis,Cardiovascular,Severe,5,8.47,Partial,Yes,"Corticosteroids, cardiac support",32,22,Yes,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,1000,Every 3 weeks,154,244,62-74,All,0-2,Severe Colitis,Gastrointestinal,Severe,13,8.44,Yes,Yes,"Corticosteroids, infliximab",11,21,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,100,Every 3 weeks,155,190,23-82,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,13,8.39,Partial,Yes,"Corticosteroids, cardiac support",85,51,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,2000,Every 3 weeks,182,58,28-73,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,15,8.24,Partial,Yes,"Corticosteroids, oxygen therapy",5,30,Yes,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,100,Bi-weekly,100,337,60-79,Female only,0-3,Severe Myocarditis,Cardiovascular,Severe,8,8.0,Partial,Yes,"Corticosteroids, cardiac support",33,25,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,1000,Every 3 weeks,197,131,46-66,Male only,0-2,Anaphylaxis,Immunological,Severe,15,7.61,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",18,47,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,100,Monthly,214,44,49-68,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,16,7.48,Partial,Yes,"Corticosteroids, oxygen therapy",1,2,Yes,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,1000,Weekly,176,364,44-78,Female only,0-3,Severe Neutropenia,Hematological,Severe,13,7.39,Yes,Yes,"G-CSF, antibiotics, dose reduction",8,58,Yes,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,2000,Monthly,263,69,29-69,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,19,7.22,Partial,Yes,"Corticosteroids, oxygen therapy",63,5,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,2000,Weekly,153,247,32-75,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,11,7.19,Partial,Yes,"Liver function monitoring, dose adjustment",35,14,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,1000,Every 3 weeks,28,365,20-78,All,0-1,Severe Pneumonitis,Respiratory,Severe,2,7.14,Partial,Yes,"Corticosteroids, oxygen therapy",64,19,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,1000,Every 3 weeks,28,365,20-78,All,0-1,Severe Neuropathy,Neurological,Severe,2,7.14,Partial,Yes,"Dose reduction, pain management",65,54,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,100,Bi-weekly,29,145,57-69,Female only,0-2,Severe Pneumonitis,Respiratory,Severe,2,6.9,Partial,Yes,"Corticosteroids, oxygen therapy",53,48,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,100,Bi-weekly,29,145,57-69,Female only,0-2,Cardiac Toxicity,Cardiovascular,Severe,2,6.9,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",28,45,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,100,Bi-weekly,29,145,57-69,Female only,0-2,Severe Neuropathy,Neurological,Severe,2,6.9,Partial,Yes,"Dose reduction, pain management",83,5,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,1000,Bi-weekly,45,353,64-81,Male only,0-2,Anaphylaxis,Immunological,Severe,3,6.67,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",34,18,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,1000,Bi-weekly,45,353,64-81,Male only,0-2,Cardiac Toxicity,Cardiovascular,Severe,3,6.67,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",57,58,Yes,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,2000,Monthly,263,69,29-69,Male only,1-2,Anaphylaxis,Immunological,Severe,17,6.46,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",25,22,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,2000,Every 3 weeks,295,265,30-85,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,19,6.44,Partial,Yes,"Liver function monitoring, dose adjustment",63,29,Yes,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,100,Monthly,286,226,37-78,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,18,6.29,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",76,14,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,100,Bi-weekly,96,35,58-82,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,6,6.25,Partial,Yes,"Liver function monitoring, dose adjustment",19,11,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,1000,Bi-weekly,322,209,33-73,Male only,1-2,Severe Neutropenia,Hematological,Severe,20,6.21,Yes,Yes,"G-CSF, antibiotics, dose reduction",53,37,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,100,Bi-weekly,336,328,47-79,Female only,0-1,Severe Neutropenia,Hematological,Severe,20,5.95,Yes,Yes,"G-CSF, antibiotics, dose reduction",8,55,Yes,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,2000,Every 3 weeks,295,265,30-85,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,17,5.76,Partial,Yes,"Corticosteroids, oxygen therapy",23,59,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,100,Monthly,286,226,37-78,Male only,1-2,Anaphylaxis,Immunological,Severe,16,5.59,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",1,40,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,1000,Every 3 weeks,335,333,30-69,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,18,5.37,Partial,Yes,"Corticosteroids, cardiac support",49,11,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,100,Every 3 weeks,325,171,61-70,All,0-2,Severe Thrombocytopenia,Hematological,Severe,17,5.23,Yes,Yes,"Platelet transfusion, dose adjustment",15,45,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,1000,Every 3 weeks,154,244,62-74,All,0-2,Severe Neuropathy,Neurological,Severe,8,5.19,Partial,Yes,"Dose reduction, pain management",21,57,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,1000,Bi-weekly,391,276,21-80,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,20,5.12,Partial,Yes,"Liver function monitoring, dose adjustment",54,51,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,1000,Weekly,176,364,44-78,Female only,0-3,Severe Neuropathy,Neurological,Severe,9,5.11,Partial,Yes,"Dose reduction, pain management",85,54,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,1000,Every 3 weeks,59,179,43-66,All,0-1,Severe Colitis,Gastrointestinal,Severe,3,5.08,Yes,Yes,"Corticosteroids, infliximab",90,59,Yes,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,1000,Every 3 weeks,59,179,43-66,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,3,5.08,Partial,Yes,"Liver function monitoring, dose adjustment",17,30,Yes,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,1000,Every 3 weeks,335,333,30-69,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,17,5.07,Partial,Yes,"Corticosteroids, cardiac support",4,40,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,100,Monthly,286,226,37-78,Male only,1-2,Cytokine Release Syndrome,Immunological,Severe,14,4.9,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",49,30,Yes,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,100,Every 3 weeks,296,31,60-66,Female only,1-2,Severe Pneumonitis,Respiratory,Severe,14,4.73,Partial,Yes,"Corticosteroids, oxygen therapy",8,11,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,1000,Weekly,387,46,38-68,All,0-2,Severe Myocarditis,Cardiovascular,Severe,18,4.65,Partial,Yes,"Corticosteroids, cardiac support",82,46,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,1000,Weekly,387,46,38-68,All,0-2,Severe Neutropenia,Hematological,Severe,18,4.65,Yes,Yes,"G-CSF, antibiotics, dose reduction",58,31,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,100,Weekly,411,208,29-79,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,19,4.62,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",24,47,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,100,Weekly,411,208,29-79,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,19,4.62,Partial,Yes,"Liver function monitoring, dose adjustment",54,45,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,2000,Weekly,153,247,32-75,All,0-2,Severe Colitis,Gastrointestinal,Severe,7,4.58,Yes,Yes,"Corticosteroids, infliximab",69,60,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,2000,Weekly,448,218,36-76,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,20,4.46,Partial,Yes,"Corticosteroids, oxygen therapy",24,43,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,2000,Bi-weekly,23,206,24-70,Female only,0-3,Severe Colitis,Gastrointestinal,Severe,1,4.35,Yes,Yes,"Corticosteroids, infliximab",54,44,Yes,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,1000,Bi-weekly,418,69,31-65,All,0-1,Anaphylaxis,Immunological,Severe,18,4.31,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",69,53,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,2000,Monthly,423,363,47-80,Female only,0-1,Anaphylaxis,Immunological,Severe,18,4.26,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",49,15,Yes,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,1000,Weekly,312,172,58-84,All,1-2,Severe Neuropathy,Neurological,Severe,13,4.17,Partial,Yes,"Dose reduction, pain management",27,25,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,100,Every 3 weeks,459,74,34-72,Female only,0-2,Cytokine Release Syndrome,Immunological,Severe,19,4.14,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",49,10,Yes,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,1000,Bi-weekly,391,276,21-80,Female only,1-2,Severe Neutropenia,Hematological,Severe,16,4.09,Yes,Yes,"G-CSF, antibiotics, dose reduction",10,5,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,1000,Weekly,453,314,56-82,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,17,3.75,Partial,Yes,"Corticosteroids, oxygen therapy",27,55,Yes,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,2000,Every 3 weeks,349,79,21-69,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,13,3.72,Partial,Yes,"Corticosteroids, oxygen therapy",46,14,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,2000,Monthly,489,177,51-71,Male only,1-2,Severe Neutropenia,Hematological,Severe,18,3.68,Yes,Yes,"G-CSF, antibiotics, dose reduction",53,27,Yes,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,100,Monthly,439,98,55-77,Female only,1-2,Anaphylaxis,Immunological,Severe,16,3.64,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",60,20,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,100,Every 3 weeks,388,330,45-65,Female only,0-2,Cytokine Release Syndrome,Immunological,Severe,14,3.61,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",4,57,Yes,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,1000,Every 3 weeks,28,365,20-78,All,0-1,Severe Neutropenia,Hematological,Severe,1,3.57,Yes,Yes,"G-CSF, antibiotics, dose reduction",61,23,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,1000,Weekly,312,172,58-84,All,1-2,Severe Thrombocytopenia,Hematological,Severe,11,3.53,Yes,Yes,"Platelet transfusion, dose adjustment",51,47,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,100,Bi-weekly,29,145,57-69,Female only,0-2,Severe Neutropenia,Hematological,Severe,1,3.45,Yes,Yes,"G-CSF, antibiotics, dose reduction",69,14,Yes,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,100,Weekly,499,175,22-78,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,16,3.21,Partial,Yes,"Corticosteroids, oxygen therapy",81,51,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,100,Every 3 weeks,459,74,34-72,Female only,0-2,Severe Pneumonitis,Respiratory,Severe,14,3.05,Partial,Yes,"Corticosteroids, oxygen therapy",34,8,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,2000,Every 3 weeks,295,265,30-85,Male only,0-2,Cardiac Toxicity,Cardiovascular,Severe,9,3.05,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",73,50,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,2000,Every 3 weeks,295,265,30-85,Male only,0-2,Severe Neutropenia,Hematological,Severe,9,3.05,Yes,Yes,"G-CSF, antibiotics, dose reduction",29,15,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,2000,Monthly,263,69,29-69,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,8,3.04,Partial,Yes,"Corticosteroids, oxygen therapy",18,33,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,2000,Bi-weekly,284,195,19-80,Female only,1-2,Anaphylaxis,Immunological,Severe,8,2.82,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",4,32,Yes,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,2000,Monthly,489,177,51-71,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,13,2.66,Partial,Yes,"Corticosteroids, oxygen therapy",33,24,Yes,No,Yes
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,1000,Bi-weekly,418,69,31-65,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,11,2.63,Partial,Yes,"Liver function monitoring, dose adjustment",23,46,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,2000,Weekly,396,84,58-66,Female only,0-3,Severe Thrombocytopenia,Hematological,Severe,10,2.53,Yes,Yes,"Platelet transfusion, dose adjustment",19,44,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,100,Bi-weekly,403,89,21-75,All,0-2,Cytokine Release Syndrome,Immunological,Severe,10,2.48,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",80,58,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,2000,Every 3 weeks,349,79,21-69,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,8,2.29,Partial,Yes,"Liver function monitoring, dose adjustment",29,5,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,2000,Weekly,448,218,36-76,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,10,2.23,Partial,Yes,"Corticosteroids, oxygen therapy",82,52,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,1000,Bi-weekly,45,353,64-81,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,1,2.22,Yes,Yes,"Platelet transfusion, dose adjustment",35,10,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,2000,Monthly,423,363,47-80,Female only,0-1,Severe Thrombocytopenia,Hematological,Severe,9,2.13,Yes,Yes,"Platelet transfusion, dose adjustment",36,55,Yes,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,2000,Bi-weekly,284,195,19-80,Female only,1-2,Severe Neutropenia,Hematological,Severe,6,2.11,Yes,Yes,"G-CSF, antibiotics, dose reduction",40,2,Yes,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,100,Monthly,286,226,37-78,Male only,1-2,Severe Neutropenia,Hematological,Severe,6,2.1,Yes,Yes,"G-CSF, antibiotics, dose reduction",85,41,No,No,Yes
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,100,Bi-weekly,336,328,47-79,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,7,2.08,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",21,36,Yes,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,2000,Weekly,486,200,49-71,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,10,2.06,Partial,Yes,"Corticosteroids, oxygen therapy",70,20,Yes,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,2000,Every 3 weeks,349,79,21-69,Female only,0-1,Severe Colitis,Gastrointestinal,Severe,7,2.01,Yes,Yes,"Corticosteroids, infliximab",49,54,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,2000,Every 3 weeks,349,79,21-69,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,7,2.01,Partial,Yes,"Liver function monitoring, dose adjustment",33,51,Yes,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,100,Every 3 weeks,388,330,45-65,Female only,0-2,Severe Pneumonitis,Respiratory,Severe,7,1.8,Partial,Yes,"Corticosteroids, oxygen therapy",48,2,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,100,Bi-weekly,403,89,21-75,All,0-2,Severe Colitis,Gastrointestinal,Severe,7,1.74,Yes,Yes,"Corticosteroids, infliximab",89,36,Yes,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,1000,Weekly,176,364,44-78,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,3,1.7,Partial,Yes,"Corticosteroids, oxygen therapy",32,8,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,100,Weekly,411,208,29-79,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,7,1.7,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",27,59,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,2000,Monthly,489,177,51-71,Male only,1-2,Severe Myocarditis,Cardiovascular,Severe,8,1.64,Partial,Yes,"Corticosteroids, cardiac support",6,17,Yes,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,1000,Weekly,387,46,38-68,All,0-2,Severe Colitis,Gastrointestinal,Severe,6,1.55,Yes,Yes,"Corticosteroids, infliximab",47,33,Yes,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,1000,Monthly,437,114,30-68,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,6,1.37,Partial,Yes,"Liver function monitoring, dose adjustment",78,17,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,100,Monthly,439,98,55-77,Female only,1-2,Severe Pneumonitis,Respiratory,Severe,6,1.37,Partial,Yes,"Corticosteroids, oxygen therapy",18,2,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,2000,Weekly,448,218,36-76,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,6,1.34,Yes,Yes,"Platelet transfusion, dose adjustment",65,30,Yes,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,100,Every 3 weeks,459,74,34-72,Female only,0-2,Cardiac Toxicity,Cardiovascular,Severe,6,1.31,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",27,31,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,1000,Every 3 weeks,154,244,62-74,All,0-2,Severe Myocarditis,Cardiovascular,Severe,2,1.3,Partial,Yes,"Corticosteroids, cardiac support",22,26,Yes,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,1000,Bi-weekly,418,69,31-65,All,0-1,Severe Pneumonitis,Respiratory,Severe,5,1.2,Partial,Yes,"Corticosteroids, oxygen therapy",57,13,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,1000,Bi-weekly,418,69,31-65,All,0-1,Severe Colitis,Gastrointestinal,Severe,5,1.2,Yes,Yes,"Corticosteroids, infliximab",37,20,Yes,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 1,100,Every 3 weeks,459,74,34-72,Female only,0-2,Severe Pneumonitis,Respiratory,Severe,5,1.09,Partial,Yes,"Corticosteroids, oxygen therapy",45,4,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,2000,Monthly,489,177,51-71,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,5,1.02,Partial,Yes,"Liver function monitoring, dose adjustment",63,31,No,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,100,Bi-weekly,100,337,60-79,Female only,0-3,Severe Neutropenia,Hematological,Severe,1,1.0,Yes,Yes,"G-CSF, antibiotics, dose reduction",74,46,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,100,Bi-weekly,403,89,21-75,All,0-2,Anaphylaxis,Immunological,Severe,4,0.99,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",48,6,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,100,Every 3 weeks,325,171,61-70,All,0-2,Cytokine Release Syndrome,Immunological,Severe,3,0.92,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",56,55,Yes,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,100,Every 3 weeks,325,171,61-70,All,0-2,Cytokine Release Syndrome,Immunological,Severe,3,0.92,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",17,43,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,100,Bi-weekly,336,328,47-79,Female only,0-1,Cardiac Toxicity,Cardiovascular,Severe,2,0.6,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",63,42,No,No,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 2,1000,Weekly,176,364,44-78,Female only,0-3,Severe Neuropathy,Neurological,Severe,1,0.57,Partial,Yes,"Dose reduction, pain management",2,41,No,Yes,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,2000,Weekly,201,296,40-65,Female only,0-2,Severe Myocarditis,Cardiovascular,Severe,1,0.5,Partial,Yes,"Corticosteroids, cardiac support",73,11,No,Yes,No
Obinutuzumab,Anti-CD20,Leukemia,Phase 3,100,Weekly,411,208,29-79,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,2,0.49,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",15,53,Yes,No,No
Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,100,Every 3 weeks,325,171,61-70,All,0-2,Anaphylaxis,Immunological,Severe,1,0.31,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",74,45,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,2,Monthly,145,321,65-82,Female only,0-3,Severe Hepatotoxicity,Hepatic,Severe,14,9.66,Partial,Yes,"Liver function monitoring, dose adjustment",52,14,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,200,Weekly,126,178,63-83,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,12,9.52,Partial,Yes,"Liver function monitoring, dose adjustment",13,21,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,2,Weekly,85,190,35-83,Female only,0-3,Severe Hepatotoxicity,Hepatic,Severe,8,9.41,Partial,Yes,"Liver function monitoring, dose adjustment",19,38,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,2,Monthly,76,93,38-67,Female only,0-2,Severe Colitis,Gastrointestinal,Severe,7,9.21,Yes,Yes,"Corticosteroids, infliximab",54,25,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,2,Monthly,177,277,28-75,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,16,9.04,Yes,Yes,"Corticosteroids, infliximab",35,25,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,10,Monthly,223,86,56-76,Male only,0-3,Severe Neuropathy,Neurological,Severe,20,8.97,Partial,Yes,"Dose reduction, pain management",35,27,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,200,Every 3 weeks,172,69,37-84,All,1-2,Anaphylaxis,Immunological,Severe,15,8.72,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",70,5,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,10,Monthly,118,90,31-67,Male only,0-1,Severe Neuropathy,Neurological,Severe,10,8.47,Partial,Yes,"Dose reduction, pain management",4,13,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,10,Monthly,166,307,34-66,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,14,8.43,Partial,Yes,"Liver function monitoring, dose adjustment",51,39,No,No,Yes
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,10,Every 3 weeks,167,336,43-80,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,14,8.38,Yes,Yes,"Platelet transfusion, dose adjustment",89,2,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,2,Bi-weekly,203,113,63-70,All,0-1,Severe Myocarditis,Cardiovascular,Severe,17,8.37,Partial,Yes,"Corticosteroids, cardiac support",88,45,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,2,Weekly,75,191,55-78,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,6,8.0,Partial,Yes,"Corticosteroids, oxygen therapy",72,50,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,10,Bi-weekly,50,203,64-82,All,0-2,Anaphylaxis,Immunological,Severe,4,8.0,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",53,23,No,No,Yes
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,2,Monthly,76,93,38-67,Female only,0-2,Anaphylaxis,Immunological,Severe,6,7.89,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",83,52,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,200,Bi-weekly,38,94,46-71,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,3,7.89,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",38,14,Yes,No,Yes
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,2,Weekly,118,101,59-66,Female only,0-1,Severe Colitis,Gastrointestinal,Severe,9,7.63,Yes,Yes,"Corticosteroids, infliximab",20,44,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,2,Monthly,145,321,65-82,Female only,0-3,Severe Myocarditis,Cardiovascular,Severe,11,7.59,Partial,Yes,"Corticosteroids, cardiac support",21,3,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,200,Monthly,176,165,23-78,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,13,7.39,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",22,49,No,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,10,Weekly,123,116,39-65,Male only,1-2,Anaphylaxis,Immunological,Severe,9,7.32,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",50,40,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,10,Bi-weekly,260,89,47-74,Female only,0-1,Cardiac Toxicity,Cardiovascular,Severe,19,7.31,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",75,31,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,10,Monthly,166,307,34-66,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,12,7.23,Partial,Yes,"Liver function monitoring, dose adjustment",7,53,Yes,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,2,Monthly,275,185,25-83,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,19,6.91,Yes,Yes,"Platelet transfusion, dose adjustment",44,50,No,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,2,Every 3 weeks,277,90,22-75,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,19,6.86,Yes,Yes,"Corticosteroids, infliximab",68,59,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,2,Weekly,277,217,54-77,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,19,6.86,Partial,Yes,"Corticosteroids, oxygen therapy",5,6,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,200,Monthly,176,165,23-78,All,1-2,Severe Myocarditis,Cardiovascular,Severe,12,6.82,Partial,Yes,"Corticosteroids, cardiac support",1,58,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,200,Monthly,176,165,23-78,All,1-2,Severe Thrombocytopenia,Hematological,Severe,12,6.82,Yes,Yes,"Platelet transfusion, dose adjustment",79,34,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,2,Weekly,118,101,59-66,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,8,6.78,Partial,Yes,"Corticosteroids, oxygen therapy",87,11,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,10,Monthly,223,86,56-76,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,15,6.73,Partial,Yes,"Liver function monitoring, dose adjustment",37,39,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,10,Weekly,286,120,44-83,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,19,6.64,Partial,Yes,"Liver function monitoring, dose adjustment",26,35,Yes,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,2,Bi-weekly,227,143,59-68,All,0-1,Severe Neutropenia,Hematological,Severe,14,6.17,Yes,Yes,"G-CSF, antibiotics, dose reduction",27,39,No,No,Yes
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,2,Every 3 weeks,277,90,22-75,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,17,6.14,Partial,Yes,"Corticosteroids, oxygen therapy",51,47,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,2,Bi-weekly,148,220,47-83,Male only,1-2,Cytokine Release Syndrome,Immunological,Severe,9,6.08,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",88,57,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,10,Every 3 weeks,165,291,23-69,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,10,6.06,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",51,34,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,10,Bi-weekly,50,203,64-82,All,0-2,Severe Thrombocytopenia,Hematological,Severe,3,6.0,Yes,Yes,"Platelet transfusion, dose adjustment",34,48,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,2,Weekly,118,101,59-66,Female only,0-1,Severe Colitis,Gastrointestinal,Severe,7,5.93,Yes,Yes,"Corticosteroids, infliximab",30,16,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,2,Monthly,191,310,35-79,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,11,5.76,Partial,Yes,"Liver function monitoring, dose adjustment",79,15,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,2,Bi-weekly,227,143,59-68,All,0-1,Cytokine Release Syndrome,Immunological,Severe,13,5.73,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",40,32,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,10,Weekly,123,116,39-65,Male only,1-2,Cytokine Release Syndrome,Immunological,Severe,7,5.69,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",60,41,No,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,200,Monthly,317,196,40-70,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,18,5.68,Partial,Yes,"Liver function monitoring, dose adjustment",52,46,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,200,Weekly,126,178,63-83,Male only,0-1,Cardiac Toxicity,Cardiovascular,Severe,7,5.56,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",52,23,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,200,Every 3 weeks,364,313,38-82,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,20,5.49,Partial,Yes,"Corticosteroids, oxygen therapy",33,30,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,10,Every 3 weeks,167,336,43-80,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,9,5.39,Partial,Yes,"Liver function monitoring, dose adjustment",30,5,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,200,Bi-weekly,38,94,46-71,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,2,5.26,Yes,Yes,"Platelet transfusion, dose adjustment",74,21,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,200,Bi-weekly,38,94,46-71,Male only,0-3,Severe Neuropathy,Neurological,Severe,2,5.26,Partial,Yes,"Dose reduction, pain management",47,59,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,2,Monthly,177,277,28-75,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,9,5.08,Partial,Yes,"Liver function monitoring, dose adjustment",5,8,Yes,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,10,Monthly,118,90,31-67,Male only,0-1,Cardiac Toxicity,Cardiovascular,Severe,6,5.08,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",46,11,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,10,Weekly,327,92,53-83,Male only,0-3,Severe Neutropenia,Hematological,Severe,16,4.89,Yes,Yes,"G-CSF, antibiotics, dose reduction",78,7,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,200,Bi-weekly,378,104,18-75,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,18,4.76,Yes,Yes,"Platelet transfusion, dose adjustment",86,36,No,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,2,Every 3 weeks,277,90,22-75,Male only,0-1,Severe Neutropenia,Hematological,Severe,13,4.69,Yes,Yes,"G-CSF, antibiotics, dose reduction",18,19,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,2,Weekly,277,217,54-77,Male only,1-2,Severe Thrombocytopenia,Hematological,Severe,13,4.69,Yes,Yes,"Platelet transfusion, dose adjustment",85,47,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,200,Monthly,155,180,30-84,All,0-2,Severe Myocarditis,Cardiovascular,Severe,7,4.52,Partial,Yes,"Corticosteroids, cardiac support",12,30,No,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,10,Bi-weekly,422,303,46-74,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,19,4.5,Partial,Yes,"Corticosteroids, cardiac support",10,16,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,200,Bi-weekly,378,104,18-75,Male only,0-2,Severe Neutropenia,Hematological,Severe,17,4.5,Yes,Yes,"G-CSF, antibiotics, dose reduction",52,43,Yes,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,200,Monthly,404,282,58-76,Male only,0-3,Severe Neutropenia,Hematological,Severe,18,4.46,Yes,Yes,"G-CSF, antibiotics, dose reduction",58,50,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,2,Monthly,275,185,25-83,Male only,0-2,Severe Colitis,Gastrointestinal,Severe,12,4.36,Yes,Yes,"Corticosteroids, infliximab",82,34,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,200,Every 3 weeks,459,112,32-70,Male only,0-1,Cardiac Toxicity,Cardiovascular,Severe,20,4.36,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",73,5,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,200,Bi-weekly,372,264,54-67,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,16,4.3,Partial,Yes,"Corticosteroids, oxygen therapy",81,57,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,200,Every 3 weeks,70,225,48-72,All,0-2,Cardiac Toxicity,Cardiovascular,Severe,3,4.29,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",23,3,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,10,Monthly,118,90,31-67,Male only,0-1,Severe Neutropenia,Hematological,Severe,5,4.24,Yes,Yes,"G-CSF, antibiotics, dose reduction",28,47,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,10,Monthly,166,307,34-66,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,7,4.22,Yes,Yes,"Corticosteroids, infliximab",80,42,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,200,Monthly,317,196,40-70,All,0-1,Severe Neuropathy,Neurological,Severe,13,4.1,Partial,Yes,"Dose reduction, pain management",86,13,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,200,Monthly,317,196,40-70,All,0-1,Cytokine Release Syndrome,Immunological,Severe,13,4.1,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",81,47,No,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,10,Weekly,464,100,60-65,All,0-2,Anaphylaxis,Immunological,Severe,19,4.09,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",52,7,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,10,Weekly,123,116,39-65,Male only,1-2,Severe Neuropathy,Neurological,Severe,5,4.07,Partial,Yes,"Dose reduction, pain management",33,26,No,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,200,Bi-weekly,372,264,54-67,Male only,1-2,Cytokine Release Syndrome,Immunological,Severe,15,4.03,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",34,46,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,10,Every 3 weeks,475,250,23-79,Male only,1-2,Severe Myocarditis,Cardiovascular,Severe,19,4.0,Partial,Yes,"Corticosteroids, cardiac support",22,24,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,2,Weekly,75,191,55-78,Male only,0-3,Severe Colitis,Gastrointestinal,Severe,3,4.0,Yes,Yes,"Corticosteroids, infliximab",69,54,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,10,Bi-weekly,50,203,64-82,All,0-2,Severe Colitis,Gastrointestinal,Severe,2,4.0,Yes,Yes,"Corticosteroids, infliximab",14,23,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,2,Monthly,176,213,51-71,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,7,3.98,Partial,Yes,"Corticosteroids, cardiac support",30,22,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,2,Monthly,76,93,38-67,Female only,0-2,Severe Myocarditis,Cardiovascular,Severe,3,3.95,Partial,Yes,"Corticosteroids, cardiac support",67,44,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,200,Bi-weekly,372,264,54-67,Male only,1-2,Severe Thrombocytopenia,Hematological,Severe,14,3.76,Yes,Yes,"Platelet transfusion, dose adjustment",77,13,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,10,Bi-weekly,325,75,39-75,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,12,3.69,Partial,Yes,"Corticosteroids, oxygen therapy",44,24,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,10,Bi-weekly,330,105,49-76,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,12,3.64,Partial,Yes,"Corticosteroids, oxygen therapy",76,42,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,10,Every 3 weeks,165,291,23-69,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,6,3.64,Yes,Yes,"Platelet transfusion, dose adjustment",36,27,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,2,Every 3 weeks,467,47,27-73,All,0-3,Severe Myocarditis,Cardiovascular,Severe,17,3.64,Partial,Yes,"Corticosteroids, cardiac support",38,18,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,10,Monthly,454,250,18-81,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,16,3.52,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",86,34,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,200,Bi-weekly,377,230,60-85,Female only,0-1,Anaphylaxis,Immunological,Severe,13,3.45,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",17,50,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,200,Monthly,262,250,63-77,Female only,0-1,Severe Neutropenia,Hematological,Severe,9,3.44,Yes,Yes,"G-CSF, antibiotics, dose reduction",51,53,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,10,Bi-weekly,325,75,39-75,Female only,0-3,Cytokine Release Syndrome,Immunological,Severe,11,3.38,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",90,35,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,10,Every 3 weeks,475,250,23-79,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,16,3.37,Yes,Yes,"Corticosteroids, infliximab",63,39,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,200,Every 3 weeks,298,76,59-71,Female only,0-1,Severe Neuropathy,Neurological,Severe,10,3.36,Partial,Yes,"Dose reduction, pain management",72,54,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,2,Bi-weekly,391,274,36-80,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,13,3.32,Partial,Yes,"Liver function monitoring, dose adjustment",41,24,No,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,10,Weekly,397,42,37-65,All,0-3,Severe Myocarditis,Cardiovascular,Severe,13,3.27,Partial,Yes,"Corticosteroids, cardiac support",69,46,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,10,Weekly,397,42,37-65,All,0-3,Severe Neutropenia,Hematological,Severe,13,3.27,Yes,Yes,"G-CSF, antibiotics, dose reduction",40,13,No,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,10,Every 3 weeks,460,351,55-79,Female only,0-1,Cardiac Toxicity,Cardiovascular,Severe,15,3.26,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",29,46,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,10,Every 3 weeks,460,351,55-79,Female only,0-1,Severe Thrombocytopenia,Hematological,Severe,15,3.26,Yes,Yes,"Platelet transfusion, dose adjustment",40,27,Yes,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,10,Weekly,466,68,35-85,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,15,3.22,Yes,Yes,"Platelet transfusion, dose adjustment",90,6,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,200,Weekly,126,178,63-83,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,4,3.17,Yes,Yes,"Corticosteroids, infliximab",61,50,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,200,Weekly,126,178,63-83,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,4,3.17,Yes,Yes,"Platelet transfusion, dose adjustment",15,33,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,10,Weekly,286,120,44-83,Male only,0-3,Severe Neutropenia,Hematological,Severe,9,3.15,Yes,Yes,"G-CSF, antibiotics, dose reduction",79,5,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,10,Weekly,327,92,53-83,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,10,3.06,Partial,Yes,"Liver function monitoring, dose adjustment",76,42,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,10,Every 3 weeks,165,291,23-69,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,5,3.03,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",31,32,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,200,Monthly,334,271,60-78,Female only,0-1,Severe Thrombocytopenia,Hematological,Severe,10,2.99,Yes,Yes,"Platelet transfusion, dose adjustment",12,50,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,10,Every 3 weeks,475,250,23-79,Male only,1-2,Anaphylaxis,Immunological,Severe,14,2.95,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",30,40,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,200,Every 3 weeks,171,152,39-71,Female only,0-1,Severe Neuropathy,Neurological,Severe,5,2.92,Partial,Yes,"Dose reduction, pain management",79,28,Yes,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,2,Monthly,275,185,25-83,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,8,2.91,Partial,Yes,"Corticosteroids, oxygen therapy",38,51,No,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,200,Weekly,412,267,22-72,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,12,2.91,Partial,Yes,"Liver function monitoring, dose adjustment",90,59,Yes,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,10,Bi-weekly,104,165,42-77,Female only,0-2,Severe Colitis,Gastrointestinal,Severe,3,2.88,Yes,Yes,"Corticosteroids, infliximab",46,46,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,200,Every 3 weeks,70,225,48-72,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,2,2.86,Partial,Yes,"Liver function monitoring, dose adjustment",29,47,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,200,Bi-weekly,36,318,41-65,All,0-3,Severe Neutropenia,Hematological,Severe,1,2.78,Yes,Yes,"G-CSF, antibiotics, dose reduction",84,45,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,2,Bi-weekly,412,247,18-74,Female only,0-3,Severe Colitis,Gastrointestinal,Severe,11,2.67,Yes,Yes,"Corticosteroids, infliximab",16,44,Yes,Yes,Yes
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,2,Weekly,75,191,55-78,Male only,0-3,Anaphylaxis,Immunological,Severe,2,2.67,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",70,18,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,200,Bi-weekly,378,104,18-75,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,10,2.65,Yes,Yes,"Platelet transfusion, dose adjustment",84,13,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,10,Weekly,464,100,60-65,All,0-2,Cytokine Release Syndrome,Immunological,Severe,12,2.59,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",46,22,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,10,Every 3 weeks,484,294,57-78,All,0-1,Cytokine Release Syndrome,Immunological,Severe,12,2.48,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",69,24,Yes,No,Yes
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,2,Weekly,326,202,22-80,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,8,2.45,Yes,Yes,"Platelet transfusion, dose adjustment",12,60,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,10,Monthly,454,250,18-81,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,11,2.42,Partial,Yes,"Liver function monitoring, dose adjustment",16,27,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,200,Monthly,334,271,60-78,Female only,0-1,Anaphylaxis,Immunological,Severe,8,2.4,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",55,6,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,10,Weekly,464,100,60-65,All,0-2,Cytokine Release Syndrome,Immunological,Severe,11,2.37,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",15,32,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,200,Monthly,262,250,63-77,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,6,2.29,Partial,Yes,"Corticosteroids, oxygen therapy",66,7,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,10,Every 3 weeks,484,294,57-78,All,0-1,Cytokine Release Syndrome,Immunological,Severe,11,2.27,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",73,9,Yes,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,2,Monthly,176,213,51-71,Female only,1-2,Anaphylaxis,Immunological,Severe,4,2.27,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",2,20,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,2,Monthly,362,53,18-67,Female only,0-2,Anaphylaxis,Immunological,Severe,8,2.21,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",87,24,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,10,Bi-weekly,330,105,49-76,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,7,2.12,Partial,Yes,"Liver function monitoring, dose adjustment",6,17,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,200,Bi-weekly,378,104,18-75,Male only,0-2,Severe Neutropenia,Hematological,Severe,8,2.12,Yes,Yes,"G-CSF, antibiotics, dose reduction",21,57,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,200,Every 3 weeks,433,129,40-72,All,1-2,Anaphylaxis,Immunological,Severe,9,2.08,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",3,42,Yes,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,2,Monthly,145,321,65-82,Female only,0-3,Anaphylaxis,Immunological,Severe,3,2.07,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",47,25,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,10,Bi-weekly,50,203,64-82,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,1,2.0,Partial,Yes,"Liver function monitoring, dose adjustment",7,36,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,2,Monthly,206,234,47-82,All,0-1,Severe Myocarditis,Cardiovascular,Severe,4,1.94,Partial,Yes,"Corticosteroids, cardiac support",51,8,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,200,Every 3 weeks,363,235,39-65,All,1-2,Severe Thrombocytopenia,Hematological,Severe,7,1.93,Yes,Yes,"Platelet transfusion, dose adjustment",56,17,No,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,10,Bi-weekly,422,303,46-74,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,8,1.9,Partial,Yes,"Liver function monitoring, dose adjustment",41,14,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,10,Monthly,454,250,18-81,All,1-2,Anaphylaxis,Immunological,Severe,8,1.76,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",47,35,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,10,Weekly,286,120,44-83,Male only,0-3,Severe Myocarditis,Cardiovascular,Severe,5,1.75,Partial,Yes,"Corticosteroids, cardiac support",31,18,No,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,2,Monthly,290,298,31-73,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,5,1.72,Yes,Yes,"Platelet transfusion, dose adjustment",45,20,No,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,200,Monthly,176,165,23-78,All,1-2,Severe Colitis,Gastrointestinal,Severe,3,1.7,Yes,Yes,"Corticosteroids, infliximab",89,13,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,2,Monthly,206,234,47-82,All,0-1,Severe Neuropathy,Neurological,Severe,3,1.46,Partial,Yes,"Dose reduction, pain management",30,46,No,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,10,Bi-weekly,422,303,46-74,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,6,1.42,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",23,49,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,10,Monthly,223,86,56-76,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,3,1.35,Yes,Yes,"Platelet transfusion, dose adjustment",77,57,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,200,Bi-weekly,377,230,60-85,Female only,0-1,Cardiac Toxicity,Cardiovascular,Severe,5,1.33,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",36,52,No,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,200,Weekly,412,267,22-72,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,5,1.21,Partial,Yes,"Corticosteroids, oxygen therapy",63,37,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,2,Weekly,85,190,35-83,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,1,1.18,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",41,24,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,2,Weekly,85,190,35-83,Female only,0-3,Severe Colitis,Gastrointestinal,Severe,1,1.18,Yes,Yes,"Corticosteroids, infliximab",51,54,Yes,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,10,Every 3 weeks,183,80,50-78,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,2,1.09,Partial,Yes,"Liver function monitoring, dose adjustment",89,20,No,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,2,Weekly,277,217,54-77,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,3,1.08,Partial,Yes,"Corticosteroids, oxygen therapy",89,28,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,2,Monthly,290,298,31-73,Male only,0-2,Cardiac Toxicity,Cardiovascular,Severe,3,1.03,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",55,39,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,10,Weekly,397,42,37-65,All,0-3,Severe Neuropathy,Neurological,Severe,4,1.01,Partial,Yes,"Dose reduction, pain management",84,5,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,2,Bi-weekly,203,113,63-70,All,0-1,Cardiac Toxicity,Cardiovascular,Severe,2,0.99,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",52,54,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,2,Bi-weekly,203,113,63-70,All,0-1,Cardiac Toxicity,Cardiovascular,Severe,2,0.99,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",72,58,No,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,2,Monthly,206,234,47-82,All,0-1,Severe Thrombocytopenia,Hematological,Severe,2,0.97,Yes,Yes,"Platelet transfusion, dose adjustment",59,40,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,10,Bi-weekly,422,303,46-74,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,4,0.95,Partial,Yes,"Corticosteroids, cardiac support",55,22,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,2,Weekly,325,198,22-83,All,0-3,Anaphylaxis,Immunological,Severe,3,0.92,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",32,13,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,2,Weekly,118,101,59-66,Female only,0-1,Severe Neutropenia,Hematological,Severe,1,0.85,Yes,Yes,"G-CSF, antibiotics, dose reduction",58,23,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,10,Monthly,118,90,31-67,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,1,0.85,Yes,Yes,"Corticosteroids, infliximab",31,55,Yes,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,10,Every 3 weeks,475,250,23-79,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,4,0.84,Partial,Yes,"Corticosteroids, oxygen therapy",15,21,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,200,Monthly,262,250,63-77,Female only,0-1,Severe Thrombocytopenia,Hematological,Severe,2,0.76,Yes,Yes,"Platelet transfusion, dose adjustment",45,7,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,2,Bi-weekly,412,247,18-74,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,3,0.73,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",77,38,Yes,No,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,2,Bi-weekly,412,247,18-74,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,3,0.73,Partial,Yes,"Corticosteroids, oxygen therapy",18,3,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,200,Weekly,412,267,22-72,Male only,0-2,Severe Neutropenia,Hematological,Severe,3,0.73,Yes,Yes,"G-CSF, antibiotics, dose reduction",14,59,Yes,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,200,Monthly,283,341,29-83,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,2,0.71,Partial,Yes,"Liver function monitoring, dose adjustment",11,34,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,2,Weekly,482,122,60-73,Male only,0-1,Anaphylaxis,Immunological,Severe,3,0.62,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",86,53,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,10,Bi-weekly,325,75,39-75,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,2,0.62,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",61,7,No,No,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,200,Every 3 weeks,363,235,39-65,All,1-2,Severe Pneumonitis,Respiratory,Severe,2,0.55,Partial,Yes,"Corticosteroids, oxygen therapy",82,52,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,200,Weekly,412,267,22-72,Male only,0-2,Cardiac Toxicity,Cardiovascular,Severe,2,0.49,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",11,53,No,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,10,Every 3 weeks,212,356,56-77,All,0-1,Severe Myocarditis,Cardiovascular,Severe,1,0.47,Partial,Yes,"Corticosteroids, cardiac support",29,10,No,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,10,Every 3 weeks,460,351,55-79,Female only,0-1,Severe Neuropathy,Neurological,Severe,2,0.43,Partial,Yes,"Dose reduction, pain management",22,55,No,Yes,No
Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,10,Weekly,327,92,53-83,Male only,0-3,Severe Neutropenia,Hematological,Severe,1,0.31,Yes,Yes,"G-CSF, antibiotics, dose reduction",58,45,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,200,Monthly,334,271,60-78,Female only,0-1,Severe Neutropenia,Hematological,Severe,1,0.3,Yes,Yes,"G-CSF, antibiotics, dose reduction",28,18,No,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,10,Every 3 weeks,370,286,30-75,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,1,0.27,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",66,1,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,2,Bi-weekly,391,274,36-80,Male only,1-2,Severe Thrombocytopenia,Hematological,Severe,1,0.26,Yes,Yes,"Platelet transfusion, dose adjustment",66,34,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,10,Weekly,464,100,60-65,All,0-2,Anaphylaxis,Immunological,Severe,1,0.22,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",73,17,No,No,No
Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,200,Every 3 weeks,459,112,32-70,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,1,0.22,Yes,Yes,"Corticosteroids, infliximab",83,54,Yes,Yes,No
Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,10,Every 3 weeks,484,294,57-78,All,0-1,Anaphylaxis,Immunological,Severe,1,0.21,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",14,36,Yes,Yes,Yes
Rituximab,Anti-CD20,Leukemia,Phase 3,1000,Monthly,30,241,56-74,All,0-3,Cytokine Release Syndrome,Immunological,Severe,3,10.0,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",89,58,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,375,Every 3 weeks,161,175,25-67,Male only,1-2,Severe Thrombocytopenia,Hematological,Severe,16,9.94,Yes,Yes,"Platelet transfusion, dose adjustment",3,44,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,375,Bi-weekly,134,41,58-71,Male only,0-2,Severe Colitis,Gastrointestinal,Severe,13,9.7,Yes,Yes,"Corticosteroids, infliximab",51,45,No,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,750,Every 3 weeks,21,163,48-78,Male only,0-3,Severe Neuropathy,Neurological,Severe,2,9.52,Partial,Yes,"Dose reduction, pain management",39,21,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,750,Every 3 weeks,21,163,48-78,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,2,9.52,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",55,34,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,750,Every 3 weeks,21,163,48-78,Male only,0-3,Severe Myocarditis,Cardiovascular,Severe,2,9.52,Partial,Yes,"Corticosteroids, cardiac support",69,2,Yes,Yes,Yes
Rituximab,Anti-CD20,Leukemia,Phase 1,500,Bi-weekly,106,272,37-65,All,0-2,Severe Neutropenia,Hematological,Severe,10,9.43,Yes,Yes,"G-CSF, antibiotics, dose reduction",22,4,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,375,Weekly,191,314,59-78,All,0-2,Severe Thrombocytopenia,Hematological,Severe,18,9.42,Yes,Yes,"Platelet transfusion, dose adjustment",54,53,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,750,Monthly,172,350,47-80,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,16,9.3,Partial,Yes,"Corticosteroids, oxygen therapy",83,26,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,500,Weekly,97,357,39-84,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,9,9.28,Partial,Yes,"Corticosteroids, oxygen therapy",46,21,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,750,Every 3 weeks,131,166,31-73,All,0-1,Anaphylaxis,Immunological,Severe,12,9.16,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",3,36,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,375,Every 3 weeks,220,113,37-72,Female only,0-1,Anaphylaxis,Immunological,Severe,20,9.09,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",70,21,No,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,500,Weekly,45,343,27-69,Male only,0-3,Severe Colitis,Gastrointestinal,Severe,4,8.89,Yes,Yes,"Corticosteroids, infliximab",80,6,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,500,Bi-weekly,104,285,63-80,Female only,0-1,Anaphylaxis,Immunological,Severe,9,8.65,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",46,42,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,1000,Monthly,197,198,48-83,All,0-2,Cytokine Release Syndrome,Immunological,Severe,17,8.63,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",78,40,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,500,Weekly,128,266,56-65,All,0-2,Anaphylaxis,Immunological,Severe,11,8.59,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",2,15,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,375,Bi-weekly,142,355,43-82,Female only,0-3,Severe Neutropenia,Hematological,Severe,12,8.45,Yes,Yes,"G-CSF, antibiotics, dose reduction",16,50,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,1000,Monthly,72,273,41-71,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,6,8.33,Partial,Yes,"Corticosteroids, cardiac support",34,11,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,500,Every 3 weeks,168,129,48-75,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,14,8.33,Partial,Yes,"Liver function monitoring, dose adjustment",14,20,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,500,Every 3 weeks,168,129,48-75,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,14,8.33,Yes,Yes,"Corticosteroids, infliximab",8,57,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,500,Weekly,121,154,59-83,Female only,0-3,Severe Myocarditis,Cardiovascular,Severe,10,8.26,Partial,Yes,"Corticosteroids, cardiac support",84,47,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,500,Monthly,109,312,57-75,Female only,1-2,Severe Neuropathy,Neurological,Severe,9,8.26,Partial,Yes,"Dose reduction, pain management",31,23,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,750,Monthly,172,350,47-80,Female only,0-3,Severe Colitis,Gastrointestinal,Severe,14,8.14,Yes,Yes,"Corticosteroids, infliximab",75,38,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,375,Every 3 weeks,161,175,25-67,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,13,8.07,Yes,Yes,"Corticosteroids, infliximab",21,55,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,375,Every 3 weeks,236,274,33-78,All,0-2,Severe Neuropathy,Neurological,Severe,19,8.05,Partial,Yes,"Dose reduction, pain management",7,48,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,500,Every 3 weeks,216,47,53-67,Female only,0-1,Anaphylaxis,Immunological,Severe,17,7.87,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",59,44,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,375,Weekly,191,314,59-78,All,0-2,Cardiac Toxicity,Cardiovascular,Severe,15,7.85,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",4,12,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,1000,Weekly,258,271,30-77,All,0-1,Cardiac Toxicity,Cardiovascular,Severe,20,7.75,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",83,3,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,750,Monthly,168,55,62-74,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,13,7.74,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",20,38,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,1000,Every 3 weeks,221,317,37-78,Female only,0-2,Severe Pneumonitis,Respiratory,Severe,17,7.69,Partial,Yes,"Corticosteroids, oxygen therapy",46,59,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 3,500,Weekly,26,230,35-65,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,2,7.69,Partial,Yes,"Corticosteroids, oxygen therapy",83,41,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 3,500,Weekly,26,230,35-65,Male only,0-1,Cytokine Release Syndrome,Immunological,Severe,2,7.69,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",72,37,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,375,Monthly,26,170,30-76,Female only,0-2,Severe Neuropathy,Neurological,Severe,2,7.69,Partial,Yes,"Dose reduction, pain management",52,23,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,1000,Bi-weekly,262,341,56-85,Male only,1-2,Severe Neutropenia,Hematological,Severe,20,7.63,Yes,Yes,"G-CSF, antibiotics, dose reduction",60,27,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,1000,Weekly,158,112,23-71,All,0-3,Cytokine Release Syndrome,Immunological,Severe,12,7.59,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",52,35,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,375,Every 3 weeks,218,130,27-65,All,0-1,Severe Thrombocytopenia,Hematological,Severe,16,7.34,Yes,Yes,"Platelet transfusion, dose adjustment",1,30,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,1000,Every 3 weeks,221,317,37-78,Female only,0-2,Severe Colitis,Gastrointestinal,Severe,16,7.24,Yes,Yes,"Corticosteroids, infliximab",39,24,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 3,500,Weekly,97,357,39-84,Female only,0-1,Severe Thrombocytopenia,Hematological,Severe,7,7.22,Yes,Yes,"Platelet transfusion, dose adjustment",16,26,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 3,375,Monthly,168,318,36-85,Male only,0-3,Anaphylaxis,Immunological,Severe,12,7.14,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",89,18,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,500,Every 3 weeks,168,129,48-75,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,12,7.14,Yes,Yes,"Platelet transfusion, dose adjustment",6,33,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,750,Bi-weekly,183,256,47-68,All,0-2,Severe Pneumonitis,Respiratory,Severe,13,7.1,Partial,Yes,"Corticosteroids, oxygen therapy",1,51,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,1000,Weekly,170,177,52-82,Male only,1-2,Severe Thrombocytopenia,Hematological,Severe,12,7.06,Yes,Yes,"Platelet transfusion, dose adjustment",16,21,No,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 3,750,Bi-weekly,72,135,22-77,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,5,6.94,Partial,Yes,"Corticosteroids, cardiac support",21,55,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,750,Bi-weekly,72,135,22-77,Female only,1-2,Anaphylaxis,Immunological,Severe,5,6.94,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",40,52,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,1000,Monthly,72,273,41-71,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,5,6.94,Yes,Yes,"Platelet transfusion, dose adjustment",33,40,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,375,Every 3 weeks,161,175,25-67,Male only,1-2,Anaphylaxis,Immunological,Severe,11,6.83,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",4,15,No,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,500,Bi-weekly,104,285,63-80,Female only,0-1,Severe Neutropenia,Hematological,Severe,7,6.73,Yes,Yes,"G-CSF, antibiotics, dose reduction",15,18,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,375,Bi-weekly,134,41,58-71,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,9,6.72,Partial,Yes,"Corticosteroids, oxygen therapy",68,12,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,375,Bi-weekly,134,41,58-71,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,9,6.72,Partial,Yes,"Liver function monitoring, dose adjustment",67,44,Yes,No,Yes
Rituximab,Anti-CD20,Autoimmune,Phase 3,750,Every 3 weeks,224,112,24-71,All,0-1,Severe Thrombocytopenia,Hematological,Severe,15,6.7,Yes,Yes,"Platelet transfusion, dose adjustment",31,51,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,1000,Monthly,30,241,56-74,All,0-3,Severe Neuropathy,Neurological,Severe,2,6.67,Partial,Yes,"Dose reduction, pain management",47,22,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,375,Bi-weekly,211,346,45-69,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,14,6.64,Partial,Yes,"Liver function monitoring, dose adjustment",59,43,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,750,Monthly,302,57,41-78,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,20,6.62,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",72,34,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,1000,Monthly,197,198,48-83,All,0-2,Severe Colitis,Gastrointestinal,Severe,13,6.6,Yes,Yes,"Corticosteroids, infliximab",88,33,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,375,Bi-weekly,185,50,26-80,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,12,6.49,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",64,56,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,500,Monthly,109,312,57-75,Female only,1-2,Cytokine Release Syndrome,Immunological,Severe,7,6.42,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",24,10,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,1000,Monthly,320,39,19-84,All,0-1,Cardiac Toxicity,Cardiovascular,Severe,20,6.25,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",12,9,No,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,375,Bi-weekly,211,346,45-69,Male only,0-3,Anaphylaxis,Immunological,Severe,13,6.16,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",1,13,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,500,Every 3 weeks,216,47,53-67,Female only,0-1,Anaphylaxis,Immunological,Severe,13,6.02,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",40,2,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,500,Monthly,332,318,51-74,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,20,6.02,Partial,Yes,"Liver function monitoring, dose adjustment",65,10,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,750,Monthly,168,55,62-74,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,10,5.95,Partial,Yes,"Corticosteroids, oxygen therapy",62,13,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,375,Every 3 weeks,236,274,33-78,All,0-2,Anaphylaxis,Immunological,Severe,14,5.93,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",8,24,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,1000,Monthly,326,204,28-82,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,19,5.83,Partial,Yes,"Liver function monitoring, dose adjustment",58,58,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,500,Bi-weekly,104,285,63-80,Female only,0-1,Severe Neuropathy,Neurological,Severe,6,5.77,Partial,Yes,"Dose reduction, pain management",89,22,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,750,Monthly,302,57,41-78,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,17,5.63,Partial,Yes,"Corticosteroids, oxygen therapy",37,32,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,500,Weekly,128,266,56-65,All,0-2,Severe Thrombocytopenia,Hematological,Severe,7,5.47,Yes,Yes,"Platelet transfusion, dose adjustment",57,38,No,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,750,Every 3 weeks,293,170,60-79,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,16,5.46,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",43,23,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,1000,Weekly,258,271,30-77,All,0-1,Severe Neuropathy,Neurological,Severe,14,5.43,Partial,Yes,"Dose reduction, pain management",75,29,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,500,Every 3 weeks,168,129,48-75,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,9,5.36,Yes,Yes,"Corticosteroids, infliximab",61,57,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,1000,Weekly,170,177,52-82,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,9,5.29,Yes,Yes,"Corticosteroids, infliximab",9,1,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 3,1000,Monthly,134,49,42-76,All,1-2,Severe Neuropathy,Neurological,Severe,7,5.22,Partial,Yes,"Dose reduction, pain management",35,44,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,500,Weekly,97,357,39-84,Female only,0-1,Severe Myocarditis,Cardiovascular,Severe,5,5.15,Partial,Yes,"Corticosteroids, cardiac support",27,51,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,750,Monthly,39,112,32-81,Female only,0-1,Cardiac Toxicity,Cardiovascular,Severe,2,5.13,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",33,29,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,750,Monthly,39,112,32-81,Female only,0-1,Anaphylaxis,Immunological,Severe,2,5.13,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",60,45,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,375,Every 3 weeks,220,113,37-72,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,11,5.0,Partial,Yes,"Liver function monitoring, dose adjustment",65,57,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 1,750,Monthly,383,308,58-76,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,18,4.7,Partial,Yes,"Corticosteroids, cardiac support",3,7,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,1000,Monthly,320,39,19-84,All,0-1,Severe Colitis,Gastrointestinal,Severe,15,4.69,Yes,Yes,"Corticosteroids, infliximab",1,59,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,1000,Bi-weekly,406,277,42-79,Female only,0-2,Anaphylaxis,Immunological,Severe,19,4.68,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",69,4,No,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 2,1000,Weekly,428,321,26-84,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,20,4.67,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",48,37,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,1000,Weekly,258,271,30-77,All,0-1,Anaphylaxis,Immunological,Severe,12,4.65,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",21,59,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,750,Monthly,433,136,53-80,Male only,0-1,Cytokine Release Syndrome,Immunological,Severe,20,4.62,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",47,56,No,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,1000,Weekly,220,273,23-81,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,10,4.55,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",58,25,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,750,Monthly,443,170,24-65,All,0-3,Anaphylaxis,Immunological,Severe,20,4.51,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",46,33,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,750,Weekly,445,155,47-74,All,0-3,Severe Colitis,Gastrointestinal,Severe,20,4.49,Yes,Yes,"Corticosteroids, infliximab",70,29,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,500,Weekly,45,343,27-69,Male only,0-3,Severe Neutropenia,Hematological,Severe,2,4.44,Yes,Yes,"G-CSF, antibiotics, dose reduction",38,39,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,500,Weekly,45,343,27-69,Male only,0-3,Severe Myocarditis,Cardiovascular,Severe,2,4.44,Partial,Yes,"Corticosteroids, cardiac support",29,20,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,1000,Weekly,158,112,23-71,All,0-3,Severe Myocarditis,Cardiovascular,Severe,7,4.43,Partial,Yes,"Corticosteroids, cardiac support",78,8,Yes,Yes,Yes
Rituximab,Anti-CD20,Leukemia,Phase 1,500,Every 3 weeks,454,186,35-68,Male only,1-2,Severe Thrombocytopenia,Hematological,Severe,20,4.41,Yes,Yes,"Platelet transfusion, dose adjustment",21,53,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 2,375,Weekly,465,301,47-81,All,0-3,Severe Pneumonitis,Respiratory,Severe,20,4.3,Partial,Yes,"Corticosteroids, oxygen therapy",19,34,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,1000,Monthly,326,204,28-82,All,1-2,Severe Pneumonitis,Respiratory,Severe,14,4.29,Partial,Yes,"Corticosteroids, oxygen therapy",44,24,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,375,Weekly,474,273,41-79,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,20,4.22,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",58,10,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,1000,Weekly,428,321,26-84,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,18,4.21,Yes,Yes,"Platelet transfusion, dose adjustment",63,26,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,1000,Weekly,220,273,23-81,Male only,0-3,Severe Pneumonitis,Respiratory,Severe,9,4.09,Partial,Yes,"Corticosteroids, oxygen therapy",77,56,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,750,Bi-weekly,441,235,44-65,Female only,0-1,Severe Neuropathy,Neurological,Severe,18,4.08,Partial,Yes,"Dose reduction, pain management",54,17,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,750,Monthly,172,350,47-80,Female only,0-3,Severe Hepatotoxicity,Hepatic,Severe,7,4.07,Partial,Yes,"Liver function monitoring, dose adjustment",10,10,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,500,Weekly,297,41,20-84,All,0-2,Cardiac Toxicity,Cardiovascular,Severe,12,4.04,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",37,42,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 1,750,Monthly,383,308,58-76,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,15,3.92,Partial,Yes,"Corticosteroids, oxygen therapy",17,59,Yes,No,Yes
Rituximab,Anti-CD20,Lymphoma,Phase 2,1000,Every 3 weeks,493,195,54-80,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,19,3.85,Partial,Yes,"Liver function monitoring, dose adjustment",48,58,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,1000,Weekly,156,359,25-83,Male only,0-3,Severe Colitis,Gastrointestinal,Severe,6,3.85,Yes,Yes,"Corticosteroids, infliximab",76,3,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,500,Weekly,26,230,35-65,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,1,3.85,Partial,Yes,"Corticosteroids, oxygen therapy",62,39,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,750,Bi-weekly,209,222,33-75,Female only,0-3,Severe Neuropathy,Neurological,Severe,8,3.83,Partial,Yes,"Dose reduction, pain management",82,58,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,375,Every 3 weeks,470,227,49-84,All,0-2,Cytokine Release Syndrome,Immunological,Severe,18,3.83,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",9,55,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,500,Weekly,262,237,34-72,Female only,0-1,Severe Colitis,Gastrointestinal,Severe,10,3.82,Yes,Yes,"Corticosteroids, infliximab",53,11,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,750,Monthly,446,298,23-69,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,17,3.81,Partial,Yes,"Liver function monitoring, dose adjustment",41,14,No,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,750,Weekly,316,355,27-78,All,0-1,Severe Pneumonitis,Respiratory,Severe,12,3.8,Partial,Yes,"Corticosteroids, oxygen therapy",29,56,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,1000,Weekly,396,163,32-69,All,0-3,Severe Thrombocytopenia,Hematological,Severe,15,3.79,Yes,Yes,"Platelet transfusion, dose adjustment",24,43,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,500,Bi-weekly,106,272,37-65,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,4,3.77,Partial,Yes,"Liver function monitoring, dose adjustment",10,59,No,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,750,Monthly,383,308,58-76,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,14,3.66,Partial,Yes,"Liver function monitoring, dose adjustment",12,16,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,375,Bi-weekly,469,206,42-82,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,17,3.62,Partial,Yes,"Corticosteroids, cardiac support",48,47,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,500,Monthly,332,318,51-74,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,12,3.61,Partial,Yes,"Liver function monitoring, dose adjustment",34,40,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,500,Monthly,332,318,51-74,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,12,3.61,Partial,Yes,"Corticosteroids, cardiac support",31,53,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,750,Weekly,445,155,47-74,All,0-3,Severe Neuropathy,Neurological,Severe,16,3.6,Partial,Yes,"Dose reduction, pain management",14,46,No,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,1000,Monthly,475,105,51-77,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,16,3.37,Partial,Yes,"Liver function monitoring, dose adjustment",74,29,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,750,Bi-weekly,119,321,58-66,Female only,1-2,Severe Pneumonitis,Respiratory,Severe,4,3.36,Partial,Yes,"Corticosteroids, oxygen therapy",85,47,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,500,Weekly,121,154,59-83,Female only,0-3,Severe Neutropenia,Hematological,Severe,4,3.31,Yes,Yes,"G-CSF, antibiotics, dose reduction",60,57,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,750,Bi-weekly,484,64,24-68,Female only,1-2,Severe Neuropathy,Neurological,Severe,16,3.31,Partial,Yes,"Dose reduction, pain management",22,44,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,500,Every 3 weeks,216,47,53-67,Female only,0-1,Severe Neutropenia,Hematological,Severe,7,3.24,Yes,Yes,"G-CSF, antibiotics, dose reduction",9,47,No,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,500,Weekly,473,67,50-82,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,15,3.17,Partial,Yes,"Liver function monitoring, dose adjustment",13,53,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,375,Weekly,474,273,41-79,All,1-2,Severe Neuropathy,Neurological,Severe,15,3.16,Partial,Yes,"Dose reduction, pain management",72,48,No,Yes,Yes
Rituximab,Anti-CD20,Lymphoma,Phase 3,1000,Monthly,475,105,51-77,All,0-3,Anaphylaxis,Immunological,Severe,15,3.16,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",80,6,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,500,Weekly,128,266,56-65,All,0-2,Cardiac Toxicity,Cardiovascular,Severe,4,3.12,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",82,34,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,750,Bi-weekly,484,64,24-68,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,15,3.1,Yes,Yes,"Platelet transfusion, dose adjustment",47,23,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,500,Weekly,97,357,39-84,Female only,0-1,Severe Neutropenia,Hematological,Severe,3,3.09,Yes,Yes,"G-CSF, antibiotics, dose reduction",31,10,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,500,Bi-weekly,461,289,59-75,Female only,0-1,Anaphylaxis,Immunological,Severe,14,3.04,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",18,27,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,500,Bi-weekly,263,122,32-77,Male only,0-2,Cytokine Release Syndrome,Immunological,Severe,8,3.04,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",82,28,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,1000,Weekly,396,163,32-69,All,0-3,Cardiac Toxicity,Cardiovascular,Severe,12,3.03,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",5,37,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,500,Monthly,265,335,56-83,Female only,1-2,Severe Neutropenia,Hematological,Severe,8,3.02,Yes,Yes,"G-CSF, antibiotics, dose reduction",53,9,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,375,Bi-weekly,134,41,58-71,Male only,0-2,Cytokine Release Syndrome,Immunological,Severe,4,2.99,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",62,22,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,375,Every 3 weeks,236,274,33-78,All,0-2,Severe Thrombocytopenia,Hematological,Severe,7,2.97,Yes,Yes,"Platelet transfusion, dose adjustment",72,56,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,1000,Bi-weekly,406,277,42-79,Female only,0-2,Severe Myocarditis,Cardiovascular,Severe,12,2.96,Partial,Yes,"Corticosteroids, cardiac support",67,30,Yes,No,Yes
Rituximab,Anti-CD20,Autoimmune,Phase 1,750,Bi-weekly,441,235,44-65,Female only,0-1,Severe Neutropenia,Hematological,Severe,13,2.95,Yes,Yes,"G-CSF, antibiotics, dose reduction",61,39,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,375,Every 3 weeks,480,129,50-68,All,0-3,Anaphylaxis,Immunological,Severe,14,2.92,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",65,5,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,750,Weekly,445,155,47-74,All,0-3,Severe Colitis,Gastrointestinal,Severe,13,2.92,Yes,Yes,"Corticosteroids, infliximab",6,18,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,500,Bi-weekly,461,289,59-75,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,13,2.82,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",4,27,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,500,Monthly,109,312,57-75,Female only,1-2,Cytokine Release Syndrome,Immunological,Severe,3,2.75,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",49,26,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,1000,Every 3 weeks,329,74,64-65,Female only,0-2,Severe Thrombocytopenia,Hematological,Severe,9,2.74,Yes,Yes,"Platelet transfusion, dose adjustment",19,60,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 2,750,Monthly,302,57,41-78,Male only,0-3,Severe Colitis,Gastrointestinal,Severe,8,2.65,Yes,Yes,"Corticosteroids, infliximab",1,36,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,1000,Every 3 weeks,493,195,54-80,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,13,2.64,Yes,Yes,"Platelet transfusion, dose adjustment",86,35,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,500,Monthly,265,335,56-83,Female only,1-2,Anaphylaxis,Immunological,Severe,7,2.64,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",65,57,No,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,500,Bi-weekly,461,289,59-75,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,12,2.6,Partial,Yes,"Corticosteroids, oxygen therapy",11,58,No,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 2,375,Weekly,465,301,47-81,All,0-3,Cardiac Toxicity,Cardiovascular,Severe,12,2.58,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",48,33,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,750,Monthly,39,112,32-81,Female only,0-1,Severe Neutropenia,Hematological,Severe,1,2.56,Yes,Yes,"G-CSF, antibiotics, dose reduction",35,8,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,750,Monthly,39,112,32-81,Female only,0-1,Severe Neuropathy,Neurological,Severe,1,2.56,Partial,Yes,"Dose reduction, pain management",52,8,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,500,Every 3 weeks,472,147,23-65,All,1-2,Anaphylaxis,Immunological,Severe,12,2.54,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",82,30,Yes,Yes,Yes
Rituximab,Anti-CD20,Autoimmune,Phase 1,1000,Every 3 weeks,321,282,26-76,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,8,2.49,Yes,Yes,"Platelet transfusion, dose adjustment",76,32,No,Yes,Yes
Rituximab,Anti-CD20,Autoimmune,Phase 2,750,Monthly,443,170,24-65,All,0-3,Cardiac Toxicity,Cardiovascular,Severe,11,2.48,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",50,4,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,1000,Every 3 weeks,493,195,54-80,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,12,2.43,Partial,Yes,"Corticosteroids, cardiac support",69,48,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,500,Monthly,419,287,41-76,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,10,2.39,Partial,Yes,"Liver function monitoring, dose adjustment",57,5,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,375,Weekly,380,305,40-81,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,9,2.37,Partial,Yes,"Liver function monitoring, dose adjustment",21,45,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,500,Weekly,297,41,20-84,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,7,2.36,Partial,Yes,"Liver function monitoring, dose adjustment",65,10,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,375,Bi-weekly,469,206,42-82,Male only,0-2,Anaphylaxis,Immunological,Severe,11,2.35,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",35,56,Yes,No,Yes
Rituximab,Anti-CD20,Autoimmune,Phase 1,1000,Weekly,170,177,52-82,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,4,2.35,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",4,36,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,500,Weekly,128,266,56-65,All,0-2,Cardiac Toxicity,Cardiovascular,Severe,3,2.34,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",14,20,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,375,Weekly,346,54,62-69,Female only,0-1,Severe Thrombocytopenia,Hematological,Severe,8,2.31,Yes,Yes,"Platelet transfusion, dose adjustment",27,37,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,375,Every 3 weeks,480,129,50-68,All,0-3,Severe Hepatotoxicity,Hepatic,Severe,11,2.29,Partial,Yes,"Liver function monitoring, dose adjustment",54,57,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,500,Weekly,262,237,34-72,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,6,2.29,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",18,42,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,375,Every 3 weeks,220,113,37-72,Female only,0-1,Severe Neutropenia,Hematological,Severe,5,2.27,Yes,Yes,"G-CSF, antibiotics, dose reduction",52,24,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,750,Bi-weekly,266,303,26-74,Female only,0-2,Severe Colitis,Gastrointestinal,Severe,6,2.26,Yes,Yes,"Corticosteroids, infliximab",26,48,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 1,500,Every 3 weeks,454,186,35-68,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,10,2.2,Yes,Yes,"Corticosteroids, infliximab",5,3,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,375,Monthly,228,174,30-69,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,5,2.19,Yes,Yes,"Platelet transfusion, dose adjustment",69,10,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,375,Weekly,465,301,47-81,All,0-3,Severe Pneumonitis,Respiratory,Severe,10,2.15,Partial,Yes,"Corticosteroids, oxygen therapy",70,43,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,375,Bi-weekly,142,355,43-82,Female only,0-3,Severe Hepatotoxicity,Hepatic,Severe,3,2.11,Partial,Yes,"Liver function monitoring, dose adjustment",11,8,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,1000,Weekly,396,163,32-69,All,0-3,Cardiac Toxicity,Cardiovascular,Severe,8,2.02,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",50,24,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,1000,Weekly,258,271,30-77,All,0-1,Cardiac Toxicity,Cardiovascular,Severe,5,1.94,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",63,60,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,500,Weekly,473,67,50-82,All,0-1,Severe Neuropathy,Neurological,Severe,9,1.9,Partial,Yes,"Dose reduction, pain management",21,6,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,1000,Every 3 weeks,321,282,26-76,Female only,1-2,Severe Myocarditis,Cardiovascular,Severe,6,1.87,Partial,Yes,"Corticosteroids, cardiac support",13,60,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,750,Every 3 weeks,329,307,19-85,All,0-3,Severe Colitis,Gastrointestinal,Severe,6,1.82,Yes,Yes,"Corticosteroids, infliximab",43,6,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,750,Monthly,168,55,62-74,Male only,0-3,Anaphylaxis,Immunological,Severe,3,1.79,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",82,39,No,Yes,Yes
Rituximab,Anti-CD20,Leukemia,Phase 3,375,Monthly,168,318,36-85,Male only,0-3,Severe Myocarditis,Cardiovascular,Severe,3,1.79,Partial,Yes,"Corticosteroids, cardiac support",42,50,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,500,Every 3 weeks,454,186,35-68,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,8,1.76,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",65,16,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 1,500,Weekly,473,67,50-82,All,0-1,Severe Neuropathy,Neurological,Severe,8,1.69,Partial,Yes,"Dose reduction, pain management",44,30,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,375,Bi-weekly,185,50,26-80,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,3,1.62,Yes,Yes,"Platelet transfusion, dose adjustment",27,56,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,1000,Every 3 weeks,312,290,24-77,All,1-2,Severe Thrombocytopenia,Hematological,Severe,5,1.6,Yes,Yes,"Platelet transfusion, dose adjustment",62,32,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,375,Monthly,446,197,56-71,Male only,0-1,Severe Neutropenia,Hematological,Severe,7,1.57,Yes,Yes,"G-CSF, antibiotics, dose reduction",25,31,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,500,Monthly,332,318,51-74,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,5,1.51,Partial,Yes,"Corticosteroids, cardiac support",13,60,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,375,Every 3 weeks,470,227,49-84,All,0-2,Severe Pneumonitis,Respiratory,Severe,7,1.49,Partial,Yes,"Corticosteroids, oxygen therapy",59,5,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,375,Weekly,474,273,41-79,All,1-2,Cardiac Toxicity,Cardiovascular,Severe,7,1.48,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",49,22,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,750,Monthly,272,67,44-73,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,4,1.47,Partial,Yes,"Corticosteroids, oxygen therapy",77,34,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,500,Bi-weekly,140,325,46-85,Male only,1-2,Severe Neutropenia,Hematological,Severe,2,1.43,Yes,Yes,"G-CSF, antibiotics, dose reduction",16,38,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,375,Bi-weekly,142,355,43-82,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,2,1.41,Partial,Yes,"Corticosteroids, oxygen therapy",27,31,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,500,Bi-weekly,72,61,61-77,All,0-3,Severe Thrombocytopenia,Hematological,Severe,1,1.39,Yes,Yes,"Platelet transfusion, dose adjustment",3,53,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,1000,Monthly,72,273,41-71,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,1,1.39,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",50,42,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,750,Bi-weekly,441,235,44-65,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,6,1.36,Partial,Yes,"Corticosteroids, oxygen therapy",80,17,No,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,375,Weekly,380,305,40-81,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,5,1.32,Partial,Yes,"Liver function monitoring, dose adjustment",32,25,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,375,Bi-weekly,469,206,42-82,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,6,1.28,Partial,Yes,"Corticosteroids, cardiac support",35,17,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,375,Bi-weekly,469,206,42-82,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,6,1.28,Partial,Yes,"Corticosteroids, cardiac support",68,14,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,375,Every 3 weeks,480,129,50-68,All,0-3,Severe Thrombocytopenia,Hematological,Severe,6,1.25,Yes,Yes,"Platelet transfusion, dose adjustment",79,31,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,750,Monthly,168,55,62-74,Male only,0-3,Severe Colitis,Gastrointestinal,Severe,2,1.19,Yes,Yes,"Corticosteroids, infliximab",27,49,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,375,Monthly,168,318,36-85,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,2,1.19,Partial,Yes,"Liver function monitoring, dose adjustment",34,13,No,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,500,Bi-weekly,461,289,59-75,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,5,1.08,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",7,33,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 1,750,Monthly,383,308,58-76,Male only,0-1,Severe Neutropenia,Hematological,Severe,4,1.04,Yes,Yes,"G-CSF, antibiotics, dose reduction",42,10,No,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,375,Every 3 weeks,480,129,50-68,All,0-3,Severe Neutropenia,Hematological,Severe,5,1.04,Yes,Yes,"G-CSF, antibiotics, dose reduction",21,60,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 1,500,Bi-weekly,106,272,37-65,All,0-2,Cytokine Release Syndrome,Immunological,Severe,1,0.94,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",5,14,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,750,Monthly,433,136,53-80,Male only,0-1,Cardiac Toxicity,Cardiovascular,Severe,4,0.92,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",58,41,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,375,Weekly,380,305,40-81,Female only,1-2,Severe Neuropathy,Neurological,Severe,3,0.79,Partial,Yes,"Dose reduction, pain management",13,57,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,750,Monthly,257,228,59-68,Male only,1-2,Severe Thrombocytopenia,Hematological,Severe,2,0.78,Yes,Yes,"Platelet transfusion, dose adjustment",49,50,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,1000,Weekly,448,362,20-68,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,3,0.67,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",90,25,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 3,750,Monthly,446,298,23-69,Male only,0-1,Anaphylaxis,Immunological,Severe,3,0.67,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",57,18,Yes,No,No
Rituximab,Anti-CD20,Leukemia,Phase 2,750,Monthly,302,57,41-78,Male only,0-3,Cytokine Release Syndrome,Immunological,Severe,2,0.66,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",14,37,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 1,375,Every 3 weeks,177,351,58-66,Female only,0-2,Severe Colitis,Gastrointestinal,Severe,1,0.56,Yes,Yes,"Corticosteroids, infliximab",16,57,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,375,Bi-weekly,185,50,26-80,Female only,1-2,Severe Neutropenia,Hematological,Severe,1,0.54,Yes,Yes,"G-CSF, antibiotics, dose reduction",4,31,Yes,Yes,No
Rituximab,Anti-CD20,Leukemia,Phase 1,375,Bi-weekly,211,346,45-69,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,1,0.47,Yes,Yes,"Platelet transfusion, dose adjustment",82,57,Yes,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,500,Every 3 weeks,216,47,53-67,Female only,0-1,Severe Neuropathy,Neurological,Severe,1,0.46,Partial,Yes,"Dose reduction, pain management",50,48,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,750,Monthly,433,136,53-80,Male only,0-1,Severe Hepatotoxicity,Hepatic,Severe,2,0.46,Partial,Yes,"Liver function monitoring, dose adjustment",4,50,No,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,500,Every 3 weeks,469,58,20-81,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,2,0.43,Partial,Yes,"Liver function monitoring, dose adjustment",9,29,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 3,500,Every 3 weeks,472,147,23-65,All,1-2,Severe Neutropenia,Hematological,Severe,2,0.42,Yes,Yes,"G-CSF, antibiotics, dose reduction",61,40,Yes,No,No
Rituximab,Anti-CD20,Autoimmune,Phase 2,500,Bi-weekly,263,122,32-77,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,1,0.38,Yes,Yes,"Platelet transfusion, dose adjustment",23,45,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,500,Weekly,297,41,20-84,All,0-2,Anaphylaxis,Immunological,Severe,1,0.34,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",58,41,No,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 3,750,Every 3 weeks,329,307,19-85,All,0-3,Severe Neuropathy,Neurological,Severe,1,0.3,Partial,Yes,"Dose reduction, pain management",14,44,Yes,Yes,No
Rituximab,Anti-CD20,Autoimmune,Phase 1,375,Weekly,346,54,62-69,Female only,0-1,Anaphylaxis,Immunological,Severe,1,0.29,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",29,48,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,375,Weekly,380,305,40-81,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,1,0.26,Yes,Yes,"Platelet transfusion, dose adjustment",65,44,No,No,No
Rituximab,Anti-CD20,Leukemia,Phase 1,500,Every 3 weeks,454,186,35-68,Male only,1-2,Severe Myocarditis,Cardiovascular,Severe,1,0.22,Partial,Yes,"Corticosteroids, cardiac support",44,1,No,Yes,No
Rituximab,Anti-CD20,Lymphoma,Phase 1,375,Weekly,474,273,41-79,All,1-2,Severe Pneumonitis,Respiratory,Severe,1,0.21,Partial,Yes,"Corticosteroids, oxygen therapy",58,23,Yes,No,No
Rituximab,Anti-CD20,Lymphoma,Phase 2,1000,Every 3 weeks,493,195,54-80,Male only,0-2,Cytokine Release Syndrome,Immunological,Severe,1,0.2,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",17,35,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,6,Weekly,193,62,50-66,All,0-3,Anaphylaxis,Immunological,Severe,19,9.84,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",43,42,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,8,Monthly,186,52,62-85,All,0-3,Severe Thrombocytopenia,Hematological,Severe,18,9.68,Yes,Yes,"Platelet transfusion, dose adjustment",46,39,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,8,Weekly,199,342,21-65,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,19,9.55,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",90,48,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,2,Monthly,168,292,30-67,Male only,0-1,Cytokine Release Syndrome,Immunological,Severe,16,9.52,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",29,38,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,6,Every 3 weeks,161,329,38-80,Female only,0-3,Severe Neuropathy,Neurological,Severe,14,8.7,Partial,Yes,"Dose reduction, pain management",31,33,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,8,Every 3 weeks,71,179,51-76,All,1-2,Severe Thrombocytopenia,Hematological,Severe,6,8.45,Yes,Yes,"Platelet transfusion, dose adjustment",24,14,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,6,Every 3 weeks,239,187,23-75,Male only,0-2,Cardiac Toxicity,Cardiovascular,Severe,20,8.37,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",7,20,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,2,Monthly,168,292,30-67,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,14,8.33,Yes,Yes,"Corticosteroids, infliximab",61,30,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,8,Weekly,60,222,19-82,Male only,0-3,Severe Neutropenia,Hematological,Severe,5,8.33,Yes,Yes,"G-CSF, antibiotics, dose reduction",50,55,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,8,Weekly,60,222,19-82,Male only,0-3,Severe Thrombocytopenia,Hematological,Severe,5,8.33,Yes,Yes,"Platelet transfusion, dose adjustment",43,32,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,4,Every 3 weeks,75,167,23-66,Female only,0-1,Cardiac Toxicity,Cardiovascular,Severe,6,8.0,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",59,46,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,4,Monthly,163,137,38-74,Male only,1-2,Anaphylaxis,Immunological,Severe,13,7.98,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",41,10,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,6,Bi-weekly,102,191,24-82,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,8,7.84,Partial,Yes,"Liver function monitoring, dose adjustment",79,5,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,4,Bi-weekly,206,331,33-71,Female only,1-2,Severe Neutropenia,Hematological,Severe,16,7.77,Yes,Yes,"G-CSF, antibiotics, dose reduction",89,46,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,4,Bi-weekly,206,331,33-71,Female only,1-2,Severe Pneumonitis,Respiratory,Severe,16,7.77,Partial,Yes,"Corticosteroids, oxygen therapy",60,18,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,6,Every 3 weeks,118,237,30-69,Male only,0-2,Severe Myocarditis,Cardiovascular,Severe,9,7.63,Partial,Yes,"Corticosteroids, cardiac support",26,25,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,4,Monthly,67,347,20-68,Female only,0-2,Severe Colitis,Gastrointestinal,Severe,5,7.46,Yes,Yes,"Corticosteroids, infliximab",25,6,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,4,Monthly,67,347,20-68,Female only,0-2,Anaphylaxis,Immunological,Severe,5,7.46,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",7,30,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,2,Bi-weekly,218,300,65-81,Female only,1-2,Cardiac Toxicity,Cardiovascular,Severe,16,7.34,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",3,26,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,6,Weekly,193,62,50-66,All,0-3,Severe Neuropathy,Neurological,Severe,14,7.25,Partial,Yes,"Dose reduction, pain management",33,51,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,8,Every 3 weeks,284,268,37-72,All,0-2,Anaphylaxis,Immunological,Severe,20,7.04,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",48,30,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,8,Weekly,199,342,21-65,Male only,1-2,Severe Neutropenia,Hematological,Severe,14,7.04,Yes,Yes,"G-CSF, antibiotics, dose reduction",12,2,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,8,Weekly,199,342,21-65,Male only,1-2,Cytokine Release Syndrome,Immunological,Severe,14,7.04,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",58,57,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,4,Monthly,242,336,45-82,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,17,7.02,Partial,Yes,"Corticosteroids, cardiac support",18,25,No,No,Yes
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,6,Weekly,57,281,33-70,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,4,7.02,Partial,Yes,"Corticosteroids, oxygen therapy",60,37,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,8,Weekly,273,294,41-74,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,19,6.96,Partial,Yes,"Corticosteroids, cardiac support",55,18,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,2,Weekly,218,163,22-85,All,0-1,Severe Myocarditis,Cardiovascular,Severe,15,6.88,Partial,Yes,"Corticosteroids, cardiac support",32,5,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,8,Every 3 weeks,220,295,21-80,All,1-2,Severe Hepatotoxicity,Hepatic,Severe,15,6.82,Partial,Yes,"Liver function monitoring, dose adjustment",32,5,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,8,Monthly,186,52,62-85,All,0-3,Cytokine Release Syndrome,Immunological,Severe,12,6.45,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",4,9,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,8,Every 3 weeks,284,268,37-72,All,0-2,Severe Hepatotoxicity,Hepatic,Severe,18,6.34,Partial,Yes,"Liver function monitoring, dose adjustment",15,7,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,2,Monthly,79,236,34-79,All,0-1,Severe Pneumonitis,Respiratory,Severe,5,6.33,Partial,Yes,"Corticosteroids, oxygen therapy",35,45,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,4,Monthly,67,347,20-68,Female only,0-2,Cytokine Release Syndrome,Immunological,Severe,4,5.97,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",77,27,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,6,Bi-weekly,102,191,24-82,Female only,0-1,Severe Neutropenia,Hematological,Severe,6,5.88,Yes,Yes,"G-CSF, antibiotics, dose reduction",19,58,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,6,Weekly,349,63,58-83,All,0-1,Severe Hepatotoxicity,Hepatic,Severe,20,5.73,Partial,Yes,"Liver function monitoring, dose adjustment",24,3,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,6,Weekly,349,63,58-83,All,0-1,Severe Thrombocytopenia,Hematological,Severe,20,5.73,Yes,Yes,"Platelet transfusion, dose adjustment",24,58,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,8,Every 3 weeks,71,179,51-76,All,1-2,Severe Pneumonitis,Respiratory,Severe,4,5.63,Partial,Yes,"Corticosteroids, oxygen therapy",60,59,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,4,Bi-weekly,215,320,44-77,Female only,1-2,Anaphylaxis,Immunological,Severe,12,5.58,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",8,56,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,8,Bi-weekly,243,207,58-66,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,13,5.35,Partial,Yes,"Corticosteroids, oxygen therapy",56,52,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,8,Bi-weekly,243,207,58-66,Female only,0-1,Severe Neutropenia,Hematological,Severe,13,5.35,Yes,Yes,"G-CSF, antibiotics, dose reduction",85,31,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,4,Every 3 weeks,319,325,28-70,Female only,0-3,Severe Pneumonitis,Respiratory,Severe,17,5.33,Partial,Yes,"Corticosteroids, oxygen therapy",29,4,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,2,Monthly,385,191,47-72,Female only,0-2,Severe Colitis,Gastrointestinal,Severe,20,5.19,Yes,Yes,"Corticosteroids, infliximab",8,17,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,2,Monthly,79,236,34-79,All,0-1,Severe Neutropenia,Hematological,Severe,4,5.06,Yes,Yes,"G-CSF, antibiotics, dose reduction",18,31,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,2,Weekly,360,355,64-81,All,0-3,Severe Neutropenia,Hematological,Severe,18,5.0,Yes,Yes,"G-CSF, antibiotics, dose reduction",75,45,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,4,Monthly,163,137,38-74,Male only,1-2,Severe Pneumonitis,Respiratory,Severe,8,4.91,Partial,Yes,"Corticosteroids, oxygen therapy",59,6,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,8,Monthly,186,52,62-85,All,0-3,Severe Neutropenia,Hematological,Severe,9,4.84,Yes,Yes,"G-CSF, antibiotics, dose reduction",56,42,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,4,Every 3 weeks,352,300,63-68,Male only,1-2,Severe Neutropenia,Hematological,Severe,17,4.83,Yes,Yes,"G-CSF, antibiotics, dose reduction",72,49,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,4,Every 3 weeks,352,300,63-68,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,17,4.83,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",70,24,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,8,Monthly,145,206,44-66,Female only,1-2,Severe Hepatotoxicity,Hepatic,Severe,7,4.83,Partial,Yes,"Liver function monitoring, dose adjustment",75,16,Yes,Yes,Yes
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,2,Bi-weekly,423,122,55-76,Male only,0-2,Severe Thrombocytopenia,Hematological,Severe,20,4.73,Yes,Yes,"Platelet transfusion, dose adjustment",64,5,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,4,Monthly,170,126,57-82,Female only,0-2,Severe Hepatotoxicity,Hepatic,Severe,8,4.71,Partial,Yes,"Liver function monitoring, dose adjustment",42,41,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,4,Monthly,170,126,57-82,Female only,0-2,Severe Neuropathy,Neurological,Severe,8,4.71,Partial,Yes,"Dose reduction, pain management",45,53,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,2,Weekly,151,182,59-72,Female only,0-1,Anaphylaxis,Immunological,Severe,7,4.64,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",85,37,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,2,Weekly,259,33,58-80,Male only,0-3,Anaphylaxis,Immunological,Severe,12,4.63,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",85,59,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,6,Every 3 weeks,239,187,23-75,Male only,0-2,Anaphylaxis,Immunological,Severe,11,4.6,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",74,56,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,4,Monthly,242,336,45-82,Male only,0-1,Severe Colitis,Gastrointestinal,Severe,11,4.55,Yes,Yes,"Corticosteroids, infliximab",52,57,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,2,Monthly,316,278,59-75,Male only,0-1,Cytokine Release Syndrome,Immunological,Severe,14,4.43,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",6,55,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,8,Every 3 weeks,440,166,40-69,All,0-1,Severe Neuropathy,Neurological,Severe,19,4.32,Partial,Yes,"Dose reduction, pain management",58,43,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,8,Weekly,325,117,54-79,Male only,0-1,Severe Neutropenia,Hematological,Severe,14,4.31,Yes,Yes,"G-CSF, antibiotics, dose reduction",22,17,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,6,Monthly,466,244,57-80,Female only,0-1,Severe Neuropathy,Neurological,Severe,20,4.29,Partial,Yes,"Dose reduction, pain management",38,26,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,2,Bi-weekly,423,122,55-76,Male only,0-2,Severe Neuropathy,Neurological,Severe,18,4.26,Partial,Yes,"Dose reduction, pain management",21,5,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,4,Bi-weekly,238,94,54-73,All,0-2,Severe Thrombocytopenia,Hematological,Severe,10,4.2,Yes,Yes,"Platelet transfusion, dose adjustment",29,56,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,8,Monthly,145,206,44-66,Female only,1-2,Severe Pneumonitis,Respiratory,Severe,6,4.14,Partial,Yes,"Corticosteroids, oxygen therapy",48,47,No,No,Yes
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,2,Weekly,485,32,51-74,Female only,0-3,Severe Thrombocytopenia,Hematological,Severe,20,4.12,Yes,Yes,"Platelet transfusion, dose adjustment",47,9,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,4,Every 3 weeks,319,325,28-70,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,13,4.08,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",19,59,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,4,Weekly,466,215,32-71,Male only,0-3,Severe Hepatotoxicity,Hepatic,Severe,19,4.08,Partial,Yes,"Liver function monitoring, dose adjustment",47,11,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,4,Every 3 weeks,75,167,23-66,Female only,0-1,Severe Myocarditis,Cardiovascular,Severe,3,4.0,Partial,Yes,"Corticosteroids, cardiac support",63,10,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,4,Every 3 weeks,75,167,23-66,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,3,4.0,Partial,Yes,"Liver function monitoring, dose adjustment",1,1,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,2,Weekly,360,355,64-81,All,0-3,Severe Colitis,Gastrointestinal,Severe,14,3.89,Yes,Yes,"Corticosteroids, infliximab",66,38,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,4,Bi-weekly,206,331,33-71,Female only,1-2,Anaphylaxis,Immunological,Severe,8,3.88,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",30,38,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,2,Bi-weekly,495,94,37-75,Male only,0-1,Severe Neuropathy,Neurological,Severe,19,3.84,Partial,Yes,"Dose reduction, pain management",43,3,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,4,Monthly,313,316,39-67,All,0-3,Severe Pneumonitis,Respiratory,Severe,12,3.83,Partial,Yes,"Corticosteroids, oxygen therapy",57,58,No,Yes,Yes
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,8,Every 3 weeks,447,142,24-77,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,17,3.8,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",67,19,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,8,Monthly,316,99,55-77,All,0-3,Severe Neutropenia,Hematological,Severe,12,3.8,Yes,Yes,"G-CSF, antibiotics, dose reduction",10,21,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,2,Monthly,429,56,35-76,Male only,0-1,Severe Neutropenia,Hematological,Severe,16,3.73,Yes,Yes,"G-CSF, antibiotics, dose reduction",8,29,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,4,Every 3 weeks,432,220,39-83,Male only,0-3,Cardiac Toxicity,Cardiovascular,Severe,16,3.7,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",64,13,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,4,Every 3 weeks,352,300,63-68,Male only,1-2,Cytokine Release Syndrome,Immunological,Severe,13,3.69,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",58,21,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,4,Every 3 weeks,352,300,63-68,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,13,3.69,Partial,Yes,"Liver function monitoring, dose adjustment",51,22,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,6,Every 3 weeks,392,315,60-80,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,14,3.57,Yes,Yes,"Platelet transfusion, dose adjustment",3,17,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,8,Every 3 weeks,284,268,37-72,All,0-2,Anaphylaxis,Immunological,Severe,10,3.52,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",53,2,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,2,Weekly,485,32,51-74,Female only,0-3,Severe Colitis,Gastrointestinal,Severe,17,3.51,Yes,Yes,"Corticosteroids, infliximab",70,58,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,2,Weekly,485,32,51-74,Female only,0-3,Severe Neuropathy,Neurological,Severe,17,3.51,Partial,Yes,"Dose reduction, pain management",64,11,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,2,Weekly,485,32,51-74,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,17,3.51,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",8,14,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,4,Every 3 weeks,319,325,28-70,Female only,0-3,Severe Neuropathy,Neurological,Severe,11,3.45,Partial,Yes,"Dose reduction, pain management",49,2,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,6,Every 3 weeks,239,187,23-75,Male only,0-2,Severe Colitis,Gastrointestinal,Severe,8,3.35,Yes,Yes,"Corticosteroids, infliximab",21,3,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,2,Weekly,360,355,64-81,All,0-3,Severe Thrombocytopenia,Hematological,Severe,12,3.33,Yes,Yes,"Platelet transfusion, dose adjustment",89,26,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,2,Bi-weekly,423,122,55-76,Male only,0-2,Severe Pneumonitis,Respiratory,Severe,14,3.31,Partial,Yes,"Corticosteroids, oxygen therapy",65,40,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,8,Every 3 weeks,220,295,21-80,All,1-2,Severe Neuropathy,Neurological,Severe,7,3.18,Partial,Yes,"Dose reduction, pain management",77,15,Yes,No,Yes
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,8,Every 3 weeks,378,361,39-71,All,1-2,Severe Thrombocytopenia,Hematological,Severe,12,3.17,Yes,Yes,"Platelet transfusion, dose adjustment",24,37,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,6,Bi-weekly,32,199,45-79,Female only,0-3,Anaphylaxis,Immunological,Severe,1,3.12,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",45,17,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,6,Bi-weekly,32,199,45-79,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,1,3.12,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",8,35,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,6,Every 3 weeks,323,295,46-79,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,10,3.1,Partial,Yes,"Liver function monitoring, dose adjustment",62,12,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,8,Weekly,489,225,26-75,All,0-3,Cytokine Release Syndrome,Immunological,Severe,15,3.07,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",85,49,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,2,Bi-weekly,423,122,55-76,Male only,0-2,Severe Colitis,Gastrointestinal,Severe,13,3.07,Yes,Yes,"Corticosteroids, infliximab",80,11,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,2,Monthly,429,56,35-76,Male only,0-1,Severe Thrombocytopenia,Hematological,Severe,13,3.03,Yes,Yes,"Platelet transfusion, dose adjustment",8,21,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,6,Monthly,364,30,57-69,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,11,3.02,Yes,Yes,"Corticosteroids, infliximab",49,30,Yes,No,Yes
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,8,Monthly,464,152,40-65,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,14,3.02,Partial,Yes,"Corticosteroids, oxygen therapy",49,31,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,4,Monthly,67,347,20-68,Female only,0-2,Anaphylaxis,Immunological,Severe,2,2.99,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",20,20,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,2,Weekly,476,114,48-67,Male only,1-2,Severe Colitis,Gastrointestinal,Severe,14,2.94,Yes,Yes,"Corticosteroids, infliximab",71,8,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,8,Every 3 weeks,378,361,39-71,All,1-2,Severe Myocarditis,Cardiovascular,Severe,11,2.91,Partial,Yes,"Corticosteroids, cardiac support",83,24,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,8,Bi-weekly,243,207,58-66,Female only,0-1,Cardiac Toxicity,Cardiovascular,Severe,7,2.88,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",70,28,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,8,Every 3 weeks,71,179,51-76,All,1-2,Severe Neuropathy,Neurological,Severe,2,2.82,Partial,Yes,"Dose reduction, pain management",89,44,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,6,Every 3 weeks,323,295,46-79,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,9,2.79,Partial,Yes,"Liver function monitoring, dose adjustment",86,43,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,8,Monthly,464,152,40-65,Male only,0-1,Severe Neuropathy,Neurological,Severe,12,2.59,Partial,Yes,"Dose reduction, pain management",70,29,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,6,Monthly,466,244,57-80,Female only,0-1,Severe Pneumonitis,Respiratory,Severe,12,2.58,Partial,Yes,"Corticosteroids, oxygen therapy",88,47,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,6,Weekly,349,63,58-83,All,0-1,Severe Neutropenia,Hematological,Severe,9,2.58,Yes,Yes,"G-CSF, antibiotics, dose reduction",58,3,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,6,Monthly,445,166,28-81,Female only,0-2,Severe Myocarditis,Cardiovascular,Severe,11,2.47,Partial,Yes,"Corticosteroids, cardiac support",35,26,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,8,Every 3 weeks,447,142,24-77,Female only,0-3,Severe Neutropenia,Hematological,Severe,11,2.46,Yes,Yes,"G-CSF, antibiotics, dose reduction",26,20,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,2,Bi-weekly,495,94,37-75,Male only,0-1,Anaphylaxis,Immunological,Severe,12,2.42,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",50,42,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,4,Bi-weekly,422,34,21-66,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,10,2.37,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",38,45,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,6,Monthly,466,244,57-80,Female only,0-1,Cardiac Toxicity,Cardiovascular,Severe,11,2.36,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",44,4,Yes,No,Yes
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,2,Monthly,385,191,47-72,Female only,0-2,Severe Neutropenia,Hematological,Severe,9,2.34,Yes,Yes,"G-CSF, antibiotics, dose reduction",2,47,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,2,Weekly,218,163,22-85,All,0-1,Severe Myocarditis,Cardiovascular,Severe,5,2.29,Partial,Yes,"Corticosteroids, cardiac support",58,44,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,8,Every 3 weeks,220,295,21-80,All,1-2,Severe Colitis,Gastrointestinal,Severe,5,2.27,Yes,Yes,"Corticosteroids, infliximab",60,58,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,2,Monthly,316,278,59-75,Male only,0-1,Cardiac Toxicity,Cardiovascular,Severe,7,2.22,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",10,1,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,4,Every 3 weeks,414,224,34-71,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,9,2.17,Partial,Yes,"Corticosteroids, oxygen therapy",9,36,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,8,Monthly,464,152,40-65,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,10,2.16,Partial,Yes,"Corticosteroids, oxygen therapy",44,34,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,4,Weekly,432,273,28-81,Female only,0-1,Severe Neuropathy,Neurological,Severe,9,2.08,Partial,Yes,"Dose reduction, pain management",89,2,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,6,Weekly,193,62,50-66,All,0-3,Severe Neuropathy,Neurological,Severe,4,2.07,Partial,Yes,"Dose reduction, pain management",21,47,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,6,Weekly,349,63,58-83,All,0-1,Severe Pneumonitis,Respiratory,Severe,7,2.01,Partial,Yes,"Corticosteroids, oxygen therapy",11,20,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,6,Monthly,466,244,57-80,Female only,0-1,Severe Thrombocytopenia,Hematological,Severe,9,1.93,Yes,Yes,"Platelet transfusion, dose adjustment",32,24,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,8,Monthly,316,99,55-77,All,0-3,Cytokine Release Syndrome,Immunological,Severe,6,1.9,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",63,42,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,8,Monthly,316,99,55-77,All,0-3,Severe Pneumonitis,Respiratory,Severe,6,1.9,Partial,Yes,"Corticosteroids, oxygen therapy",24,10,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,4,Monthly,163,137,38-74,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,3,1.84,Partial,Yes,"Liver function monitoring, dose adjustment",22,41,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,8,Every 3 weeks,447,142,24-77,Female only,0-3,Anaphylaxis,Immunological,Severe,8,1.79,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",21,20,Yes,No,Yes
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,2,Bi-weekly,227,96,64-81,Female only,1-2,Severe Colitis,Gastrointestinal,Severe,4,1.76,Yes,Yes,"Corticosteroids, infliximab",58,10,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,6,Weekly,285,305,58-81,All,0-3,Severe Neuropathy,Neurological,Severe,5,1.75,Partial,Yes,"Dose reduction, pain management",55,4,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,6,Weekly,57,281,33-70,Female only,0-3,Cytokine Release Syndrome,Immunological,Severe,1,1.75,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",80,48,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,4,Bi-weekly,422,34,21-66,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,7,1.66,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",36,16,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,8,Bi-weekly,243,207,58-66,Female only,0-1,Severe Hepatotoxicity,Hepatic,Severe,4,1.65,Partial,Yes,"Liver function monitoring, dose adjustment",82,57,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,8,Every 3 weeks,378,361,39-71,All,1-2,Severe Myocarditis,Cardiovascular,Severe,6,1.59,Partial,Yes,"Corticosteroids, cardiac support",88,52,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,2,Monthly,316,278,59-75,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,5,1.58,Partial,Yes,"Corticosteroids, oxygen therapy",66,50,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,4,Weekly,466,215,32-71,Male only,0-3,Severe Neutropenia,Hematological,Severe,7,1.5,Yes,Yes,"G-CSF, antibiotics, dose reduction",39,54,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,4,Bi-weekly,422,34,21-66,Male only,1-2,Anaphylaxis,Immunological,Severe,6,1.42,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",75,18,No,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,8,Every 3 weeks,284,268,37-72,All,0-2,Cytokine Release Syndrome,Immunological,Severe,4,1.41,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",27,6,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,8,Monthly,145,206,44-66,Female only,1-2,Anaphylaxis,Immunological,Severe,2,1.38,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",16,2,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,6,Monthly,364,30,57-69,Female only,1-2,Severe Neuropathy,Neurological,Severe,5,1.37,Partial,Yes,"Dose reduction, pain management",37,15,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,8,Every 3 weeks,440,166,40-69,All,0-1,Cytokine Release Syndrome,Immunological,Severe,6,1.36,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",80,47,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,2,Weekly,151,182,59-72,Female only,0-1,Cytokine Release Syndrome,Immunological,Severe,2,1.32,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",11,42,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,4,Monthly,313,316,39-67,All,0-3,Anaphylaxis,Immunological,Severe,4,1.28,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",37,2,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,2,Weekly,476,114,48-67,Male only,1-2,Severe Hepatotoxicity,Hepatic,Severe,6,1.26,Partial,Yes,"Liver function monitoring, dose adjustment",63,44,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,8,Every 3 weeks,440,166,40-69,All,0-1,Severe Colitis,Gastrointestinal,Severe,5,1.14,Yes,Yes,"Corticosteroids, infliximab",55,25,No,Yes,Yes
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,6,Monthly,364,30,57-69,Female only,1-2,Severe Neuropathy,Neurological,Severe,4,1.1,Partial,Yes,"Dose reduction, pain management",24,8,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,8,Weekly,489,225,26-75,All,0-3,Severe Neuropathy,Neurological,Severe,5,1.02,Partial,Yes,"Dose reduction, pain management",40,56,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,8,Weekly,199,342,21-65,Male only,1-2,Severe Neutropenia,Hematological,Severe,2,1.01,Yes,Yes,"G-CSF, antibiotics, dose reduction",28,23,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,4,Bi-weekly,422,34,21-66,Male only,1-2,Severe Thrombocytopenia,Hematological,Severe,4,0.95,Yes,Yes,"Platelet transfusion, dose adjustment",79,11,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,2,Monthly,429,56,35-76,Male only,0-1,Cytokine Release Syndrome,Immunological,Severe,4,0.93,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",23,56,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,4,Every 3 weeks,432,220,39-83,Male only,0-3,Severe Neuropathy,Neurological,Severe,4,0.93,Partial,Yes,"Dose reduction, pain management",89,28,No,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,4,Bi-weekly,215,320,44-77,Female only,1-2,Severe Thrombocytopenia,Hematological,Severe,2,0.93,Yes,Yes,"Platelet transfusion, dose adjustment",15,57,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,8,Every 3 weeks,220,295,21-80,All,1-2,Severe Myocarditis,Cardiovascular,Severe,2,0.91,Partial,Yes,"Corticosteroids, cardiac support",87,54,Yes,Yes,Yes
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,8,Every 3 weeks,447,142,24-77,Female only,0-3,Cardiac Toxicity,Cardiovascular,Severe,4,0.89,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",44,49,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,6,Weekly,228,238,49-74,Male only,0-3,Severe Myocarditis,Cardiovascular,Severe,2,0.88,Partial,Yes,"Corticosteroids, cardiac support",29,13,No,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,6,Every 3 weeks,239,187,23-75,Male only,0-2,Severe Hepatotoxicity,Hepatic,Severe,2,0.84,Partial,Yes,"Liver function monitoring, dose adjustment",27,30,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,2,Weekly,360,355,64-81,All,0-3,Severe Thrombocytopenia,Hematological,Severe,3,0.83,Yes,Yes,"Platelet transfusion, dose adjustment",7,57,Yes,Yes,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,8,Weekly,489,225,26-75,All,0-3,Cytokine Release Syndrome,Immunological,Severe,4,0.82,Yes,Yes,"Tocilizumab, corticosteroids, supportive care",18,32,No,Yes,Yes
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,4,Every 3 weeks,432,220,39-83,Male only,0-3,Severe Colitis,Gastrointestinal,Severe,3,0.69,Yes,Yes,"Corticosteroids, infliximab",35,43,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,8,Monthly,316,99,55-77,All,0-3,Anaphylaxis,Immunological,Severe,2,0.63,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",70,60,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,8,Weekly,325,117,54-79,Male only,0-1,Severe Neutropenia,Hematological,Severe,2,0.62,Yes,Yes,"G-CSF, antibiotics, dose reduction",11,49,Yes,No,No
Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,2,Monthly,168,292,30-67,Male only,0-1,Severe Pneumonitis,Respiratory,Severe,1,0.6,Partial,Yes,"Corticosteroids, oxygen therapy",1,53,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,2,Weekly,430,56,46-71,All,0-2,Anaphylaxis,Immunological,Severe,2,0.47,Yes,Yes,"Epinephrine, antihistamines, corticosteroids",11,56,Yes,No,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,6,Monthly,445,166,28-81,Female only,0-2,Severe Myocarditis,Cardiovascular,Severe,2,0.45,Partial,Yes,"Corticosteroids, cardiac support",15,18,Yes,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,4,Monthly,242,336,45-82,Male only,0-1,Severe Myocarditis,Cardiovascular,Severe,1,0.41,Partial,Yes,"Corticosteroids, cardiac support",67,33,No,Yes,No
Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,2,Weekly,476,114,48-67,Male only,1-2,Cardiac Toxicity,Cardiovascular,Severe,1,0.21,Partial,Yes,"Cardiac monitoring, ACE inhibitors, beta-blockers",24,8,No,No,No
